<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for emergency contraception - Shen, J - 2019 | Cochrane Library</title> <meta content="Interventions for emergency contraception - Shen, J - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001324.pub6/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for emergency contraception - Shen, J - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001324.pub6/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001324.pub6" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for emergency contraception" name="citation_title"/> <meta content="Jie Shen" name="citation_author"/> <meta content="Key Laboratory of Reproduction Regulation of NPFPC, SIPPR, IRD, Fudan University" name="citation_author_institution"/> <meta content="Yan Che" name="citation_author"/> <meta content="Key Laboratory of Reproduction Regulation of NPFPC, SIPPR, IRD, Fudan University" name="citation_author_institution"/> <meta content="cheyan2004@163.com" name="citation_author_email"/> <meta content="Emily Showell" name="citation_author"/> <meta content="University of Otago" name="citation_author_institution"/> <meta content="Ke Chen" name="citation_author"/> <meta content="Key Laboratory of Reproduction Regulation of NPFPC, SIPPR, IRD, Fudan University" name="citation_author_institution"/> <meta content="Linan Cheng" name="citation_author"/> <meta content="Key Laboratory of Reproduction Regulation of NPFPC, SIPPR, IRD, Fudan University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD001324.pub6" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/01/20" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001324.pub6/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001324.pub6/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001324.pub6/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Contraception, Postcoital [adverse effects, *methods]; Contraceptives, Postcoital [*administration &amp; dosage, adverse effects]; Drug Administration Schedule; Estradiol [administration &amp; dosage, adverse effects]; Intrauterine Devices, Copper [adverse effects]; Intrauterine Devices, Medicated [adverse effects]; Levonorgestrel [administration &amp; dosage, adverse effects]; Mifepristone [administration &amp; dosage, adverse effects]; Norpregnadienes [administration &amp; dosage, adverse effects]; Pregnancy Rate; Randomized Controlled Trials as Topic; Unsafe Sex" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001324.pub6&amp;doi=10.1002/14651858.CD001324.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="xcg9958b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001324\x2epub6\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001324\x2epub6\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001324\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001324\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","th","ms","ja","pl","ko","hr","fa","zh_HANT"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001324.pub6",title:"Interventions for emergency contraception",firstPublishedDate:"Jan 20, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Fertility Regulation Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001324.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001324.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001324.pub6/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001324.pub6/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001324.pub6%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001324.PUB6" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001324.pub6/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001324.PUB6" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001324.pub6/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001324.pub6/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>12082 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001324.pub6" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-sec-0203"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-sec-0067"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-sec-0197"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/appendices#CD001324-sec-0208"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/table_n/CD001324StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/table_n/CD001324StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for emergency contraception</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/information#CD001324-cr-0002">Jie Shen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/information#CD001324-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Yan Che</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/information#CD001324-cr-0004">Emily Showell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/information#CD001324-cr-0005">Ke Chen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001324.pub6/information#CD001324-cr-0006">Linan Cheng</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/information/en#CD001324-sec-0238">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 20 January 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001324.pub6">https://doi.org/10.1002/14651858.CD001324.pub6</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001324-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001324-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001324-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001324-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD001324-abs-0012">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD001324-abs-0002">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001324-abs-0001" lang="en"> <section id="CD001324-sec-0001"> <h3 class="title" id="CD001324-sec-0001">Background</h3> <p>Emergency contraception (EC) is using a drug or copper intrauterine device (Cu‐IUD) to prevent pregnancy shortly after unprotected intercourse. Several interventions are available for EC. Information on the comparative effectiveness, safety and convenience of these methods is crucial for reproductive healthcare providers and the women they serve. This is an update of a review previously published in 2009 and 2012. </p> </section> <section id="CD001324-sec-0002"> <h3 class="title" id="CD001324-sec-0002">Objectives</h3> <p>To determine which EC method following unprotected intercourse is the most effective, safe and convenient to prevent pregnancy. </p> </section> <section id="CD001324-sec-0003"> <h3 class="title" id="CD001324-sec-0003">Search methods</h3> <p>In February 2017 we searched CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, Popline and PubMed, The Chinese biomedical databases and UNDP/UNFPA/WHO/World Bank Special Programme on Human Reproduction (HRP) emergency contraception database. We also searched ICTRP and ClinicalTrials.gov as well as contacting content experts and pharmaceutical companies, and searching reference lists of appropriate papers. </p> </section> <section id="CD001324-sec-0004"> <h3 class="title" id="CD001324-sec-0004">Selection criteria</h3> <p>Randomised controlled trials including women attending services for EC following a single act of unprotected intercourse were eligible. </p> </section> <section id="CD001324-sec-0005"> <h3 class="title" id="CD001324-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures recommended by Cochrane. The primary review outcome was observed number of pregnancies. Side effects and changes of menses were secondary outcomes. </p> </section> <section id="CD001324-sec-0006"> <h3 class="title" id="CD001324-sec-0006">Main results</h3> <p>We included 115 trials with 60,479 women in this review. The quality of the evidence for the primary outcome ranged from moderate to high, and for other outcomes ranged from very low to high. The main limitations were risk of bias (associated with poor reporting of methods), imprecision and inconsistency. </p> <p><i>Comparative effectiveness of different emergency contraceptive pills (ECP)</i> </p> <p>Levonorgestrel was associated with fewer pregnancies than Yuzpe (estradiol‐levonorgestrel combination) (RR 0.57, 95% CI 0.39 to 0.84, 6 RCTs, n = 4750, I<sup>2</sup> = 23%, high‐quality evidence). This suggests that if the chance of pregnancy using Yuzpe is assumed to be 29 women per 1000, the chance of pregnancy using levonorgestrel would be between 11 and 24 women per 1000. </p> <p>Mifepristone (all doses) was associated with fewer pregnancies than Yuzpe (RR 0.14, 95% CI 0.05 to 0.41, 3 RCTs, n = 2144, I<sup>2</sup> = 0%, high‐quality evidence). This suggests that if the chance of pregnancy following Yuzpe is assumed to be 25 women per 1000 women, the chance following mifepristone would be between 1 and 10 women per 1000. </p> <p>Both low‐dose mifepristone (less than 25 mg) and mid‐dose mifepristone (25 mg to 50 mg) were probably associated with fewer pregnancies than levonorgestrel (RR 0.72, 95% CI 0.52 to 0.99, 14 RCTs, n = 8752, I<sup>2</sup> = 0%, high‐quality evidence; RR 0.61, 95% CI 0.45 to 0.83, 27 RCTs, n = 6052, I<sup>2</sup> = 0%, moderate‐quality evidence; respectively). This suggests that if the chance of pregnancy following levonorgestrel is assumed to be 20 women per 1000, the chance of pregnancy following low‐dose mifepristone would be between 10 and 20 women per 1000; and that if the chance of pregnancy following levonorgestrel is assumed to be 35 women per 1000, the chance of pregnancy following mid‐dose mifepristone would be between 16 and 29 women per 1000. </p> <p>Ulipristal acetate (UPA) was associated with fewer pregnancies than levonorgestrel (RR 0.59; 95% CI 0.35 to 0.99, 2 RCTs, n = 3448, I<sup>2</sup> = 0%, high‐quality evidence). </p> <p><i>Comparative effectiveness of different ECP doses</i> </p> <p>It was unclear whether there was any difference in pregnancy rate between single‐dose levonorgestrel (1.5 mg) and the standard two‐dose regimen (0.75 mg 12 hours apart) (RR 0.84, 95% CI 0.53 to 1.33, 3 RCTs, n = 6653, I<sup>2</sup> = 0%, moderate‐quality evidence). </p> <p>Mid‐dose mifepristone was associated with fewer pregnancies than low‐dose mifepristone (RR 0.73; 95% CI 0.55 to 0.97, 25 RCTs, n = 11,914, I<sup>2</sup> = 0%, high‐quality evidence). </p> <p><i>Comparative effectiveness of Cu‐IUD versus mifepristone</i> </p> <p>There was no conclusive evidence of a difference in the risk of pregnancy between the Cu‐IUD and mifepristone (RR 0.33, 95% CI 0.04 to 2.74, 2 RCTs, n = 395, low‐quality evidence). </p> <p><i>Adverse effects</i> </p> <p>Nausea and vomiting were the main adverse effects associated with emergency contraception. There is probably a lower risk of nausea (RR 0.63, 95% CI 0.53 to 0.76, 3 RCTs, n = 2186 , I<sup>2</sup> = 59%, moderate‐quality evidence) or vomiting (RR 0.12, 95% CI 0.07 to 0.20, 3 RCTs, n = 2186, I<sup>2</sup> = 0%, high‐quality evidence) associated with mifepristone than with Yuzpe. levonorgestrel is probably associated with a lower risk of nausea (RR 0.40, 95% CI 0.36 to 0.44, 6 RCTs, n = 4750, I<sup>2</sup> = 82%, moderate‐quality evidence), or vomiting (RR 0.29, 95% CI 0.24 to 0.35, 5 RCTs, n = 3640, I<sup>2</sup> = 78%, moderate‐quality evidence) than Yuzpe. Levonorgestrel users were less likely to have any side effects than Yuzpe users (RR 0.80, 95% CI 0.75 to 0.86; 1 RCT, n = 1955, high‐quality evidence). UPA users were more likely than levonorgestrel users to have resumption of menstruation after the expected date (RR 1.65, 95% CI 1.42 to 1.92, 2 RCTs, n = 3593, I<sup>2</sup> = 0%, high‐quality evidence). Menstrual delay was more common with mifepristone than with any other intervention and appeared to be dose‐related. Cu‐IUD may be associated with higher risks of abdominal pain than mifepristone (18 events in 95 women using Cu‐IUD versus no events in 190 women using mifepristone, low‐quality evidence). </p> </section> <section id="CD001324-sec-0007"> <h3 class="title" id="CD001324-sec-0007">Authors' conclusions</h3> <p>Levonorgestrel and mid‐dose mifepristone (25 mg to 50 mg) were more effective than Yuzpe regimen. Both mid‐dose (25 mg to 50 mg) and low‐dose mifepristone(less than 25 mg) were probably more effective than levonorgestrel (1.5 mg). Mifepristone low dose (less than 25 mg) was less effective than mid‐dose mifepristone. UPA may be more effective than levonorgestrel. </p> <p>Levonorgestrel users had fewer side effects than Yuzpe users, and appeared to be more likely to have a menstrual return before the expected date. UPA users were probably more likely to have a menstrual return after the expected date. Menstrual delay was probably the main adverse effect of mifepristone and seemed to be dose‐related. Cu‐IUD may be associated with higher risks of abdominal pain than ECPs. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001324-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001324-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001324-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001324-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001324-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001324-abs-0014">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD001324-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD001324-abs-0013">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001324-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD001324-abs-0010">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001324-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD001324-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD001324-abs-0017">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001324-abs-0004" lang="en"> <h3>Methods of emergency contraception</h3> <p><b>Review question</b> </p> <p>The aim of this Cochrane Review was to evaluate the effectiveness and safety of different methods of emergency contraception to prevent pregnancy following unprotected intercourse. </p> <p><b>Background</b> </p> <p>Emergency contraception (EC) is using a drug or copper intrauterine device (Cu‐IUD) to prevent pregnancy shortly after unprotected intercourse. Several interventions are available for EC. Information on the comparative effectiveness, safety and convenience of these methods is crucial for reproductive healthcare providers and the women they serve. Researchers in Cochrane collected and analyzed all relevant studies to answer this question. </p> <p><b>Study characteristics</b> </p> <p>We searched 10 English‐language and three Chinese‐language databases for published studies in any language, in February 2017. We also searched grey literature databases and websites and contacted experts and authors for eligible studies. Studies had to report information on interventions to prevent pregnancy after a single act of unprotected intercourse. We included 115 randomized controlled trials with 60,479 women in this review. Ninety‐two trials were conducted in China. The evidence is up‐to‐date to February 2017. </p> <p><b>Key results</b> </p> <p>The studies compared 25 different interventions of different types of emergency contraception. The studies showed the following. </p> <p>Levonorgestrel and mifepristone were more effective than Yuzpe regimen (estradiol‐levonorgestrel combination). Our findings suggest that if 29 women per 1000 become pregnant with Yuzpe, between 11 and 24 women per 1000 will do so with the levonorgestrel, and that if 25 women per 1000 become pregnant with Yuzpe, between one and 10 women per 1000 will do so with mifepristone. </p> <p>Mid‐dose mifepristone (25 mg to 50 mg) was probably more effective than levonorgestrel. Low‐dose mifepristone (less than 25 mg) was probably less effective than mid‐dose mifepristone, but both were more effective than levonorgestrel (two doses of 0.75 mg). Ulipristal acetate (UPA) was also more effective than levonorgestrel. </p> <p>Levonorgestrel users had fewer side effects than Yuzpe users, and might be more likely to resume menstruation before the expected date. UPA users were probably more likely to resume menstruation after the expected date. Menstrual delay was probably the main adverse effect of mifepristone and seemed to be dose‐related. Cu‐IUD may be associated with higher risks of abdominal pain than mifepristone. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence for the primary outcome (observed number of pregnancies) ranged from moderate to high, and for other outcomes ranged from very low to high. The main limitations were risk of bias (associated with poor reporting of methods), imprecision and inconsistency. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001324-sec-0203" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001324-sec-0203"></div> <h3 class="title" id="CD001324-sec-0204">Implications for practice</h3> <section id="CD001324-sec-0204"> <p>Levonorgestrel and mid‐dose mifepristone (25 mg to 50 mg) were more effective than Yuzpe regimen (estradiol‐levonorgestrel combination). Both mid‐dose (25 mg to 50 mg) and low‐dose mifepristone (less than 25 mg) were probably more effective than levonorgestrel (1.5 mg). Low‐dose mifepristone (less than 25 mg) was less effective than mid‐dose mifepristone. Ulipristal acetate (UPA) may be more effective than levonorgestrel. </p> <p>Levonorgestrel users had fewer side effects than Yuzpe users, and appeared to be more likely to have a menstrual return before the expected date. UPA users were probably more likely to have a menstrual return after the expected date. Menstrual delay was probably the main adverse effect of mifepristone and seemed to be dose‐related. Copper intrauterine device (Cu‐IUD) may be associated with higher risks of abdominal pain than emergency contraceptive pills (ECPs). </p> <p>Emergency contraception (EC) should be offered to all women requesting this service. Women should start the method as soon as possible to maximise effectiveness, preferably within 72 hours of intercourse. </p> </section> <h3 class="title" id="CD001324-sec-0205">Implications for research</h3> <section id="CD001324-sec-0205"> <p>In order to demonstrate the relative effectiveness of UPA against levonorgestrel more data are needed. The effectiveness of levonorgestrel, UPA and mifepristone in relation to time since unprotected intercourse is not confirmed and more studies are needed. Moreover, the effectiveness of Cu‐IUD for EC should be further evaluated. There is also a need to compare the effectiveness and safety of UPA and mifepristone (in countries where it is applicable) in order to provide evidence for clients and service providers. Studies are needed that investigate whether BMI influences the effectiveness of EC, and a review of the evidence on emergency contraception versus lactational amenorrhoea method would also be useful. Trial protocols should clearly state when equivalence is sought and trials should be powered accordingly. Most of the trials included in this review did not have sufficiently detailed reporting to enable satisfactory assessment of risk of bias. Future trials should report their methods in sufficient detail to allow this assessment. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001324-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001324-sec-0036"></div> <div class="table" id="CD001324-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Levonorgestrel compared to Yuzpe for emergency contraception</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Levonorgestrel compared to Yuzpe for emergency contraception</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population: W</b> omen seeking emergency contraception<br/> <b>Setting:</b> China (3), Italy (2), multinational (1); family planning clinics<br/> <b>Intervention:</b> Levonorgestrel<br/> <b>Comparison:</b> Yuzpe </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Yuzpe</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Levonorgestrel</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observed number of pregnancies (all women)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1,000<br/> (11 to 24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.57<br/> (0.39 to 0.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4750<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any side effect</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>681 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>545 per 1,000<br/> (511 to 586) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80<br/> (0.75 to 0.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1955<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ Nausea</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>447 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1,000<br/> (161 to 197) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.40<br/> (0.36 to 0.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4750<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ Vomiting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>254 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1,000<br/> (61 to 89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.29<br/> (0.24 to 0.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3640<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ Spotting/bleeding after treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1,000<br/> (119 to 210) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.82<br/> (1.37 to 2.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1614<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ Early</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>119 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>137 per 1,000<br/> (103 to 182) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.15<br/> (0.86 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1310<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ Delay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>103 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>127 per 1,000<br/> (99 to 162) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.23<br/> (0.96 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1988<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The quality of evidence was downgraded by one level for “inconsistency” because of high heterogeneity in the meta‐analysis </p> <p><sup>2</sup> The quality of evidence was downgraded by one level for “imprecision” because the 95% CI overlaps no effect and CI fails to exclude important benefit or important harm. </p> <p><sup>3</sup> The quality of evidence was downgraded by one level for “ serious risk of bias” associated with poor reporting of randomization methods </p> <p><sup>4</sup> The quality of evidence was downgraded by one level for “imprecision” because the total (cumulative) sample size is lower than the calculated optimal information size (OIS) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001324-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Mid‐dose mifepristone (25 mg‐50 mg) versus levonorgestrel 1.5 mg for emergency contraception</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mid‐dose mifepristone (25 mg‐50 mg) compared to levonorgestrel 1.5 mg for emergency contraception</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women seeking emergency contraception<br/> <b>Setting:</b> China (27); family planning clinics<br/> <b>Intervention:</b> mifepristone, mid‐dose (25 mg‐50 mg)<br/> <b>Comparison:</b> levonorgestrel 1.5 mg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with levonorgestrel 1.5 mg</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with mid‐dose mifepristone (25 mg‐50 mg)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observed number of pregnancies (all women)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/> (16 to 29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.61<br/> (0.45 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6052<br/> (27 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any side effect</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>202 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000<br/> (81 to 150) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.55<br/> (0.40 to 0.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4352<br/> (18 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effect ‐ nausea</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000<br/> (39 to 109) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.81<br/> (0.48 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>713<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effect ‐ vomiting</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effect ‐ spotting/bleeding after treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000<br/> (32 to 68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.61<br/> (0.42 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1796<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ early</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<br/> (47 to 97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.72<br/> (0.50 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1324<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ delay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>108 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000<br/> (117 to 166) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.29<br/> (1.09 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3615<br/> (17 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level for serious risk of bias associated with poor reporting of randomization methods.<br/> <sup>2</sup>We downgraded the quality of evidence by one level for inconsistency because of high heterogeneity in the meta‐analysis.<br/> <sup>3</sup>We downgraded the quality of evidence by one level for imprecision because the total (cumulative) sample size was lower than the calculated optimal information size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001324-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Low‐dose mifepristone (&lt; 25 mg) versus levonorgestrel 1.5 mg for emergency contraception</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Low‐dose mifepristone (&lt; 25 mg) versus levonorgestrel 1.5 mg for emergency contraception</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women seeking emergency contraception<br/> <b>Setting:</b> China (12), UK (1), multinational (1); family planning clinics<br/> <b>Intervention:</b> mifepristone, low dose (&lt; 25 mg)<br/> <b>Comparison:</b> levonorgestrel 1.5 mg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with levonorgestrel 1.5 mg</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with low‐dose mifepristone (&lt; 25 mg)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observed number of pregnancies (all women)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<br/> (10 to 20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.72<br/> (0.52 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8752<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any side effect</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>342 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1000<br/> (58 to 130) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.26<br/> (0.17 to 0.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>609<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effect ‐ nausea</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000<br/> (112 to 145) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95<br/> (0.84 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6384<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effect ‐ vomiting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000<br/> (8 to 41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.22<br/> (0.55 to 2.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6085<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effect ‐ spotting/bleeding after treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>284 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>173 per 1000<br/> (153 to 196) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.61<br/> (0.54 to 0.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4598<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ early</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000<br/> (64 to 108) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.45<br/> (0.35 to 0.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1800<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ delay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1000<br/> (98 to 131) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.70<br/> (1.48 to 1.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7520<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level for serious risk of bias associated with poor reporting of randomization methods.<br/> <sup>2</sup>We downgraded the quality of evidence by one level for imprecision because the total (cumulative) sample size was lower than the calculated optimal information size.<br/> <sup>3</sup>We downgraded the quality of evidence by one level for imprecision because the 95% CI overlaps no effect and CI fails to exclude important benefit or important harm.<br/> <sup>4</sup>We downgraded the quality of evidence by one level for inconsistency because of high heterogeneity in the meta‐analysis. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001324-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Mifepristone (all doses) versus Yuzpe for emergency contraception</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mifepristone (all doses) versus Yuzpe for emergency contraception</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women seeking emergency contraception<br/> <b>Setting:</b> UK (3); family planning clinics<br/> <b>Intervention:</b> mifepristone (all doses)<br/> <b>Comparison:</b> Yuzpe </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Yuzpe</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with mifepristone (all doses)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observed number of pregnancies (all women)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/> (1 to 10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.14<br/> (0.05 to 0.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2144<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any side effect</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>735 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>610 per 1000<br/> (566 to 647) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.83<br/> (0.77 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1693<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ nausea</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>424 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>267 per 1000<br/> (225 to 322) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.63<br/> (0.53 to 0.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2186<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ vomiting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/> (9 to 27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.12<br/> (0.07 to 0.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2186<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ abdominal pain</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>276 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1000<br/> (168 to 262) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.76<br/> (0.61 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ spotting/bleeding after treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ delay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>311 per 1000<br/> (253 to 381) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.83<br/> (2.30 to 3.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1924<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level for inconsistency because of high heterogeneity in the meta‐analysis.<br/> <sup>2</sup>We downgraded the quality of evidence by one level for imprecision because the total (cumulative) sample size was lower than the calculated optimal information size. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001324-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Ulipristal acetate (all doses) versus levonorgestrel for emergency contraception</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ulipristal acetate (all doses) versus levonorgestrel for emergency contraception</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women seeking emergency contraception<br/> <b>Setting:</b> multinational (2); family planning clinics<br/> <b>Intervention:</b> ulipristal acetate (all doses)<br/> <b>Comparison:</b> levonorgestrel </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with levonorgestrel</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ulipristal acetate (all doses)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observed number of pregnancies (all women)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000<br/> (8 to 22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.59<br/> (0.35 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3448<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any side effect</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ nausea</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000<br/> (74 to 112) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.14<br/> (0.93 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3770<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ vomiting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/> (0 to 18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/> (0.14 to 7.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1549<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ spotting/bleeding after treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/> (2 to 20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.71<br/> (0.23 to 2.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1549<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ early</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>256 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000<br/> (95 to 128) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.43<br/> (0.37 to 0.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3593<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ delay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>208 per 1000<br/> (179 to 241) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.65<br/> (1.42 to 1.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3593<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level for imprecision because the 95% CI overlaps no effect and CI fails to exclude important benefit or important harm.<br/> <sup>2</sup>We downgraded the quality of evidence by one level for imprecision because the total (cumulative) sample size is lower than the calculated optimal information size.<br/> <sup>3</sup>We downgraded the quality of evidence by one level for inconsistency because of high heterogeneity in the meta‐analysis. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001324-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Single‐dose levonorgestrel versus split‐dose levonorgestrel for emergency contraception</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Single‐dose levonorgestrel versus split‐dose levonorgestrel for emergency contraception</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women seeking emergency contraception<br/> <b>Setting:</b> multinational (3); family planning clinics<br/> <b>Intervention</b> : levonorgestrel, single‐dose<br/> <b>Comparison</b>: levonorgestrel, split‐dose </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with split‐dose levonorgestrel</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with single‐dose levonorgestrel</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observed number of pregnancies (all women)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (6 to 16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.84<br/> (0.53 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6653<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any side effect</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ nausea</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>195 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 per 1000<br/> (171 to 208) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.97<br/> (0.88 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6804<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ vomiting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000<br/> (48 to 70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01<br/> (0.83 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6804<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ spotting/bleeding after treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>313 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>313 per 1000<br/> (282 to 351) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/> (0.90 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2720<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ early</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>299 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000<br/> (162 to 245) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.67<br/> (0.54 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1118<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ delay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000<br/> (74 to 112) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.18<br/> (0.96 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3784<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level for imprecision because the 95% CI overlaps no effect and CI fails to exclude important benefit or important harm.<br/> <sup>2</sup>We downgraded the quality of evidence by one level for inconsistency because of high heterogeneity in the meta‐analysis. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001324-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Mid‐dose mifepristone (25 mg‐50 mg) versus low‐dose mifepristone (&lt; 25 mg) for emergency contraception</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mid‐dose mifepristone (25 mg‐50 mg) versus low‐dose mifepristone (&lt; 25 mg) for emergency contraception</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women seeking emergency contraception<br/> <b>Setting:</b> China (25); family planning clinics<br/> <b>Intervention:</b> mifepristone, mid‐dose (25 mg‐50 mg)<br/> <b>Comparison:</b> mifepristone, low‐doses (&lt; 25 mg) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with low‐dose mifepristone<br/> (&lt; 25 mg)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with mid‐dose mifepristone<br/> (25 mg‐50 mg)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observed number of pregnancies (all women)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/> (9 to 16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.73<br/> (0.55 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11914<br/> (25 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any side effect</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115 per 1000<br/> (89 to 149) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.31<br/> (1.01 to 1.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2464<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ nausea</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>114 per 1000<br/> (100 to 128) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.10<br/> (0.97 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7948<br/> (13 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ vomiting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (4 to 13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.22<br/> (0.68 to 2.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6082<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ spotting/bleeding after treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>127 per 1000<br/> (107 to 151) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.85<br/> (1.55 to 2.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5078<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ early</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000<br/> (103 to 160) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.09<br/> (0.87 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2136<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ delay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>117 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1000<br/> (130 to 172) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.28<br/> (1.11 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11282<br/> (21 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level for risk of bias because we judged allocation concealment to be inadequate in the meta‐analysis.<br/> <sup>2</sup>We downgraded the quality of evidence by one level for imprecision because the 95% CI overlaps no effect and CI fails to exclude important benefit or important harm.<br/> <sup>3</sup>We downgraded the quality of evidence by one level for inconsistency because of high heterogeneity in the meta‐analysis. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001324-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Copper intrauterine device versus mifepristone (all doses) for emergency contraception</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Copper intrauterine device versus mifepristone (all doses) for emergency contraception</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population: w</b> omen seeking emergency contraception<br/> <b>Setting:</b> China (2); family planning clinics<br/> <b>Intervention:</b> copper intrauterine device<br/> <b>Comparison:</b> mifepristone (all doses) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with mifepristone<br/> (all doses)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with copper intrauterine device</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observed number of pregnancies (all women)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/> (0 to 34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33<br/> (0.04 to 2.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>395<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any side effect</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/> (0 to 83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.06<br/> (0.00 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ nausea</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ vomiting</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ lower abdominal pain</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 73.61<br/> (4.48 to 1208.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ spotting/bleeding after treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ delay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000<br/> (16 to 115) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.23<br/> (0.09 to 0.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>284<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level for serious risk of bias associated with poor reporting of randomization method.<br/> <sup>2</sup>We downgraded the quality of evidence by one level for imprecision because the total (cumulative) sample size was lower than the calculated optimal information size. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001324-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001324-sec-0037"></div> <section id="CD001324-sec-0038"> <h3 class="title" id="CD001324-sec-0038">Description of the condition</h3> <p>Unwanted pregnancy is a common problem. Worldwide, over 40 million pregnancies end in abortion each year (<a href="./references#CD001324-bbs2-0240" title="SedghG , SinghS , ShahIH , AhmanE , HenshawSK , BankoleA . Induced abortion: incidence and trends worldwide from 1995 to 2008. Lancet2012;379(9816):625‐32. ">Sedgh 2012</a>; <a href="./references#CD001324-bbs2-0241" title="SedghG , SinghS , HussainR . Intended and unintended pregnancies worldwide in 2012 and recent trends. Studies in Family Planning2014;45(3):301‐14. ">Sedgh 2014</a>). The standard approach to this problem has been primary prevention (contraception), backed up by induced abortion. However, for a long time, 'contraception' has generally been understood to mean only anticipatory contraception. The definition of the primary prevention of unintended pregnancy could and should be expanded to include post hoc contraception (<a href="./references#CD001324-bbs2-0223" title="GrimesDA . Emergency contraception: expanding opportunities for primary prevention. New England Journal of Medicine1997;337:1078‐9. ">Grimes 1997</a>). </p> </section> <section id="CD001324-sec-0039"> <h3 class="title" id="CD001324-sec-0039">Description of the intervention</h3> <p>Emergency contraception (EC) is defined as the use of a drug or device as an emergency measure to prevent pregnancy after unprotected intercourse. From this definition it follows that methods of EC are used after coitus but before pregnancy occurs, and that they are intended as a back‐up for occasional use rather than a regular form of contraception (<a href="./references#CD001324-bbs2-0244" title="VanLookPFA , vonHertzenH . Emergency contraception. British Medical Bulletin1993;49:158‐70. ">Van Look 1993</a>). Although the terms 'morning after pill' and 'after‐sex pill' are also used to describe the same approach, these can cause confusion regarding the timing and purpose, and are best avoided. EC implies something not to be used routinely (there are far more effective methods for regular contraception) but which can still prevent pregnancy if other options have failed or regular contraception was not used (<a href="./references#CD001324-bbs2-0245" title="WebbA . Emergency contraception. Fertility Control Reviews1995;4:3‐7. ">Webb 1995</a>). </p> <p>To date, no contraceptive method is 100% reliable and few people use their method perfectly each time they have sexual intercourse, in particularly the short‐acting contraceptives like oral pills and condoms. Furthermore, EC is useful in cases of sexual assault. EC is especially important for outreach to the 4.6 million women at risk of pregnancy but not using a regular method by providing a bridge to use of an ongoing contraceptive method (<a href="./references#CD001324-bbs2-0243" title="TrussellJ , RaymondEG . Emergency contraception: a last chance to prevent unwanted pregnancy. April 2012. ec.princeton.edu/questions/ec‐review.pdf (accessed 3 June 2012). ">Trussell 2012</a>). </p> <p>EC is widely available in Western Europe and in China. However, use of this method is rising rapidly in low‐ and middle‐income countries. For example, the 2008 to 2009 Demographic and Health Survey (DHS) data showed that 22% of unmarried sexually active women in Albania had used EC. In Colombia, Kenya and Nigeria, according to data from DHS, 10% to 16% of unmarried, sexually active women used EC (<a href="./references#CD001324-bbs2-0227" title="International Consortium for Emergency Contraception (ICEC). Knowledge and ever used of emergency contraception in Latin America. www.cecinfo.org/custom‐content/uploads/UserFiles/File/DHS/Emergency%20Contraception%20in%20Latin%20America.pdf (Posted on April 25, 2011). ">ICEC 2012a</a>, <a href="./references#CD001324-bbs2-0228" title="ICEC . Knowledge and ever used of emergency contraception in Africa. www.cecinfo.org/custom‐content/uploads/UserFiles/File/DHS/Emergency%20Contraception%20in%20Africa.pdf (Posted on April 25, 2011). ">ICEC 2012b</a>, <a href="./references#CD001324-bbs2-0229" title="ICEC . Knowledge and ever used of emergency contraception in Europe and West Asia.. www.cecinfo.org/custom‐content/uploads/UserFiles/File/DHS/Emergency%20Contraception%20in%20Europe%20and%20West%20Asia.pdf (Posted on April 25, 2011). ">ICEC 2012c</a>). This proportion in Peru was 35% in 2010 (<a href="./references#CD001324-bbs2-0230" title="Instituto Nacional De Estadística E Informática (INEI) and ICF Macro. Peru: DHS, 2010 ‐ Final report continuous (2010). ORC Macro / Measure DHS+, May 2011. ">INEI 2011</a>). However, EC is largely under‐utilised in many other countries. Examining data from 45 countries surveyed between 2000 and 2012, in 16 countries, fewer than 10% of women aged 15 to 49 years had heard of EC; in 36 countries, the rate of use of EC was less than 3% among women who had ever had sex (<a href="./references#CD001324-bbs2-0238" title="PalermoT , BleckJ , WestleyE . Knowledge and use of emergency contraception: a multicountry analysis. International Perspectives on Sexual and Reproductive Health2014;40(2):79‐86. [DOI: 10.1363/4007914] ">Palermo 2014</a>). The low awareness of emergency contraceptive pills (ECPs) and the lack of access to EC may subject women to unsafe abortions, which contribute significantly to maternal mortality and morbidity. </p> <p>Although attempted throughout history, EC methods only started to become effective in the 1960s when hormonal regimens were first introduced. Following the introduction of high‐dose oestrogens, the so‐called Yuzpe regimen, involving the combined use of oestrogen (ethinyl oestradiol 100 μg) and progestogen (levonorgestrel 0.5 mg or dl‐norgestrel 1 mg), repeated once 12 hours apart, with the first dose given within 72 hours of unprotected intercourse, became popular in the late 1970s and early 1980s (<a href="./references#CD001324-bbs2-0199" title="YuzpeAA , LanceeWJ . Ethinylestradiol and dl‐norgestrel as a postcoital contraceptive. Fertility and Sterility1977;28:932‐6. ">Yuzpe 1977</a>). </p> <p>Since the 1990s, there have been several different interventions available for EC (<a href="./references#CD001324-bbs2-0220" title="GlasierA . Emergency postcoital contraception. New England Journal of Medicine1997;337:1058‐64. ">Glasier 1997</a>). Interest in the development of alternative regimens has led to trials of the progestogen levonorgestrel, the anti‐gonadotropin danazol, and the anti‐progestins mifepristone and ulipristal acetate (UPA) (<a href="./references#CD001324-bbs2-0243" title="TrussellJ , RaymondEG . Emergency contraception: a last chance to prevent unwanted pregnancy. April 2012. ec.princeton.edu/questions/ec‐review.pdf (accessed 3 June 2012). ">Trussell 2012</a>). Like the Yuzpe regimen, these methods are recommended for use within 72 hours of unprotected intercourse although levonorgestrel and mifepristone had been tested up to 120 hours (five days) after unprotected intercourse, for research purposes <a href="./references#CD001324-bbs2-0029" title="GlasierAF , CameronST , FinePM , LoganSJ , CasaleW , VanHornJ , et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non‐inferiority trial and meta‐analysis. Lancet2010;375(9714):555‐62. ">Glasier 2010</a>. The postcoital insertion of a copper intrauterine device (Cu‐IUD) is an option that can be used up to five days after the estimated time of ovulation and can be left in the uterus as a long‐term regular contraceptive method. </p> <p>The main side effects caused by hormonal emergency contraceptives are nausea and vomiting, which seem to be more frequent with oestrogen‐containing regimens such as Yuzpe regimen and high‐dose oestrogen alone compared to progestogen or anti‐progestogen treatment. Mifepristone can cause menstrual delay, while levonorgestrel may cause earlier menses. IUD insertion can cause discomfort and requires trained staff and facilities. It is generally recommended that the Cu‐IUD be avoided in women at high risk of sexually transmitted diseases. </p> </section> <section id="CD001324-sec-0040"> <h3 class="title" id="CD001324-sec-0040">How the intervention might work</h3> <p>EC can prevent pregnancy after unprotected intercourse but it does not always work effectively. Many factors may affect the effectiveness of EC, and different methods of EC may have different effectiveness. The risk of failure of a less effective method of EC is the major factor to be taken into account when estimating the risk of pregnancy. </p> <p>For all ECs, the risk of pregnancy is related to the cycle day of intercourse. Women who have intercourse the day before estimated day of ovulation have a fourfold increased risk of pregnancy (odds ratio (OR) 4.42, 95% confidence interval (CI), 2.33 to 8.20; P &lt; 0.0001) compared with women having sex outside the fertile window (<a href="./references#CD001324-bbs2-0221" title="GlasierA , CameronST , BlitheD , ScherrerB , MatheH , LevyD , et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception2011;84:363‐7. ">Glasier 2011</a>). Time elapsed since intercourse (coitus‐treatment interval) and further acts of intercourse during the same cycle in which EC was used are two other factors affecting the success of EC. It is suggested that emergency contraception may be less effective among obese women, though clinical data are sparse (<a href="./references#CD001324-bbs2-0231" title="JatlaouiTC , CurtisKM . Safety and effectiveness data for emergency contraceptive pills among women with obesity: a systematic review. Contraception2016;94:605‐11. ">Jatlaoui 2016a</a>). This is biologically plausible, as there is evidence that among women taking the same dose of levonorgestrel, the serum concentration of levonorgestrel is 50% lower in those who are obese (BMI of 30 kg/m<sup>2</sup> or more) than in those with a normal or low BMI (less than 25 kg/m<sup>2</sup>) (<a href="./references#CD001324-bbs2-0216" title="EdelmanAB , CheralaG , BlueSW , EriksonDW , JensenJT . Impact of obesity on the pharmacokinetics of levonorgestrel‐based emergency contraception: single and double dosing. Contraception2016;94:52‐7. ">Edelman 2016</a>). </p> <p>Levonorgestrel is used in ECPs, both in a combined Yuzpe regimen which includes estrogen, and as a levonorgestrel‐only method. The primary mechanism of action of levonorgestrel as a progestogen‐only emergency contraceptive pill is to prevent fertilisation by inhibition of ovulation (<a href="./references#CD001324-bbs2-0120" title="BracheV , CochonL , DeniaudM , CroxattoHB . Ulipristal acetate prevents ovulation more effectively than levonorgestral: analysis of pooled data from three randomized trials of emergency contraception regimens. Contraception2013;88(5):611‐8. ">Brache 2013</a>; <a href="./references#CD001324-bbs2-0218" title="Gemzell‐DanielssonK , MarionsL . Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception. Hum Reprod Update2004;10:341‐8. ">Gemzell‐Danielsson 2004</a>) and thickening of cervical mucus (<a href="./references#CD001324-bbs2-0234" title="LalitkumarPGL . Emergency contraception. Best Practice and Research: Clinical Endocrinology and Metabolism 27;1:91‐101. ">Lalitkumar 2013</a>). levonorgestrel can disrupt or inhibit ovulation in 96% of cycles if it is given in the presence of an ovarian follicle measuring 12 mm to 17 mm in diameter. Once the luteinising hormone (LH) surge has started levonorgestrel has no effect on ovulation. Review of the evidence suggests that levonorgestrel ECPs cannot prevent implantation of a fertilised egg. This explains the need to take levonorgestrel as soon as possible after intercourse, especially within 72 hours. </p> <p>Ulipristal acetate (UPA) is a selective progesterone receptor modulator and also works by delaying or inhibiting ovulation. UPA remains reasonably effective even if given after the LH surge has started, delaying ovulation in 79% of cycles at this time, while levonorgestrel delays ovulation in only 14% (and placebo in 10%). Once LH has reached its peak, UPA no longer has any effect on ovulation. When UPA is given before the start of the LH surge, follicle rupture is delayed or inhibited in 100% of cycles (<a href="./references#CD001324-bbs2-0213" title="BairdDT , CameronS , EversJLH , Gemzell‐DanielssonK , GlasierA , MoreauC , et al. Emergency contraception. Widely available and effective but disappointing as a public health intervention: a review. Hum Reprod2015;30(4):751‐60. ">Baird 2015</a>). UPA can be used up to 120 hours after intercourse (<a href="./references#CD001324-bbs2-0217" title="FineP , MatheH , GindeS , CullinsV , MorfesisJ , GainerE . Ulipristal acetate taken 48–120 hours after intercourse for emergency contraception.. Obstet Gynecol2010;115:257‐63. ">Fine 2010a</a>), but should be taken as soon as possible after intercourse (since if the woman has not yet ovulated, the longer she delays using EC the more likely she will be close to ovulation). </p> <p>Mifepristone, another selective progesterone receptor modulator, has an effect on the endometrium and can both inhibit implantation and induce abortion (<a href="./references#CD001324-bbs2-0218" title="Gemzell‐DanielssonK , MarionsL . Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception. Hum Reprod Update2004;10:341‐8. ">Gemzell‐Danielsson 2004</a>). </p> <p>The Cu‐IUD used for EC may prevent an oocyte from being fertilised if inserted before fertilisation has occurred but will also prevent implantation if it is inserted later (<a href="./references#CD001324-bbs2-0214" title="ClelandK , ZhuH , GoldstuckN , ChengL , TrussellJ . The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience.. Hum Reprod2012;27:1994‐2000. ">Cleland 2012</a>). </p> </section> <section id="CD001324-sec-0041"> <h3 class="title" id="CD001324-sec-0041">Why it is important to do this review</h3> <p>Information on the comparative effectiveness, safety and convenience of an EC method is crucial for reproductive healthcare providers and the women they serve. The present review aims to search systematically for, and combine, all evidence from randomized controlled trials (RCTs) and controlled clinical trials relating to the effectiveness of different EC methods in order to supply the best evidence currently available on which to base recommendations for clinical practice and further research. </p> <p>In the previous version of this Cochrane Review, 100 RCTs and 25 comparisons were included. The findings included evidence that intermediate‐dose mifepristone was superior to LNG and Yuzpe regimens and that low‐dose mifepristone and UPA might possibly be more effective than LNG. As this version of the review was published 5 years ago (2012), and failed to evaluate the quality of the evidence using GRADE methods, we considered that with more recent evidence and updated methods our conclusions might be changed. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001324-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001324-sec-0042"></div> <p>To determine which EC method following unprotected intercourse is the most effective, safe and convenient to prevent pregnancy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001324-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001324-sec-0043"></div> <section id="CD001324-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001324-sec-0045"> <h4 class="title">Types of studies</h4> <p>We considered RCTs comparing different EC methods, or comparing one method with expectant management or placebo for inclusion. The unit of randomization in all these studies was the individual. Only trials measuring clinical outcomes were considered for inclusion. </p> </section> <section id="CD001324-sec-0046"> <h4 class="title">Types of participants</h4> <p>Women with regular menses requesting EC following unprotected intercourse. Women attending clinics for 'once‐a‐month' contraception in the form of luteal phase contraceptives and menstrual regulation using mifepristone and prostaglandin analogues were not eligible for inclusion in this review. </p> </section> <section id="CD001324-sec-0047"> <h4 class="title">Types of interventions</h4> <p>To be included, the intervention had to be applied to women seeking EC following unprotected intercourse. Those studies in which similar interventions were used by women as regular postcoital contraception were not eligible. Comparisons of different delivery systems such as advance provision or over‐the‐counter delivery, and any kind of educational interventions, were not eligible for inclusion in this review. </p> <p>Trials evaluating the following interventions were included in this review:</p> <p> <ol id="CD001324-list-0001"> <li> <p>Any regimen versus no intervention/placebo. <i>Please note that this comparison is now considered unethical and is included only for completeness.</i> </p> </li> <li> <p>Hormonal ECPs: comparison of different regimens</p> </li> <li> <p>IUD compared with ECP</p> </li> </ol> </p> <p>Combination treatments and comparison of these with other treatments alone or in combination were considered for inclusion when such data were available, including different doses. </p> </section> <section id="CD001324-sec-0048"> <h4 class="title">Types of outcome measures</h4> <section id="CD001324-sec-0049"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD001324-list-0002"> <li> <p>Observed number of pregnancies (all women), including number of ectopic pregnancies (if reported) </p> </li> </ol> </p> </section> <section id="CD001324-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD001324-list-0003"> <li> <p>Side effects:</p> <ol id="CD001324-list-0004"> <li> <p>any side effect,</p> </li> <li> <p>nausea,</p> </li> <li> <p>vomiting,</p> </li> <li> <p>headache,</p> </li> <li> <p>dizziness,</p> </li> <li> <p>fatigue,</p> </li> <li> <p>breast tenderness,</p> </li> <li> <p>diarrhoea,</p> </li> <li> <p>spotting or bleeding,</p> </li> <li> <p>abdominal pain,</p> </li> <li> <p>others</p> </li> </ol> </li> <li> <p>Menses: early (return before the expected date), delayed (return after the expected date) </p> </li> </ol> </p> </section> </section> </section> <section id="CD001324-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all published and unpublished RCTs using the following search strategy, without language or date restriction and in consultation with the Information Specialists of both Cochrane Gynaecology and Fertility, and Cochrane Fertility Regulation. We identified relevant trials from electronic databases and other resources. </p> <section id="CD001324-sec-0052"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases, trials registers and websites from their inception to 22 February 2017. </p> <p> <ol id="CD001324-list-0005"> <li> <p>The Cochrane Central Register of Studies (CENTRAL; 2017, issue 2) via the Cochrane Register of Studies Online (CRSO) (<a href="./appendices#CD001324-sec-0209">Appendix 1</a>) </p> </li> <li> <p>English language electronic databases:</p> <ol id="CD001324-list-0006"> <li> <p>Ovid MEDLINE (from 1946 to 22 February 2017) (<a href="./appendices#CD001324-sec-0210">Appendix 2</a>); </p> </li> <li> <p>Ovid Embase (from 1980 to 22 February 2017) (<a href="./appendices#CD001324-sec-0211">Appendix 3</a>); </p> </li> <li> <p>Ovid PsycINFO (from 1806 to 22 February 2017) (<a href="./appendices#CD001324-sec-0212">Appendix 4</a>); and </p> </li> <li> <p>EBSCO CINAHL (from inception to 22 February 2017) (<a href="./appendices#CD001324-sec-0213">Appendix 5</a>). </p> </li> </ol> </li> <li> <p>We ran searches of other databases including:</p> <ol id="CD001324-list-0007"> <li> <p>the Database of Chinese Scientific Journals (from inception to February 2017) (左炔诺孕酮 or 米非司酮 or RU486 or UPA or ulipristal acetate or 乌利司他 or 醋酸优力司特 or 醋酸乌利司他 or Yuzpe or 紧急避孕药 or 毓婷 or 宫内节育器 or IUD or 环) and 紧急避孕 and (临床试验 or 随机对照 or 比较 or 对比) (<a href="./appendices#CD001324-sec-0214">Appendix 6</a>); </p> </li> <li> <p>Popline (inception to February 2017);</p> </li> <li> <p>LILACS (inception to February 2017);</p> </li> <li> <p>PubMed (inception to February 2017);</p> </li> </ol> </li> <li> <p>and the clinical trials registers (to 22 February 2017):</p> <ol id="CD001324-list-0008"> <li> <p><a href="https://www.clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> (<a href="./appendices#CD001324-sec-0215">Appendix 7</a>) </p> </li> <li> <p>The World Health Organization (WHO) International Clinical Trials Registry Platform search portal (<a href="http://apps.who.int/trialsearch/Default.aspx" target="_blank">ICTRP</a>) (<a href="./appendices#CD001324-sec-0215">Appendix 7</a>). </p> </li> </ol> </li> </ol> </p> <p>We combined the MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying RCTs, in Chapter 6, <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001324-bbs2-0235" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Lefebvre 2011</a>). We combined the Embase search with trial filters developed by the Scottish Intercollegiate Guidelines Network (<a href="http://www.sign.ac.uk/search-filters.html" target="_blank">SIGN</a>). </p> </section> <section id="CD001324-sec-0053"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD001324-list-0009"> <li> <p>World Health Organization (WHO) <a href="http://www.who.int/hrh/resources/en/" target="_blank">RESOURCES</a> (February 2017). We contacted HRP (Human Reproduction Program)/WHO to seek any published or unpublished trials we had missed. </p> </li> <li> <p><a href="http://ec.princeton.edu/worldwide/" target="_blank">Emergency Contraception Website</a> (February 2017). We checked the Emergency Contraception World Wide Web server operated by the Office of Population Research at Princeton University, USA, to identify any relevant publications. </p> </li> <li> <p>Pharmaceutical companies (February 2017). We contacted the pharmaceutical companies (Bayer, Beijing Zizhu Pharmaceutical Co., Biopharm Chemical Company, Gador SA, Gedeon Richter, Laboratoire HRA Pharma, Shanghai New Hualian Pharmaceutical Co., Shenyang No. 1 Pharmaceutical Co., Teva, Xianju Pharmaceutical Co.) that are marketing dedicated products for EC to check if they knew of any unpublished trials that were eligible for inclusion in the review. All Chinese companies, and Bayer, Laboratoire HRA Pharma, and Teva responded but they did not have information on, or knowledge of, other trials. </p> </li> <li> <p>Others (February 2017). We performed the usual steps in the searches of a systematic review, such as searching the reference lists of published articles and contacting investigators active in this area. </p> </li> </ol> </p> </section> </section> <section id="CD001324-sec-0054"> <h3 class="title" id="CD001324-sec-0054">Data collection and analysis</h3> <section id="CD001324-sec-0055"> <h4 class="title">Selection of studies</h4> <p>We initially checked the trials identified by our search strategy for duplicates and relevance for the review by looking at the titles and abstracts. If it was not possible to exclude a publication by looking at the title or the abstract, we retrieved the full paper. Two review authors independently selected trials for inclusion and resolved any differences by discussion and consultation of other review authors if needed. Trials were excluded if the loss to follow‐up was greater than 20%. There were no language preferences in the search or the selection of articles. </p> </section> <section id="CD001324-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>We systematically extracted data from each trial for the following variables.</p> <p> <ol id="CD001324-list-0010"> <li> <p>Intervention and control treatment. Because of the large variation in mifepristone doses, we categorised the doses arbitrarily (before data extraction) as high (more than 50 mg), mid (25 mg to 50 mg) and low (less than 25 mg). We also conducted separate meta‐analyses to validate our groupings of the different doses. </p> </li> <li> <p>Clinical outcomes: observed number of pregnancies, ectopic pregnancies, side effects (any, nausea, vomiting, headache, dizziness, fatigue, breast tenderness, spotting/bleeding, diarrhoea, others), timing of menses, coitus‐treatment interval, high‐/low‐risk behaviour. </p> </li> <li> <p>Methodology: random allocation techniques, blinding, post‐randomisation exclusions, loss to follow‐up. </p> </li> <li> <p>Demographics: type of healthcare setting, city, country, total number of women included, and inclusion and exclusion criteria. </p> </li> </ol> </p> <p>For articles written in English, two review authors independently carried out data extraction and another review author checked the data entry. </p> </section> <section id="CD001324-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the included studies for risk of bias using the Cochrane tool for assessing risk of bias (<a href="./references#CD001324-bbs2-0226" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>) to assess: selection (random sequence generation and allocation concealment); performance (blinding of participants and personnel); detection (blinding of outcome assessors); attrition (incomplete outcome data); reporting (selective reporting); and other bias. We assigned judgements as recommended in chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001324-bbs2-0226" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We resolved disagreements by discussion. We described all judgements fully and presented the conclusions in the 'Risk of bias' table, which we incorporated into the interpretation of review findings as part of the GRADE assessment of the evidence (Summary of findings tables) (<a href="./references#CD001324-sec-0244" title="">Characteristics of included studies</a>). </p> </section> <section id="CD001324-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>We used Review Manager 5 (RevMan5) (<a href="./references#CD001324-bbs2-0239" title="Nordic Cochrane Centre, The Cochrane Collabortion. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collabortion, 2014. ">RevMan 2014</a>) to calculate treatment effects using risk ratio (RR) estimates with 95% confidence intervals (CI). We used risk difference (RD) to analyze effects when there were very few or no events and the number of participants was large. We presented 95% CIs for all outcomes. </p> </section> <section id="CD001324-sec-0059"> <h4 class="title">Unit of analysis issues</h4> <p>Analysis was per woman.</p> </section> <section id="CD001324-sec-0060"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to extract data from all studies that would allow intention‐to‐treat (ITT) analysis. For outcomes with loss to follow‐up, the number of women with outcome data was taken as the denominator (available case analysis). In the levonorgestrel versus Yuzpe comparison and levonorgestrel versus mid‐dose mifepristone, we imputed outcomes for missing participants under two extreme scenarios (i.e. all missing in one arm had an event and all missing in the other arm did not have an event and vice versa). </p> </section> <section id="CD001324-sec-0061"> <h4 class="title">Assessment of heterogeneity</h4> <p>We reviewed heterogeneity in the setting, interventions, and outcomes of included studies in order to make a qualitative assessment of the extent to which the included studies were similar to each other. We examined the forest plots visually to assess the levels of heterogeneity. We considered meta‐analyses with a P value for the Chi<sup>2</sup> test of less than 0.1 to have considerable statistical heterogeneity (<a href="./references#CD001324-bbs2-0215" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). We used an I<sup>2</sup> statistic of 50% or more to quantify the level of statistical heterogeneity (<a href="./references#CD001324-bbs2-0225" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). </p> </section> <section id="CD001324-sec-0062"> <h4 class="title">Assessment of reporting biases</h4> <p>The comprehensive search strategy for this review helped to reduce the risk of reporting bias. If there were 10 or more studies in an analysis, we used a funnel plot to explore the possibility of small study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies). </p> </section> <section id="CD001324-sec-0063"> <h4 class="title">Data synthesis</h4> <p>We performed meta‐analysis using a fixed‐effect model, where two or more trials with suitable data and homogeneity existed (I<sup>2</sup> greater than 50%). In case of heterogeneity (P &lt; 0.10), we used the random‐effects model to produce summary estimates (except when heterogeneity occurred in subgroup analyses where it was not possible to conduct separate analyses). </p> <p>We planned to make the following comparisons.</p> <p> <ol id="CD001324-list-0011"> <li> <p>Any regimen versus no intervention/placebo</p> </li> <li> <p>Hormonal ECPs: comparison of different regimens</p> <ol id="CD001324-list-0012"> <li> <p>levonorgestrel versus Yuzpe</p> </li> <li> <p>levonorgestrel versus anordrin</p> </li> <li> <p>mifepristone versus levonorgestrel</p> </li> <li> <p>mifepristone versus Yuzpe</p> </li> <li> <p>mifepristone versus anordrin</p> </li> <li> <p>mifepristone versus mifepristone + anordrin</p> </li> <li> <p>mifepristone versus mifepristone + misoprostol</p> </li> <li> <p>mifepristone versus mifepristone + tamoxifen</p> </li> <li> <p>mifepristone versus mifepristone + methotrexate</p> </li> <li> <p>mifepristone versus danazol</p> </li> <li> <p>mifepristone versus gestrinone</p> </li> <li> <p>High‐dose oestrogen versus Yuzpe</p> </li> <li> <p>danazol versus Yuzpe</p> </li> <li> <p>UPA versus levonorgestrel</p> </li> <li> <p>drug/dose comparisons</p> </li> <li> <p>others</p> </li> </ol> </li> <li> <p>IUD comparisons to ECPs</p> </li> </ol> </p> <p>We have produced 'Summary of findings' tables to present each outcome for the main comparisons. </p> <section id="CD001324-sec-0064"> <h5 class="title">Assessment of quality of evidence</h5> <p>Two review authors independently rated the overall quality of evidence (high, moderate, low or very low) for each of our seven main outcomes using the GRADE system, with any disagreements resolved via consensus or, if required, by consulting a third review author (<a href="./references#CD001324-bbs2-0222" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 15 March 2017. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a>). </p> <p>The GRADE system defines the quality of the body of evidence for each review outcome regarding the extent to which one can be confident in the review findings. GRADE criteria include: </p> <p> <ol id="CD001324-list-0013"> <li> <p>risk of bias;</p> </li> <li> <p>consistency of effect;</p> </li> <li> <p>imprecision;</p> </li> <li> <p>indirectness; and</p> </li> <li> <p>publication bias.</p> </li> </ol> </p> <p>With respect to assessment of imprecision, we made the judgement based on published guidance for the use of GRADE (<a href="./references#CD001324-bbs2-0224" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. ">Guyatt 2011</a>). </p> <p> <ol id="CD001324-list-0014"> <li> <p>"If the optimal information size (OIS) criterion is not met, rate down for imprecision, unless the sample size is very large (at least 2,000 and perhaps 4,000 patients)" </p> </li> <li> <p>"If the OIS criterion is met and the 95% CI excludes no effect (i.e. CI around RR excludes 1.0) precision adequate" </p> </li> <li> <p>"If OIS is met, and CI overlaps no effect (i.e. CI includes RR of 1.0) rate down if CI fails to exclude important benefit or important harm." </p> </li> </ol> </p> <p>If there were very few or no events and the number of participants was large, we made judgements about imprecision based on the absolute (rather than the relative) effect measures. Wide CIs around a relative risk effect estimate may translate to clinically small differences in absolute effects. We consulted Figure five in <a href="./references#CD001324-bbs2-0224" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology2011;64(12):1283‐93. ">Guyatt 2011</a> to estimate the OIS, as an alternative to calculating the OIS. For comparisons in which most of the studies failed to provide adequate details of their randomization methods, we did not downgrade the evidence for risk of bias if the analysis also included a large study at low risk of bias which had findings consistent with the smaller studies. </p> <p>We used the four <a href="./references#CD001324-bbs2-0222" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 15 March 2017. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a> quality ratings to describe the quality of the body of evidence for each outcome and we included these in the 'Summary of findings' table: </p> <p> <ol id="CD001324-list-0015"> <li> <p><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect </p> </li> <li> <p><b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different </p> </li> <li> <p><b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect </p> </li> <li> <p><b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </li> </ol> </p> <p>There are eight main comparisons in our review (levonorgestrel versus Yuzpe, levonorgestrel single versus split dose, mifepristone mid‐dose versus levonorgestrel, mifepristone low‐dose versus levonorgestrel, UPA versus levonorgestrel, mifepristone mid‐dose versus mifepristone low‐dose, mifepristone versus Yuzpe, Cu‐IUD versus mifepristone). For each comparison, the primary outcome measure was the pregnancy rate in women receiving different regimens (or control). Each of the 'Summary of findings' tables lists the following seven outcomes. </p> <p> <ol id="CD001324-list-0016"> <li> <p>Observed number of pregnancies (all women)</p> </li> <li> <p>Any side effect</p> </li> <li> <p>Specific side effects ‐ nausea</p> </li> <li> <p>Specific side effects ‐ vomiting</p> </li> <li> <p>Specific side effects ‐ spotting/bleeding after treatment</p> </li> <li> <p>Specific side effects ‐ abdominal pain</p> </li> <li> <p>Menses ‐ early/delayed</p> </li> </ol> </p> <p>We justified, documented, and incorporated judgements into reporting of results for each outcome, describing our reasons for downgrading in particular. </p> </section> </section> <section id="CD001324-sec-0065"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Several factors may affect the success of EC and we considered subgroup analyses when there were sufficient data in an appropriate format to allow such analyses. We considered the following categories for subgroup analyses. </p> <p> <ol id="CD001324-list-0017"> <li> <p>Time elapsed since intercourse (coitus‐treatment interval)</p> <ol id="CD001324-list-0018"> <li> <p>24 hours or less</p> </li> <li> <p>more than 24 hours to 48 hours</p> </li> <li> <p>more than 48 hours to 72 hours</p> </li> <li> <p>more than 72 hours to 120 hours</p> </li> <li> <p>more than 120 hours</p> </li> </ol> </li> <li> <p>Risk status</p> <ol id="CD001324-list-0019"> <li> <p>high‐risk: women who had further acts of intercourse during the same cycle in which EC was used </p> </li> <li> <p>low‐risk: women without further acts of coitus during that cycle</p> </li> </ol> </li> <li> <p>BMI</p> <ol id="CD001324-list-0020"> <li> <p>obese: BMI 30 kg/m<sup>2</sup> or above </p> </li> <li> <p>overweight: BMI 25 kg/m<sup>2</sup> to 30 kg/m<sup>2</sup> </p> </li> <li> <p>lower BMI: less than 25 kg/m<sup>2</sup> </p> </li> </ol> </li> </ol> </p> <p>We considered meta‐analyses with a P value for the Chi<sup>2</sup> test of less than 0.1 to have considerable statistical heterogeneity (<a href="./references#CD001324-bbs2-0215" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). We used an I<sup>2</sup> statistic of 50% or more to quantity the level of statistical heterogeneity (<a href="./references#CD001324-bbs2-0225" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). Where the I<sup>2</sup> statistic was over 50%, we considered whether there were any methodological or clinical differences between the studies that might explain the inconsistency in findings. </p> </section> <section id="CD001324-sec-0066"> <h4 class="title">Sensitivity analysis</h4> <p>No sensitivity analyses were planned.</p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001324-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001324-sec-0067"></div> <section id="CD001324-sec-0068"> <h3 class="title">Description of studies</h3> <section id="CD001324-sec-0069"> <h4 class="title">Results of the search</h4> <p>We included 115 studies with 60,479 women in this review (<a href="#CD001324-fig-0001">Figure 1</a>). Ninety‐two trials were conducted in China. All Chinese trials were relatively recent (earliest trial published in 1993) indicating the interest in EC research in China. Except for the <a href="./references#CD001324-bbs2-0022" title="EllertsonC , WebbA , BlanchardK , BigriggA , HaskellS , ShochetT , et al. Modifying the Yuzpe regimen of emergency contraception: a multicenter randomized controlled trial. Obstetrics and Gynecology2003;101:1160‐7. ">Ellertson 2003a</a>, <a href="./references#CD001324-bbs2-0029" title="GlasierAF , CameronST , FinePM , LoganSJ , CasaleW , VanHornJ , et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non‐inferiority trial and meta‐analysis. Lancet2010;375(9714):555‐62. ">Glasier 2010</a>; <a href="./references#CD001324-bbs2-0077" title="vonHertzenH , PiaggioG , DingJ , ChenJ , SongS , BartfaiG , et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception. Lancet2002;360:1803‐10. ">von Hertzen 2002</a>; <a href="./references#CD001324-bbs2-0090" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet1998;352:428‐33. ">WHO 1998</a>; <a href="./references#CD001324-bbs2-0091" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet1999;353:697‐702. ">WHO 1999</a> trials, all had been conducted in a single country, although some were multicenter trials. WHO trials were multinational involving large numbers of diverse populations (see <a href="./references#CD001324-sec-0244" title="">Characteristics of included studies</a>). </p> <div class="figure" id="CD001324-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD001324-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>Three trials are ongoing, all of which are registered in <a href="https://www.clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> (<a href="./references#CD001324-bbs2-0210" title="NCT01539720 . Levonorgestrel intrauterine system for emergency contraception (LIFE). clinicaltrials.gov/show/NCT01539720 first received: 21 February, 2012. ">NCT01539720</a>; <a href="./references#CD001324-bbs2-0211" title="NCT02175030 . RAPID EC ‐ RCT assessing pregnancy with intrauterine devices for EC. clinicaltrials.gov/show/NCT02175030 first received: 23 June , 2014. ">NCT02175030</a>; <a href="./references#CD001324-bbs2-0212" title="NCT02577601 . Impact of combined hormonal contraceptives on UPA. clinicaltrials.gov/show/NCT02577601 first received: 5 August , 2015. ">NCT02577601</a>). They compared ulipristal acetate versus levonorgestrel IUS; Cu‐IUD versus levonorgestrel IUD; ulipristal acetate versus levonorgestrel/ethinyl estradiol birth control pill (see <a href="./references#CD001324-sec-0246" title="">Characteristics of ongoing studies</a>). </p> </section> <section id="CD001324-sec-0070"> <h4 class="title">Included studies</h4> <section id="CD001324-sec-0071"> <h5 class="title">Design</h5> <p>All the included studies were RCTs.</p> <p>We included <a href="./references#CD001324-bbs2-0003" title="AskalaniAH , Al‐SenityAM , Al‐AgizyHM , SalamHI , Al‐MasryGI , El‐SadekSM . Evaluation of copper T‐200 as a post‐coital contraceptive. Egyptian Journal of Obstetrics and Gynaecology1987;13:63‐6. ">Askalani 1987</a> in the review because random allocation was explicitly mentioned. Unfortunately, no other methodological details were available for this trial. One trial (<a href="./references#CD001324-bbs2-0087" title="WebbAM . Alternative treatments in oral postcoital contraception: interim results. Advances in Contraception1991;7:271‐9. WebbAMC , RussellJ , ElsteinM . Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. BMJ1992;305:927‐31. ">Webb 1992</a>) was stopped early for effectiveness reasons. Sixteen trials reported appropriate power calculations for the sample size (<a href="./references#CD001324-bbs2-0001" title="ArowojoluAO , OkewoleLA , AdekunleAO . Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians. Contraception2002;66:269‐73. ">Arowojolu 2002</a>; <a href="./references#CD001324-bbs2-0002" title="AshokPW , StalderC , WagaarachchiPT , FlettGM , MelvinL , TempletonA . A randomised study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception. BJOG2002;109:553‐60. ">Ashok 2002</a>; <a href="./references#CD001324-bbs2-0017" title="CreininMD , SchlaffW , ArcherDF , WanL , FrezieresR , TomasM , et al. Progesterone receptor modulator for emergency contraception. A randomized controlled trial. Obstetrics &amp; Gynecology2006;108:1089‐97. ">Creinin 2006</a>; <a href="./references#CD001324-bbs2-0018" title="DadaOA , GodfreyEM , PiaggioG , vonHertzenH , Nigerian Network for Reproductive Health Research and Training. A randomized, double‐blind, noninferiority study to compare two regimens of levonorgestrel for emergency contraception in Nigeria. Contraception2010;82(4):373‐8. ">Dada 2010</a>; <a href="./references#CD001324-bbs2-0022" title="EllertsonC , WebbA , BlanchardK , BigriggA , HaskellS , ShochetT , et al. Modifying the Yuzpe regimen of emergency contraception: a multicenter randomized controlled trial. Obstetrics and Gynecology2003;101:1160‐7. ">Ellertson 2003a</a>; <a href="./references#CD001324-bbs2-0029" title="GlasierAF , CameronST , FinePM , LoganSJ , CasaleW , VanHornJ , et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non‐inferiority trial and meta‐analysis. Lancet2010;375(9714):555‐62. ">Glasier 2010</a>; <a href="./references#CD001324-bbs2-0030" title="HamodaH , AshokPW , StalderC , FlettGMM , KennedyE , TempletonA . A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraception. Obstetrics &amp; Gynecology2004;104:1307‐13. ">Hamoda 2004</a>; <a href="./references#CD001324-bbs2-0037" title="HoseiniFS , EslamiM , AbbasiM , Noroozi FashkhamiF , BesharatiS . A randomized, controlled trial of levonorgestrel vs. the Yuzpe regimen as emergency contraception method among Iranian women. Iranian Journal of Public Health2013;42(10):1158‐66. ">Hoseini 2013</a>; <a href="./references#CD001324-bbs2-0058" title="NgaiSW , FanS , LiS , ChengL , DingJ , JingX , et al. A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraception. Human Reproduction2005;20:307‐11. ">Ngai 2005</a>; <a href="./references#CD001324-bbs2-0064" title="SangGW , ShaoQ , ZhangJ , ZhangM , ChenS , SongS , et al. A randomized multicentre clinical trial on different doses of mifepristone alone and in combination with anordrin as emergency contraception [不同剂量米非司酮及合并双炔失碳酯用于紧急避孕的多中心随机临床研究]. Chinese Journal of Obstetrics and Gynaecology1999;34(6):331‐4. ">Sang 1999</a>; <a href="./references#CD001324-bbs2-0077" title="vonHertzenH , PiaggioG , DingJ , ChenJ , SongS , BartfaiG , et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception. Lancet2002;360:1803‐10. ">von Hertzen 2002</a>; <a href="./references#CD001324-bbs2-0087" title="WebbAM . Alternative treatments in oral postcoital contraception: interim results. Advances in Contraception1991;7:271‐9. WebbAMC , RussellJ , ElsteinM . Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. BMJ1992;305:927‐31. ">Webb 1992</a>; <a href="./references#CD001324-bbs2-0090" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet1998;352:428‐33. ">WHO 1998</a>; <a href="./references#CD001324-bbs2-0091" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet1999;353:697‐702. ">WHO 1999</a>; <a href="./references#CD001324-bbs2-0094" title="WuS , DongJ , CongJ , WangCP , vonHertzenH , GodfreyEM . Gestrinone compared with mifepristone for emergency contraception: a randomized controlled trial. Obstetrics and Gynecology2010;115(4):740‐4. ">Wu 2010</a>; <a href="./references#CD001324-bbs2-0095" title="XiaoBL , vonHertzenH , PiaggioG . A randomized double‐blind comparison of two single doses of mifepristone for emergency contraception. Human Reproduction2002;17:3084‐9. ">Xiao 2002</a>). </p> </section> <section id="CD001324-sec-0072"> <h5 class="title">Participants</h5> <p>The inclusion and exclusion criteria were similar with some minor differences between trials. In general, women attending after 72 hours (after 120 hours in Cu‐IUD, some mifepristone and levonorgestrel trials), with multiple episodes of unprotected intercourse, with irregular menstrual periods and those using hormonal contraception were excluded. All trials except <a href="./references#CD001324-bbs2-0064" title="SangGW , ShaoQ , ZhangJ , ZhangM , ChenS , SongS , et al. A randomized multicentre clinical trial on different doses of mifepristone alone and in combination with anordrin as emergency contraception [不同剂量米非司酮及合并双炔失碳酯用于紧急避孕的多中心随机临床研究]. Chinese Journal of Obstetrics and Gynaecology1999;34(6):331‐4. ">Sang 1999</a> started the intervention as soon as the women came to the clinic. <a href="./references#CD001324-bbs2-0064" title="SangGW , ShaoQ , ZhangJ , ZhangM , ChenS , SongS , et al. A randomized multicentre clinical trial on different doses of mifepristone alone and in combination with anordrin as emergency contraception [不同剂量米非司酮及合并双炔失碳酯用于紧急避孕的多中心随机临床研究]. Chinese Journal of Obstetrics and Gynaecology1999;34(6):331‐4. ">Sang 1999</a> included only women who had had unprotected intercourse 24 to 96 hours before attending the clinic. </p> </section> <section id="CD001324-sec-0073"> <h5 class="title">Interventions</h5> <p>Eighteen out of 115 trials had two or more treatment arms. Fifty‐six trials involved dose‐comparison studies of mifepristone in doses from 5 mg to 600 mg. Forty‐one trials compared levonorgestrel with mifepristone. Six trials compared levonorgestrel with the Yuzpe regimen. Three trials (<a href="./references#CD001324-bbs2-0001" title="ArowojoluAO , OkewoleLA , AdekunleAO . Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians. Contraception2002;66:269‐73. ">Arowojolu 2002</a>; <a href="./references#CD001324-bbs2-0018" title="DadaOA , GodfreyEM , PiaggioG , vonHertzenH , Nigerian Network for Reproductive Health Research and Training. A randomized, double‐blind, noninferiority study to compare two regimens of levonorgestrel for emergency contraception in Nigeria. Contraception2010;82(4):373‐8. ">Dada 2010</a>; <a href="./references#CD001324-bbs2-0077" title="vonHertzenH , PiaggioG , DingJ , ChenJ , SongS , BartfaiG , et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception. Lancet2002;360:1803‐10. ">von Hertzen 2002</a>) compared a split dose with a single dose of levonorgestrel and one trial compared a 24‐hour with a 12‐hour double‐dose regimen of levonorgestrel. Two trials (<a href="./references#CD001324-bbs2-0017" title="CreininMD , SchlaffW , ArcherDF , WanL , FrezieresR , TomasM , et al. Progesterone receptor modulator for emergency contraception. A randomized controlled trial. Obstetrics &amp; Gynecology2006;108:1089‐97. ">Creinin 2006</a>; <a href="./references#CD001324-bbs2-0029" title="GlasierAF , CameronST , FinePM , LoganSJ , CasaleW , VanHornJ , et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non‐inferiority trial and meta‐analysis. Lancet2010;375(9714):555‐62. ">Glasier 2010</a>) compared UPA, a second‐generation progesterone receptor modulator, with levonorgestrel. One trial (<a href="./references#CD001324-bbs2-0094" title="WuS , DongJ , CongJ , WangCP , vonHertzenH , GodfreyEM . Gestrinone compared with mifepristone for emergency contraception: a randomized controlled trial. Obstetrics and Gynecology2010;115(4):740‐4. ">Wu 2010</a>) compared mifepristone with gestrinone. Other interventions were high‐dose oestrogen, danazol and Cu‐IUD. Anordrin is a steroid hormone with weak oestrogenic effects and is only used in China as a visiting‐contraceptive pill (a type of oral pill that is used for couples who do not cohabit but visit home for a short period. It can start at any day during a menstrual cycle, one pill a day continuing no less than 14 days). In Chinese EC trials, investigators used locally manufactured mifepristone and levonorgestrel. </p> <p>Two studies (<a href="./references#CD001324-bbs2-0068" title="SuW , ChuiJY , LiuP . A comparative study of IUCD with mifepristone and with levonorgestrel for emergency contraception [米非司酮、 左炔诺孕酮和IUCD用于紧急避孕的临床观察研究]. Journal of Baotou Medicine2001;25:24. ">Su 2001</a>; <a href="./references#CD001324-bbs2-0079" title="WangC , TianM , ChangY , ShaoM . A clinical comparative observation among copper IUD, lower dose mifepristone and levonorgestrel for emergency contraception [含铜IUD、小剂量米非司酮与左炔诺孕酮用于紧急避孕的临床比较观察]. Journal of Chinese Physician2000;2:271‐3. ">Wang 2000a</a>) had three treatment arms (levonorgestrel versus mifepristone versus Cu‐IUD) but the Cu‐IUD comparison was not randomized. Hence, we excluded this comparison and included only the mifepristone vs levonorgestrel comparison. </p> </section> <section id="CD001324-sec-0074"> <h5 class="title">Outcomes</h5> <p>Most of the trials reported observed number of pregnancies in comparison to expected number of pregnancies according to estimated probability of pregnancy on the day of the menstrual cycle when unprotected intercourse took place. This information is provided in the <a href="./references#CD001324-sec-0244" title="">Characteristics of included studies</a> table without a formal summary analysis. </p> <p>In general, side effects were assessed by women themselves on diary charts.</p> </section> </section> <section id="CD001324-sec-0075"> <h4 class="title">Excluded studies</h4> <p>For this update of the review we excluded 2454 records after initial screening (<a href="#CD001324-fig-0001">Figure 1</a>). We excluded 39 studies after examining 57 full‐text articles. Most of these were case‐series, reports without a comparison group, EC education or meta‐analysis. Six studies (<a href="./references#CD001324-bbs2-0127" title="DongSZ , WuSH . Comparing mifepristone, levonorgestrel and the copper IUD for emergency contraception: a report of 268 cases. Journal of Chinese Modern Gynecology and Obstetrics 4;2:127‐9. ">Dong 2007</a>; <a href="./references#CD001324-bbs2-0155" title="LiF , QianX , WuW . A comparative study of mifepristone with Cu‐IUD for emergency contraception. Journal of Practice Medicine2005;21:2313‐4. ">Li 2005a</a>; <a href="./references#CD001324-bbs2-0158" title="LiuY , ChenX . A comparative study of mifepristone with Cu‐IUD for emergency contraception. Journal of Qiqihar Medical College2002;23:890‐1. ">Liu 2002a</a>; <a href="./references#CD001324-bbs2-0183" title="TianQ . A comparative study of mifepristone with Cu‐IUD for emergency contraception. Journal of Henan Medical College for Staff and Workers2000;12:51. ">Tian 2000</a>; <a href="./references#CD001324-bbs2-0184" title="TurokDK , GurtcheffSE , HandleyE , SimonsenSE , SokC , MurphyP . A pilot study of the copper T380A IUD and oral levonorgestrel for emergency contraception. Contraception2010;82:520‐5. ">Turok 2010</a>; <a href="./references#CD001324-bbs2-0201" title="ZhangJ , JingX , WongL . Cu‐IUD versus mifepristone for emergency contraception. Chinese Journal of Obstetrics and Gynecology1999;34:569‐70. ">Zhang 1999a</a>) compared Cu‐IUDs versus mifepristone with or without levonorgestrel by informed choice (i.e. not randomly allocated). Two studies (<a href="./references#CD001324-bbs2-0166" title="PolakowFS . Levonorgestrel used for emergency contraception during lactation‐A prospective observational cohort study on maternal and infant safety. Journal of Maternal‐Fetal and Neonatal Medicine2013;26(3):219‐21. ">Polakow 2013</a>, <a href="./references#CD001324-bbs2-0178" title="ShaabanOM , HassenSG , NourSA , et al. Emergency contraceptive pills as a backup for lactational amenorrhea method (LAM) of contraception: a randomized controlled trial. Contraception2013;87:363‐369. ">Shaaban 2013</a>) compared EC with lactational amenorrhoea method (LAM) (see <a href="./references#CD001324-sec-0245" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD001324-sec-0076"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD001324-sec-0077"> <h4 class="title">Allocation</h4> <p>Twenty‐five trials (<a href="./references#CD001324-bbs2-0001" title="ArowojoluAO , OkewoleLA , AdekunleAO . Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians. Contraception2002;66:269‐73. ">Arowojolu 2002</a>; <a href="./references#CD001324-bbs2-0002" title="AshokPW , StalderC , WagaarachchiPT , FlettGM , MelvinL , TempletonA . A randomised study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception. BJOG2002;109:553‐60. ">Ashok 2002</a>; <a href="./references#CD001324-bbs2-0007" title="CarbonellJL , GarciaR , GonzalezA . Mifepristone 5 mg versus 10 mg for emergency contraception: double‐blinded randomized clinical trial. International Journal of Women's Health2015;7:95‐102. ">Carbonell 2015</a>; <a href="./references#CD001324-bbs2-0015" title="ChengL , TongCH , XiaoZH . Low doses of mifepristone for emergency postcoital contraception [不同剂量米非司酮用于紧急避孕的临床多中心研究]. Chinese Journal of Obstetrics and Gynaecology1999;6:335‐8. ">Cheng 1999a</a>; <a href="./references#CD001324-bbs2-0017" title="CreininMD , SchlaffW , ArcherDF , WanL , FrezieresR , TomasM , et al. Progesterone receptor modulator for emergency contraception. A randomized controlled trial. Obstetrics &amp; Gynecology2006;108:1089‐97. ">Creinin 2006</a>; <a href="./references#CD001324-bbs2-0018" title="DadaOA , GodfreyEM , PiaggioG , vonHertzenH , Nigerian Network for Reproductive Health Research and Training. A randomized, double‐blind, noninferiority study to compare two regimens of levonorgestrel for emergency contraception in Nigeria. Contraception2010;82(4):373‐8. ">Dada 2010</a>; <a href="./references#CD001324-bbs2-0022" title="EllertsonC , WebbA , BlanchardK , BigriggA , HaskellS , ShochetT , et al. Modifying the Yuzpe regimen of emergency contraception: a multicenter randomized controlled trial. Obstetrics and Gynecology2003;101:1160‐7. ">Ellertson 2003a</a>; <a href="./references#CD001324-bbs2-0029" title="GlasierAF , CameronST , FinePM , LoganSJ , CasaleW , VanHornJ , et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non‐inferiority trial and meta‐analysis. Lancet2010;375(9714):555‐62. ">Glasier 2010</a>; <a href="./references#CD001324-bbs2-0030" title="HamodaH , AshokPW , StalderC , FlettGMM , KennedyE , TempletonA . A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraception. Obstetrics &amp; Gynecology2004;104:1307‐13. ">Hamoda 2004</a>; <a href="./references#CD001324-bbs2-0035" title="HeCH , GuiYL , YangJ , WangBS , ZhengE , GaoES , et al. A randomized comparative study on mifepristone alone and in combination with tamoxifen for emergency contraception. Contraception2002;66:221‐4. ">He 2002</a>; <a href="./references#CD001324-bbs2-0037" title="HoseiniFS , EslamiM , AbbasiM , Noroozi FashkhamiF , BesharatiS . A randomized, controlled trial of levonorgestrel vs. the Yuzpe regimen as emergency contraception method among Iranian women. Iranian Journal of Public Health2013;42(10):1158‐66. ">Hoseini 2013</a>; <a href="./references#CD001324-bbs2-0051" title="LiuJL , LiuLH , LiKZ , LiuHL . Comparative study of the efficacy of low‐dose mifepristone and levonorgestrel on the emergency contraception [低剂量米非司酮与左旋18甲基炔谱酮紧急避孕临床效果观察]. Practical Preventive Medicine2000;7:126‐7. ">Liu 2000</a>; <a href="./references#CD001324-bbs2-0058" title="NgaiSW , FanS , LiS , ChengL , DingJ , JingX , et al. A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraception. Human Reproduction2005;20:307‐11. ">Ngai 2005</a>; <a href="./references#CD001324-bbs2-0060" title="QiY , ZhangJ , CaoY , ZhangZ . A comparative clinical trial on two low doses of mifepristone for emergency contraception [两种低剂量米非司酮用于紧急避孕随机对比临床观察]. Maternal and Child Health Care of China2000;15:701‐4. ">Qi 2000a</a>; <a href="./references#CD001324-bbs2-0076" title="VanSantenMR , HaspelsAA . A comparison of high‐dose estrogens versus low‐dose ethinylestradiol and norgestrel combination in postcoital interception: a study in 493 women. Fertility and Sterility1985;43:206‐13. VanSantenMR , HaspelsAA . Comparative randomized double‐blind study of high dosage ethinylestradiol versus ethinylestradiol and norgestrel combination in postcoital contraception. Acta Endocrinologica1982;99(suppl 246):2. ">Van Santen 1985a</a>; <a href="./references#CD001324-bbs2-0077" title="vonHertzenH , PiaggioG , DingJ , ChenJ , SongS , BartfaiG , et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception. Lancet2002;360:1803‐10. ">von Hertzen 2002</a>; <a href="./references#CD001324-bbs2-0081" title="WangSZ , HuangZK , LiS . Clinical trial of mifepristone in different dose for emergency contraception [不同剂量米非司酮用于紧急避孕的临床比较观察]. Chinese Journal of Practical Gynaecology and Obstetrics2001;9:534‐6. ">Wang 2001</a>; <a href="./references#CD001324-bbs2-0087" title="WebbAM . Alternative treatments in oral postcoital contraception: interim results. Advances in Contraception1991;7:271‐9. WebbAMC , RussellJ , ElsteinM . Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. BMJ1992;305:927‐31. ">Webb 1992</a>; <a href="./references#CD001324-bbs2-0090" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet1998;352:428‐33. ">WHO 1998</a>; <a href="./references#CD001324-bbs2-0091" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet1999;353:697‐702. ">WHO 1999</a>; <a href="./references#CD001324-bbs2-0092" title="WuS , WangC , WangY , ChengW , ZuoS , LiH , et al. A randomized, double‐blind, multicentre study on comparing levonorgestrel and mifepristone for emergency contraception [左炔诺孕酮和小剂量米非司酮用于紧急避孕的临床观察]. Chinese Journal of Obstetrics and Gynaecology1999;34:327‐30. ">Wu 1999a</a>; <a href="./references#CD001324-bbs2-0093" title="WuXZ , SaoJY , ChenCQ , YanY , FaYY , LiuJH , et al. A comparative study on methods for emergency contraception [两种紧急避孕方法比较性研究]. Reproduction &amp; Contraception (China)2002;22:152‐5. ">Wu 2002</a>; <a href="./references#CD001324-bbs2-0094" title="WuS , DongJ , CongJ , WangCP , vonHertzenH , GodfreyEM . Gestrinone compared with mifepristone for emergency contraception: a randomized controlled trial. Obstetrics and Gynecology2010;115(4):740‐4. ">Wu 2010</a>; <a href="./references#CD001324-bbs2-0111" title="ZhangH . A comparative clinical study on mifepristone with levonorgestrel for emergency contraception [左炔诺孕酮和米非司酮用于紧急避孕的临床观察]. Guide of China Medicine2012;10(26):576‐7. ">Zhang 2012</a>; <a href="./references#CD001324-bbs2-0115" title="ZuoSH , WuJ , LiuL , LiuJ , GaoY . A clinical trial on two low doses of mifepristone for emergency contraception [两种低剂量米非司酮用于房事后紧急避孕的临床研究]. Reproduction &amp; Contraception (China)1999;6:352‐6. ">Zuo 1999</a>) had detailed explanation of randomization and we rated them as low risk of bias (see 'Risk of bias' tables in <a href="./references#CD001324-sec-0244" title="">Characteristics of included studies</a>)<b>.</b> Most of the remaining trials had insufficient information on randomization and concealment of allocation, and only used terms such as 'randomly allocated', which we rated as unclear risk of bias (<a href="./references#CD001324-sec-0244" title="">Characteristics of included studies</a>; <a href="#CD001324-fig-0002">Figure 2</a>; <a href="#CD001324-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD001324-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD001324-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD001324-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD001324-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <p>We included <a href="./references#CD001324-bbs2-0003" title="AskalaniAH , Al‐SenityAM , Al‐AgizyHM , SalamHI , Al‐MasryGI , El‐SadekSM . Evaluation of copper T‐200 as a post‐coital contraceptive. Egyptian Journal of Obstetrics and Gynaecology1987;13:63‐6. ">Askalani 1987</a> in the review because they explicitly mentioned random allocation. Unfortunately, no other methodological details were available for this trial. One trial (<a href="./references#CD001324-bbs2-0087" title="WebbAM . Alternative treatments in oral postcoital contraception: interim results. Advances in Contraception1991;7:271‐9. WebbAMC , RussellJ , ElsteinM . Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. BMJ1992;305:927‐31. ">Webb 1992</a>) was stopped early for effectiveness reasons. Sixteen trials reported appropriate power calculations for the sample size (<a href="./references#CD001324-bbs2-0001" title="ArowojoluAO , OkewoleLA , AdekunleAO . Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians. Contraception2002;66:269‐73. ">Arowojolu 2002</a>; <a href="./references#CD001324-bbs2-0002" title="AshokPW , StalderC , WagaarachchiPT , FlettGM , MelvinL , TempletonA . A randomised study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception. BJOG2002;109:553‐60. ">Ashok 2002</a>; <a href="./references#CD001324-bbs2-0017" title="CreininMD , SchlaffW , ArcherDF , WanL , FrezieresR , TomasM , et al. Progesterone receptor modulator for emergency contraception. A randomized controlled trial. Obstetrics &amp; Gynecology2006;108:1089‐97. ">Creinin 2006</a>; <a href="./references#CD001324-bbs2-0018" title="DadaOA , GodfreyEM , PiaggioG , vonHertzenH , Nigerian Network for Reproductive Health Research and Training. A randomized, double‐blind, noninferiority study to compare two regimens of levonorgestrel for emergency contraception in Nigeria. Contraception2010;82(4):373‐8. ">Dada 2010</a>; <a href="./references#CD001324-bbs2-0022" title="EllertsonC , WebbA , BlanchardK , BigriggA , HaskellS , ShochetT , et al. Modifying the Yuzpe regimen of emergency contraception: a multicenter randomized controlled trial. Obstetrics and Gynecology2003;101:1160‐7. ">Ellertson 2003a</a>; <a href="./references#CD001324-bbs2-0029" title="GlasierAF , CameronST , FinePM , LoganSJ , CasaleW , VanHornJ , et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non‐inferiority trial and meta‐analysis. Lancet2010;375(9714):555‐62. ">Glasier 2010</a>; <a href="./references#CD001324-bbs2-0030" title="HamodaH , AshokPW , StalderC , FlettGMM , KennedyE , TempletonA . A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraception. Obstetrics &amp; Gynecology2004;104:1307‐13. ">Hamoda 2004</a>; <a href="./references#CD001324-bbs2-0037" title="HoseiniFS , EslamiM , AbbasiM , Noroozi FashkhamiF , BesharatiS . A randomized, controlled trial of levonorgestrel vs. the Yuzpe regimen as emergency contraception method among Iranian women. Iranian Journal of Public Health2013;42(10):1158‐66. ">Hoseini 2013</a>; <a href="./references#CD001324-bbs2-0058" title="NgaiSW , FanS , LiS , ChengL , DingJ , JingX , et al. A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraception. Human Reproduction2005;20:307‐11. ">Ngai 2005</a>; <a href="./references#CD001324-bbs2-0064" title="SangGW , ShaoQ , ZhangJ , ZhangM , ChenS , SongS , et al. A randomized multicentre clinical trial on different doses of mifepristone alone and in combination with anordrin as emergency contraception [不同剂量米非司酮及合并双炔失碳酯用于紧急避孕的多中心随机临床研究]. Chinese Journal of Obstetrics and Gynaecology1999;34(6):331‐4. ">Sang 1999</a>; <a href="./references#CD001324-bbs2-0077" title="vonHertzenH , PiaggioG , DingJ , ChenJ , SongS , BartfaiG , et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception. Lancet2002;360:1803‐10. ">von Hertzen 2002</a>; <a href="./references#CD001324-bbs2-0087" title="WebbAM . Alternative treatments in oral postcoital contraception: interim results. Advances in Contraception1991;7:271‐9. WebbAMC , RussellJ , ElsteinM . Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. BMJ1992;305:927‐31. ">Webb 1992</a>; <a href="./references#CD001324-bbs2-0090" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet1998;352:428‐33. ">WHO 1998</a>; <a href="./references#CD001324-bbs2-0091" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet1999;353:697‐702. ">WHO 1999</a>; <a href="./references#CD001324-bbs2-0094" title="WuS , DongJ , CongJ , WangCP , vonHertzenH , GodfreyEM . Gestrinone compared with mifepristone for emergency contraception: a randomized controlled trial. Obstetrics and Gynecology2010;115(4):740‐4. ">Wu 2010</a>; <a href="./references#CD001324-bbs2-0095" title="XiaoBL , vonHertzenH , PiaggioG . A randomized double‐blind comparison of two single doses of mifepristone for emergency contraception. Human Reproduction2002;17:3084‐9. ">Xiao 2002</a>). </p> </section> <section id="CD001324-sec-0078"> <h4 class="title">Blinding</h4> <p>Twenty‐three trials were reported as double‐blinded (<a href="./references#CD001324-bbs2-0001" title="ArowojoluAO , OkewoleLA , AdekunleAO . Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians. Contraception2002;66:269‐73. ">Arowojolu 2002</a>; <a href="./references#CD001324-bbs2-0007" title="CarbonellJL , GarciaR , GonzalezA . Mifepristone 5 mg versus 10 mg for emergency contraception: double‐blinded randomized clinical trial. International Journal of Women's Health2015;7:95‐102. ">Carbonell 2015</a>; <a href="./references#CD001324-bbs2-0017" title="CreininMD , SchlaffW , ArcherDF , WanL , FrezieresR , TomasM , et al. Progesterone receptor modulator for emergency contraception. A randomized controlled trial. Obstetrics &amp; Gynecology2006;108:1089‐97. ">Creinin 2006</a>; <a href="./references#CD001324-bbs2-0018" title="DadaOA , GodfreyEM , PiaggioG , vonHertzenH , Nigerian Network for Reproductive Health Research and Training. A randomized, double‐blind, noninferiority study to compare two regimens of levonorgestrel for emergency contraception in Nigeria. Contraception2010;82(4):373‐8. ">Dada 2010</a>; <a href="./references#CD001324-bbs2-0022" title="EllertsonC , WebbA , BlanchardK , BigriggA , HaskellS , ShochetT , et al. Modifying the Yuzpe regimen of emergency contraception: a multicenter randomized controlled trial. Obstetrics and Gynecology2003;101:1160‐7. ">Ellertson 2003a</a>; <a href="./references#CD001324-bbs2-0035" title="HeCH , GuiYL , YangJ , WangBS , ZhengE , GaoES , et al. A randomized comparative study on mifepristone alone and in combination with tamoxifen for emergency contraception. Contraception2002;66:221‐4. ">He 2002</a>; <a href="./references#CD001324-bbs2-0037" title="HoseiniFS , EslamiM , AbbasiM , Noroozi FashkhamiF , BesharatiS . A randomized, controlled trial of levonorgestrel vs. the Yuzpe regimen as emergency contraception method among Iranian women. Iranian Journal of Public Health2013;42(10):1158‐66. ">Hoseini 2013</a>; <a href="./references#CD001324-bbs2-0050" title="LinN , ChengW , YangY , ShaoL . A comparative study of mifepristone and LNG for emergency contraception [小剂量米非司酮与左旋18‐甲基炔诺酮单方用于紧急避孕的比较研究]. Tianjing Medical Journal2000;28:601‐3. ">Lin 2000</a>; <a href="./references#CD001324-bbs2-0051" title="LiuJL , LiuLH , LiKZ , LiuHL . Comparative study of the efficacy of low‐dose mifepristone and levonorgestrel on the emergency contraception [低剂量米非司酮与左旋18甲基炔谱酮紧急避孕临床效果观察]. Practical Preventive Medicine2000;7:126‐7. ">Liu 2000</a>; <a href="./references#CD001324-bbs2-0058" title="NgaiSW , FanS , LiS , ChengL , DingJ , JingX , et al. A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraception. Human Reproduction2005;20:307‐11. ">Ngai 2005</a>; <a href="./references#CD001324-bbs2-0060" title="QiY , ZhangJ , CaoY , ZhangZ . A comparative clinical trial on two low doses of mifepristone for emergency contraception [两种低剂量米非司酮用于紧急避孕随机对比临床观察]. Maternal and Child Health Care of China2000;15:701‐4. ">Qi 2000a</a>; <a href="./references#CD001324-bbs2-0076" title="VanSantenMR , HaspelsAA . A comparison of high‐dose estrogens versus low‐dose ethinylestradiol and norgestrel combination in postcoital interception: a study in 493 women. Fertility and Sterility1985;43:206‐13. VanSantenMR , HaspelsAA . Comparative randomized double‐blind study of high dosage ethinylestradiol versus ethinylestradiol and norgestrel combination in postcoital contraception. Acta Endocrinologica1982;99(suppl 246):2. ">Van Santen 1985a</a>; <a href="./references#CD001324-bbs2-0077" title="vonHertzenH , PiaggioG , DingJ , ChenJ , SongS , BartfaiG , et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception. Lancet2002;360:1803‐10. ">von Hertzen 2002</a>; <a href="./references#CD001324-bbs2-0081" title="WangSZ , HuangZK , LiS . Clinical trial of mifepristone in different dose for emergency contraception [不同剂量米非司酮用于紧急避孕的临床比较观察]. Chinese Journal of Practical Gynaecology and Obstetrics2001;9:534‐6. ">Wang 2001</a>; <a href="./references#CD001324-bbs2-0088" title="WeiRH . Low dose of mifepristone for emergency contraception ‐ 200 cases report [小剂量米非司酮用于紧急避孕200例的临床观察]. Shanghai Sheng Wu Yi Xue Gong Cheng Zha Zi2002;23:39‐42. ">Wei 2002a</a>; <a href="./references#CD001324-bbs2-0090" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet1998;352:428‐33. ">WHO 1998</a>; <a href="./references#CD001324-bbs2-0091" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet1999;353:697‐702. ">WHO 1999</a>; <a href="./references#CD001324-bbs2-0092" title="WuS , WangC , WangY , ChengW , ZuoS , LiH , et al. A randomized, double‐blind, multicentre study on comparing levonorgestrel and mifepristone for emergency contraception [左炔诺孕酮和小剂量米非司酮用于紧急避孕的临床观察]. Chinese Journal of Obstetrics and Gynaecology1999;34:327‐30. ">Wu 1999a</a>; <a href="./references#CD001324-bbs2-0093" title="WuXZ , SaoJY , ChenCQ , YanY , FaYY , LiuJH , et al. A comparative study on methods for emergency contraception [两种紧急避孕方法比较性研究]. Reproduction &amp; Contraception (China)2002;22:152‐5. ">Wu 2002</a>; <a href="./references#CD001324-bbs2-0094" title="WuS , DongJ , CongJ , WangCP , vonHertzenH , GodfreyEM . Gestrinone compared with mifepristone for emergency contraception: a randomized controlled trial. Obstetrics and Gynecology2010;115(4):740‐4. ">Wu 2010</a>; <a href="./references#CD001324-bbs2-0095" title="XiaoBL , vonHertzenH , PiaggioG . A randomized double‐blind comparison of two single doses of mifepristone for emergency contraception. Human Reproduction2002;17:3084‐9. ">Xiao 2002</a>; <a href="./references#CD001324-bbs2-0110" title="ZhangL , LaiL , DengX . Single and small dose of Mifepristone for emergency contraception of curative effect observe [单次小剂量米非司酮用于紧急避孕的疗效观察]. Journal of Gannan Medical College2005;3:328‐30. ">Zhang 2005</a>; <a href="./references#CD001324-bbs2-0115" title="ZuoSH , WuJ , LiuL , LiuJ , GaoY . A clinical trial on two low doses of mifepristone for emergency contraception [两种低剂量米非司酮用于房事后紧急避孕的临床研究]. Reproduction &amp; Contraception (China)1999;6:352‐6. ">Zuo 1999</a>) and two as single‐blinded (<a href="./references#CD001324-bbs2-0029" title="GlasierAF , CameronST , FinePM , LoganSJ , CasaleW , VanHornJ , et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non‐inferiority trial and meta‐analysis. Lancet2010;375(9714):555‐62. ">Glasier 2010</a>; <a href="./references#CD001324-bbs2-0064" title="SangGW , ShaoQ , ZhangJ , ZhangM , ChenS , SongS , et al. A randomized multicentre clinical trial on different doses of mifepristone alone and in combination with anordrin as emergency contraception [不同剂量米非司酮及合并双炔失碳酯用于紧急避孕的多中心随机临床研究]. Chinese Journal of Obstetrics and Gynaecology1999;34(6):331‐4. ">Sang 1999</a>) (<a href="./references#CD001324-sec-0244" title="">Characteristics of included studies</a>; <a href="#CD001324-fig-0002">Figure 2</a>; <a href="#CD001324-fig-0003">Figure 3</a>). </p> </section> <section id="CD001324-sec-0079"> <h4 class="title">Incomplete outcome data</h4> <p>ITT analysis was available (or possible) for the <a href="./references#CD001324-bbs2-0017" title="CreininMD , SchlaffW , ArcherDF , WanL , FrezieresR , TomasM , et al. Progesterone receptor modulator for emergency contraception. A randomized controlled trial. Obstetrics &amp; Gynecology2006;108:1089‐97. ">Creinin 2006</a>; <a href="./references#CD001324-bbs2-0029" title="GlasierAF , CameronST , FinePM , LoganSJ , CasaleW , VanHornJ , et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non‐inferiority trial and meta‐analysis. Lancet2010;375(9714):555‐62. ">Glasier 2010</a>; <a href="./references#CD001324-bbs2-0036" title="HoPC , KwanMSW . A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post‐coital contraception. Human Reproduction1993;8:389‐92. ">Ho 1993</a>; <a href="./references#CD001324-bbs2-0058" title="NgaiSW , FanS , LiS , ChengL , DingJ , JingX , et al. A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraception. Human Reproduction2005;20:307‐11. ">Ngai 2005</a>; <a href="./references#CD001324-bbs2-0090" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet1998;352:428‐33. ">WHO 1998</a>; <a href="./references#CD001324-bbs2-0091" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet1999;353:697‐702. ">WHO 1999</a>; <a href="./references#CD001324-bbs2-0095" title="XiaoBL , vonHertzenH , PiaggioG . A randomized double‐blind comparison of two single doses of mifepristone for emergency contraception. Human Reproduction2002;17:3084‐9. ">Xiao 2002</a> trials and not mentioned in the other studies. Thirty trials (<a href="./references#CD001324-bbs2-0001" title="ArowojoluAO , OkewoleLA , AdekunleAO . Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians. Contraception2002;66:269‐73. ">Arowojolu 2002</a>; <a href="./references#CD001324-bbs2-0002" title="AshokPW , StalderC , WagaarachchiPT , FlettGM , MelvinL , TempletonA . A randomised study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception. BJOG2002;109:553‐60. ">Ashok 2002</a>; <a href="./references#CD001324-bbs2-0007" title="CarbonellJL , GarciaR , GonzalezA . Mifepristone 5 mg versus 10 mg for emergency contraception: double‐blinded randomized clinical trial. International Journal of Women's Health2015;7:95‐102. ">Carbonell 2015</a>; <a href="./references#CD001324-bbs2-0009" title="ChenR , LiQ , ZhangY , HuangM , ChenY , ZhongX , et al. A comparative study of low‐dose mifepristone for emergency contraception [两种不同小剂量米非司酮用于紧急避孕的临床研究]. Shi Yong Yi Xue Zha Zi2002;10:1028‐9. ">Chen 2002a</a>; <a href="./references#CD001324-bbs2-0015" title="ChengL , TongCH , XiaoZH . Low doses of mifepristone for emergency postcoital contraception [不同剂量米非司酮用于紧急避孕的临床多中心研究]. Chinese Journal of Obstetrics and Gynaecology1999;6:335‐8. ">Cheng 1999a</a>; <a href="./references#CD001324-bbs2-0017" title="CreininMD , SchlaffW , ArcherDF , WanL , FrezieresR , TomasM , et al. Progesterone receptor modulator for emergency contraception. A randomized controlled trial. Obstetrics &amp; Gynecology2006;108:1089‐97. ">Creinin 2006</a>; <a href="./references#CD001324-bbs2-0019" title="DingG . Different doses of mifepristone for emergency contraception [不同剂量米非司酮用于紧急避孕的临床观察]. Journal of Practical Diagnosis and Therapy2005;19:226‐7. ">Ding 2005</a>; <a href="./references#CD001324-bbs2-0022" title="EllertsonC , WebbA , BlanchardK , BigriggA , HaskellS , ShochetT , et al. Modifying the Yuzpe regimen of emergency contraception: a multicenter randomized controlled trial. Obstetrics and Gynecology2003;101:1160‐7. ">Ellertson 2003a</a>; <a href="./references#CD001324-bbs2-0023" title="FanH , ChengY , GuoF , WuS , TanY , ChenX , et al. Low dose of mifepristone for emergency contraception. Hubei Yu Fang Yi Xue Zha Zi2001;23:52. ">Fan 2001a</a>; <a href="./references#CD001324-bbs2-0025" title="FarajkhodaT , KhoshbinA , EnjezabB , BokaeiM , Karimi ZarchiM . Assessment of two emergency contraceptive regimens in Iran: levonorgestrel versus the Yuzpe. Niger Journal of Clinical Practice2009;12(4):450‐2. ">Farajkhoda 2009</a>; <a href="./references#CD001324-bbs2-0028" title="GlasierA , ThongKJ , DewarM , MackieM , BairdD . Postcoital contraception with mifepristone (letter). Lancet1991;337:1414‐5. GlasierA , ThongKJ , DewarM , MackieM , BairdDT . Mifepristone (RU 486) compared with high‐dose estrogen and progestogen for emergency postcoital contraception. New England Journal of Medicine1992;327:1041‐4. ">Glasier 1992</a>; <a href="./references#CD001324-bbs2-0029" title="GlasierAF , CameronST , FinePM , LoganSJ , CasaleW , VanHornJ , et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non‐inferiority trial and meta‐analysis. Lancet2010;375(9714):555‐62. ">Glasier 2010</a>; <a href="./references#CD001324-bbs2-0030" title="HamodaH , AshokPW , StalderC , FlettGMM , KennedyE , TempletonA . A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraception. Obstetrics &amp; Gynecology2004;104:1307‐13. ">Hamoda 2004</a>; <a href="./references#CD001324-bbs2-0035" title="HeCH , GuiYL , YangJ , WangBS , ZhengE , GaoES , et al. A randomized comparative study on mifepristone alone and in combination with tamoxifen for emergency contraception. Contraception2002;66:221‐4. ">He 2002</a>; <a href="./references#CD001324-bbs2-0036" title="HoPC , KwanMSW . A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post‐coital contraception. Human Reproduction1993;8:389‐92. ">Ho 1993</a>; <a href="./references#CD001324-bbs2-0040" title="LaiZ , WangJ , ZhouZ , LuH , SongX , SunJ . A comparative study of low‐dose mifepristone for emergency contraception [低剂量米非司酮用于紧急避孕的临床观察]. Maternal and Child Health Care of China2004;19(2):36‐8. ">Lai 2004</a>; <a href="./references#CD001324-bbs2-0051" title="LiuJL , LiuLH , LiKZ , LiuHL . Comparative study of the efficacy of low‐dose mifepristone and levonorgestrel on the emergency contraception [低剂量米非司酮与左旋18甲基炔谱酮紧急避孕临床效果观察]. Practical Preventive Medicine2000;7:126‐7. ">Liu 2000</a>; <a href="./references#CD001324-bbs2-0058" title="NgaiSW , FanS , LiS , ChengL , DingJ , JingX , et al. A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraception. Human Reproduction2005;20:307‐11. ">Ngai 2005</a>; <a href="./references#CD001324-bbs2-0063" title="RowlandsS , GuillebaudJ , BoundsW , BoothM . Side effects of danazol compared with an ethinyloestradiol/norgestrel combination when used for postcoital contraception. Contraception1983;27:39‐49. RowlandsS , KubbaAA , GuillebaudJ , BoundsW . A possible mechanism of action of danazol and an ethinylestradiol/norgestrel combination used as postcoital contraceptive agents. Contraception1986;33:539‐45. ">Rowlands 1983</a>; <a href="./references#CD001324-bbs2-0064" title="SangGW , ShaoQ , ZhangJ , ZhangM , ChenS , SongS , et al. A randomized multicentre clinical trial on different doses of mifepristone alone and in combination with anordrin as emergency contraception [不同剂量米非司酮及合并双炔失碳酯用于紧急避孕的多中心随机临床研究]. Chinese Journal of Obstetrics and Gynaecology1999;34(6):331‐4. ">Sang 1999</a>; <a href="./references#CD001324-bbs2-0077" title="vonHertzenH , PiaggioG , DingJ , ChenJ , SongS , BartfaiG , et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception. Lancet2002;360:1803‐10. ">von Hertzen 2002</a>; <a href="./references#CD001324-bbs2-0082" title="WangY , LiuH . A comparative study on low doses of mifepristone with levonorgestrel for emergency contraception [左炔诺孕酮和小剂量米非司酮用于紧急避孕的临床观察]. Chinese Journal of Family Planning2003;8:505‐6. ">Wang 2003</a>; <a href="./references#CD001324-bbs2-0090" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet1998;352:428‐33. ">WHO 1998</a>; <a href="./references#CD001324-bbs2-0091" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet1999;353:697‐702. ">WHO 1999</a>; <a href="./references#CD001324-bbs2-0092" title="WuS , WangC , WangY , ChengW , ZuoS , LiH , et al. A randomized, double‐blind, multicentre study on comparing levonorgestrel and mifepristone for emergency contraception [左炔诺孕酮和小剂量米非司酮用于紧急避孕的临床观察]. Chinese Journal of Obstetrics and Gynaecology1999;34:327‐30. ">Wu 1999a</a>; <a href="./references#CD001324-bbs2-0093" title="WuXZ , SaoJY , ChenCQ , YanY , FaYY , LiuJH , et al. A comparative study on methods for emergency contraception [两种紧急避孕方法比较性研究]. Reproduction &amp; Contraception (China)2002;22:152‐5. ">Wu 2002</a>; <a href="./references#CD001324-bbs2-0094" title="WuS , DongJ , CongJ , WangCP , vonHertzenH , GodfreyEM . Gestrinone compared with mifepristone for emergency contraception: a randomized controlled trial. Obstetrics and Gynecology2010;115(4):740‐4. ">Wu 2010</a>; <a href="./references#CD001324-bbs2-0095" title="XiaoBL , vonHertzenH , PiaggioG . A randomized double‐blind comparison of two single doses of mifepristone for emergency contraception. Human Reproduction2002;17:3084‐9. ">Xiao 2002</a>; <a href="./references#CD001324-bbs2-0105" title="ZhangY , QiaoG , ZhuP , ZhangS , ZhangJ , ZhuN . Clinical observation of three lower doses of mifepristone for emergency contraception [三种低剂量米非司酮用于紧急避孕的临床观察]. Chinese Journal of Family Planning1998;6:343‐5. ">Zhang 1998</a>; <a href="./references#CD001324-bbs2-0115" title="ZuoSH , WuJ , LiuL , LiuJ , GaoY . A clinical trial on two low doses of mifepristone for emergency contraception [两种低剂量米非司酮用于房事后紧急避孕的临床研究]. Reproduction &amp; Contraception (China)1999;6:352‐6. ">Zuo 1999</a>) reported the number of lost follow‐up or post‐randomisation exclusions. The average proportion of loss to follow‐up or post‐randomisation exclusion was 3.3% (range 0.2% to 16.9%). Although several trials did not mention post‐randomisation exclusions, these studies did not explicitly mention ITT analyses either. As there were only a few reported pregnancies, it was possible that some pregnancies could well have been excluded after randomization (<a href="./references#CD001324-bbs2-0087" title="WebbAM . Alternative treatments in oral postcoital contraception: interim results. Advances in Contraception1991;7:271‐9. WebbAMC , RussellJ , ElsteinM . Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. BMJ1992;305:927‐31. ">Webb 1992</a>) (<a href="./references#CD001324-sec-0244" title="">Characteristics of included studies</a>; <a href="#CD001324-fig-0002">Figure 2</a>; <a href="#CD001324-fig-0003">Figure 3</a>). </p> </section> <section id="CD001324-sec-0080"> <h4 class="title">Selective reporting</h4> <p>We used a funnel plot to explore the possibility of reporting bias when the intervention included more than eight studies. Funnel plots for the primary outcomes (observed number of pregnancies) of the comparison between low‐dose mifepristone and levonorgestrel showed asymmetric features, indicating possible reporting bias. We rated all the other studies as at low risk of selective reporting bias. </p> </section> <section id="CD001324-sec-0081"> <h4 class="title">Other potential sources of bias</h4> <p>No other potential source of bias was identified and all studies were rated as at low risk in this domain. </p> </section> </section> <section id="CD001324-sec-0082"> <h3 class="title" id="CD001324-sec-0082">Effects of interventions</h3> <p>See: <a href="./full#CD001324-tbl-0001"><b>Summary of findings for the main comparison</b> Levonorgestrel compared to Yuzpe for emergency contraception</a>; <a href="./full#CD001324-tbl-0002"><b>Summary of findings 2</b> Mid‐dose mifepristone (25 mg‐50 mg) versus levonorgestrel 1.5 mg for emergency contraception</a>; <a href="./full#CD001324-tbl-0003"><b>Summary of findings 3</b> Low‐dose mifepristone (&lt; 25 mg) versus levonorgestrel 1.5 mg for emergency contraception</a>; <a href="./full#CD001324-tbl-0004"><b>Summary of findings 4</b> Mifepristone (all doses) versus Yuzpe for emergency contraception</a>; <a href="./full#CD001324-tbl-0005"><b>Summary of findings 5</b> Ulipristal acetate (all doses) versus levonorgestrel for emergency contraception</a>; <a href="./full#CD001324-tbl-0006"><b>Summary of findings 6</b> Single‐dose levonorgestrel versus split‐dose levonorgestrel for emergency contraception</a>; <a href="./full#CD001324-tbl-0007"><b>Summary of findings 7</b> Mid‐dose mifepristone (25 mg‐50 mg) versus low‐dose mifepristone (&lt; 25 mg) for emergency contraception</a>; <a href="./full#CD001324-tbl-0008"><b>Summary of findings 8</b> Copper intrauterine device versus mifepristone (all doses) for emergency contraception</a> </p> <section id="CD001324-sec-0083"> <h4 class="title">1. Any regimen versus no intervention/placebo</h4> <section id="CD001324-sec-0084"> <h5 class="title">1.1 IUD versus expectant management</h5> <p><a href="./references#CD001324-bbs2-0003" title="AskalaniAH , Al‐SenityAM , Al‐AgizyHM , SalamHI , Al‐MasryGI , El‐SadekSM . Evaluation of copper T‐200 as a post‐coital contraceptive. Egyptian Journal of Obstetrics and Gynaecology1987;13:63‐6. ">Askalani 1987</a> compared Cu‐IUD (Cu‐T 200) insertion with expectant management in women requesting EC within four days of unprotected intercourse. </p> <section id="CD001324-sec-0085"> <h6 class="title">1.1.1 Observed number of pregnancies</h6> <p>Notwithstanding the ethical aspects of this trial, the report was brief and only reported data on number of pregnancies. The evidence suggested a lower number of pregnancies in the IUD group (RR 0.09, 95% CI 0.03 to 0.26，1 RCT, n = 300) (<a href="./references#CD001324-fig-0007" title="">Analysis 1.1</a>). This indicated that IUD use would significantly decrease the number of pregnancies compared to expectant management, which suggests that if the observed number of pregnancies following expectant management is assumed to be 220 per 1000 women, the number following IUD would be between 7 to 57 per 1000 women. </p> </section> <section id="CD001324-sec-0086"> <h6 class="title">1.1.2 Side effects</h6> <p>No data were available.</p> </section> <section id="CD001324-sec-0087"> <h6 class="title">1.1.3. Effects on menses</h6> <p>No data were available.</p> </section> </section> </section> <section id="CD001324-sec-0088"> <h4 class="title">2. Hormonal ECPs: comparison of different regimens</h4> <section id="CD001324-sec-0089"> <h5 class="title">2.1 Levonorgestrel versus Yuzpe regimen</h5> <p>Six trials (three Chinese (<a href="./references#CD001324-bbs2-0036" title="HoPC , KwanMSW . A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post‐coital contraception. Human Reproduction1993;8:389‐92. ">Ho 1993</a>; <a href="./references#CD001324-bbs2-0067" title="Sheng SY . A clinical study of LNG‐COC for emergency contraception [复方左炔诺孕酮用于紧急避孕的临床观察]. Asia‐Pacific Traditional Medicine2008;4(9):93‐4. ">Sheng 2008</a>; <a href="./references#CD001324-bbs2-0071" title="Sun MX . A clinical comparative study of LNG vs. LNG‐COC for emergency contraception [左炔诺孕酮和复方短效避孕药用于紧急避孕的临床观察]. Chinese Journal of Family Planning2007;15(6):366‐7. ">Sun 2007</a>), two Iranian (<a href="./references#CD001324-bbs2-0025" title="FarajkhodaT , KhoshbinA , EnjezabB , BokaeiM , Karimi ZarchiM . Assessment of two emergency contraceptive regimens in Iran: levonorgestrel versus the Yuzpe. Niger Journal of Clinical Practice2009;12(4):450‐2. ">Farajkhoda 2009</a>; <a href="./references#CD001324-bbs2-0037" title="HoseiniFS , EslamiM , AbbasiM , Noroozi FashkhamiF , BesharatiS . A randomized, controlled trial of levonorgestrel vs. the Yuzpe regimen as emergency contraception method among Iranian women. Iranian Journal of Public Health2013;42(10):1158‐66. ">Hoseini 2013</a>) and one multinational (<a href="./references#CD001324-bbs2-0090" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet1998;352:428‐33. ">WHO 1998</a>)) compared the Yuzpe regimen with levonorgestrel 0.75 mg given twice, 12 hours apart. The six studies recruited a total of 4750 women. </p> <section id="CD001324-sec-0090"> <h6 class="title">2.1.1 Observed number of pregnancies</h6> <p>The levonorgestrel regimen was associated with fewer pregnancies than the Yuzpe regimen (RR 0.57, 95% CI 0.39 to 0.84, 6 RCTs, n = 4750, I<sup>2</sup> = 23%, high‐quality evidence) (<a href="#CD001324-fig-0004">Figure 4</a>; <a href="./references#CD001324-fig-0008" title="">Analysis 2.1</a>; <a href="./full#CD001324-tbl-0001">summary of findings Table for the main comparison</a>). The evidence suggests that if the chance of pregnancy using Yuzpe is assumed to be 29 per 1000 women, the chance of pregnancy using levonorgestrel would be between 11 to 24 per 1000 women. </p> <div class="figure" id="CD001324-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison 2.1: levonorgestrel versus Yuzpe, outcome 2.1.1 Observed number of pregnancies (all women)" data-id="CD001324-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 2.1: levonorgestrel versus Yuzpe, outcome 2.1.1 Observed number of pregnancies (all women) </p> </div> </div> </div> </section> <section id="CD001324-sec-0091"> <h6 class="title">2.1.2. Side effects</h6> <p>Levonorgestrel was associated with fewer overall side effects than Yuzpe (RR 0.80, 95% CI 0.75 to 0.86, 1 RCT, n = 1955, high‐quality evidence) (<a href="./full#CD001324-tbl-0001">summary of findings Table for the main comparison</a>) and probably with fewer complaints of nausea (RR 0.40, 95% CI 0.36 to 0.44, 6 RCTs, n = 4750, I<sup>2</sup> = 82%, moderate‐quality evidence), vomiting (RR 0.29, 95% CI 0.24 to 0.35, 5 RCTs, n = 3640, I<sup>2</sup> = 78%, moderate‐quality evidence), spotting/bleeding (RR 1.82, 95% CI 1.37 to 2.41, 2 RCTs, n = 1614 , I<sup>2</sup> = 60%, moderate‐quality evidence), headache (RR 0.82, 95% CI 0.71 to 0.94, 3 RCTs, n = 2606, I<sup>2</sup> = 63%), dizziness (RR 0.74, 95% CI 0.65 to 0.85, 3 RCTs, n = 3318, I<sup>2</sup> = 0%) and fatigue (RR 0.67, 95% CI 0.60 to 0.74, 6 RCTs, n = 4750, I<sup>2</sup> = 57%). There was no conclusive evidence of a difference between the groups for breast tenderness (RR 0.90, 95% CI 0.76 to 1.06, 3 RCTs, n = 3318, I<sup>2</sup> = 39%) or abdominal pain (RR 0.84, 95% CI 0.70 to 1.01), although findings suggested a benefit for levonorgestrel. There was insufficient evidence to determine whether there was a difference between the groups for other reported side effects, which included diarrhoea, hot flushes, stomach pain and "nose spot" (<a href="./references#CD001324-fig-0013" title="">Analysis 2.6</a>; <a href="./full#CD001324-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD001324-sec-0092"> <h6 class="title">2.1.3. Effects on menses</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in the rates of early menses (RR 1.15, 95% CI 0.86 to 1.52; 2 RCTs, n = 1310; low‐quality evidence) or menstrual delay (RR 1.23, 95% CI 0.96 to 1.57; 3 RCTs, n = 1988; I<sup>2</sup> = 0%, low‐quality evidence) (<a href="./full#CD001324-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> </section> <section id="CD001324-sec-0093"> <h5 class="title">2.2 Levonorgestrel versus anordrin</h5> <p>One trial from China (<a href="./references#CD001324-bbs2-0098" title="XuZ . A comparative study of mifepristone, anordrin and levonorgestrel for emergency contraception [米非司酮、双炔失碳酯、左炔诺孕酮用于紧急避孕的临床观察]. Journal of Yichun Medical College2000;12:248‐9. ">Xu 2000a</a>) compared levonorgestrel split‐dose regimen with anordrin (7.5 mg, two doses, 12 hours apart, then 7.5 mg per day for eight days) in 172 women. </p> <section id="CD001324-sec-0094"> <h6 class="title">2.2.1 Observed number of pregnancies</h6> <p>The data were too imprecise to determine whether there was a difference between the two regimens in pregnancy rates (RR 0.67, 95% CI 0.11 to 3.89, 1 RCT, n = 172) (<a href="./references#CD001324-fig-0015" title="">Analysis 3.1</a>). </p> </section> <section id="CD001324-sec-0095"> <h6 class="title">2.2.2 Side effects</h6> <p>The data were too imprecise to determine whether there was a difference between the two regimens in overall side effects (RR 0.75, 95% CI 0.27 to 2.07, 1 RCT, n = 172) (<a href="./references#CD001324-fig-0016" title="">Analysis 3.2</a>). </p> <p>No data were available on any of our other secondary outcomes</p> </section> </section> <section id="CD001324-sec-0096"> <h5 class="title">2.3 Mid‐dose mifepristone (25 mg to 50 mg) versus levonorgestrel</h5> <p>Twenty‐seven trials (<a href="./references#CD001324-bbs2-0006" title="CaoYQ , YangAH , ZhuXL . A comparative clinical study on mifepristone with levonorgestrel for emergency contraception [米非司酮和左炔诺孕酮在紧急避孕中的临床研究]. Chinese Journal of General Practice2011;9(7):1087‐8. ">Cao 2011</a>; <a href="./references#CD001324-bbs2-0011" title="Chen Y . A comparative study of mifepristone and LNG for emergency contraception [米非司酮、左炔诺孕酮用于紧急避孕的临床效果对比性观察]. China Foreign Medical Treatment2008;34:60. ">Chen 2008</a>; <a href="./references#CD001324-bbs2-0013" title="ChenSJ , WenCX , HuangCX . A comparative study on mifepristone with levonorgestrel for emergency contraception [左炔诺孕酮与米非司酮用于紧急避孕的效果比较]. Chinese Journal of Ethnomedicine and Ethnopharmacy2013;10:105. ">Chen 2013</a>; <a href="./references#CD001324-bbs2-0014" title="ChenCX . A comparative study on mifepristone with levonorgestrel for emergency contraception [米非司酮与左炔诺孕酮用于紧急避孕临床对比研究]. Medical Forums in Basic2015;8:1024‐5. ">Chen 2015</a>; <a href="./references#CD001324-bbs2-0016" title="Cheng S . Clinical observation on YUTING for emergency contraception [毓婷预防早孕的临床疗效观察]. Chinese Journal of Modern Drug Application2009;8:147‐8. ">Cheng 2009</a>; <a href="./references#CD001324-bbs2-0027" title="Gan XH ,  Jiang H ,  Li LP . A clinical study of low‐dose mifepristone for emergency contraception [小剂量米非司酮用于紧急避孕的临床观察]. Modern Medicine Health2007;23(11):1634‐5. ">Gan 2007</a>; <a href="./references#CD001324-bbs2-0033" title="HanX , JinX , WengL . A comparative study of mifepristone with levonorgestrel for emergency contraception [左炔诺孕酮或米非司酮用于紧急避孕的临床观察]. Journal of Practical Obstetrics and Gynecology1999;6:294‐5. ">Han 1999a</a>; <a href="./references#CD001324-bbs2-0038" title="HuX , LuC . A comparative study of mifepristone with levonorgestrel for emergency contraception [米非司酮、左炔诺孕酮用于紧急避孕的临床效果观察]. Sichuan Medical Journal2003;24(8):F004. ">Hu 2003</a>; <a href="./references#CD001324-bbs2-0039" title="JinYC , JinYY . A comparative study on efficiency and side effects of mifepristone with levonorgestrel for emergency contraception [毓婷与米非司酮在紧急避孕中的效果及不良反应分析]. Seek Medical and Ask the Medicine2012;10(2):167‐8. ">Jin 2012</a>; <a href="./references#CD001324-bbs2-0043" title="LiA , ZhangY . Low dose of mifepristone for emergency contraception [小剂量米非司酮用于紧急避孕的疗效观察]. Journal of Guangxi Medical University2000;17:857. ">Li 2000a</a>; <a href="./references#CD001324-bbs2-0047" title="LiJ . A comparative study of mifepristone with levonorgestrel for emergency contraception [米非司酮和左炔诺酮用于紧急避孕效果观察]. Anthology of Medicine2005;5:754. ">Li 2005b</a>; <a href="./references#CD001324-bbs2-0048" title="LiangJZ , ZhouMR . A randomised comparative study on mifepristone and levonorgestrel for emergency contraception [米非司酮和左炔诺孕酮在紧急避孕中的临床观察]. Heilongjiang Medical Journal2001;25:594. ">Liang 2001</a>; <a href="./references#CD001324-bbs2-0049" title="LiaoAH , ChangCF , ZhuJW . Randomised controlled prospective studies of mifepristone in small doses and levonorgestrel for emergency contraception [小剂量米非司酮和左炔诺孕酮用于紧急避孕的随机对照研究]. Chinese Journal of Practical Gynaecology and Obstetrics2003;19:25‐7. ">Liao 2003</a>; <a href="./references#CD001324-bbs2-0054" title="Liu RQ . A comparative study of mifepristone and LNG for emergency contraception [米非司酮和毓婷紧急避孕的有效性和安全性评价]. China Pharmaceuticals 2009;19:68‐9. ">Liu 2009</a>; <a href="./references#CD001324-bbs2-0061" title="QiM , WangY , YanL . A comparative study of low‐dose mifepristone with levonorgestrel for emergency contraception ‐ 288 cases report [小剂量米非司酮与左炔诺孕酮片紧急避孕288例观察]. Journal of Qinghai Medical College2003;24:255‐6. ">Qi 2003</a>; <a href="./references#CD001324-bbs2-0065" title="Shao XY . Clinical observation on mifepristone for emergency contraception [米非司酮用于紧急避孕的临床观察]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine  2010;10(3):55. ">Shao 2010</a>; <a href="./references#CD001324-bbs2-0068" title="SuW , ChuiJY , LiuP . A comparative study of IUCD with mifepristone and with levonorgestrel for emergency contraception [米非司酮、 左炔诺孕酮和IUCD用于紧急避孕的临床观察研究]. Journal of Baotou Medicine2001;25:24. ">Su 2001</a>; <a href="./references#CD001324-bbs2-0069" title="SunY , WangX . A clinical comparative study of mifepristone with levonorgestrel for emergency contraception [米非司酮,左炔诺孕酮用于紧急避孕的临床效果观察]. Chinese Journal of Family Planning2000;8:172‐3. ">Sun 2000</a>; <a href="./references#CD001324-bbs2-0070" title="SunP . Mifepristone for emergency contraception [米非司酮用于紧急避孕的研究]. Journal of Chinese Practice Medicine2003;5:92. ">Sun 2003</a>; <a href="./references#CD001324-bbs2-0074" title="TaoXL , XiongJ . A study on mifepristone for emergency contraception [复方米非司酮应用于紧急避孕150例]. Herald of Medicine2014;33(6):742‐3. ">Tao 2014</a>; <a href="./references#CD001324-bbs2-0080" title="WangQ , LiA . A comparative study of levonorgestrel with low dose mifepristone for emergency contraception [左炔诺孕酮和小剂量米非司酮用于紧急避孕的临床观察]. Northwestern Pharmaceutical Journal2000;15:72. ">Wang 2000b</a>; <a href="./references#CD001324-bbs2-0082" title="WangY , LiuH . A comparative study on low doses of mifepristone with levonorgestrel for emergency contraception [左炔诺孕酮和小剂量米非司酮用于紧急避孕的临床观察]. Chinese Journal of Family Planning2003;8:505‐6. ">Wang 2003</a>; <a href="./references#CD001324-bbs2-0098" title="XuZ . A comparative study of mifepristone, anordrin and levonorgestrel for emergency contraception [米非司酮、双炔失碳酯、左炔诺孕酮用于紧急避孕的临床观察]. Journal of Yichun Medical College2000;12:248‐9. ">Xu 2000a</a>; <a href="./references#CD001324-bbs2-0099" title="XuL , WangZ . A comparative study on low dose mifepristone with levonorgestrel for emergency contraception [低剂量米非司酮、左炔诺孕酮用于紧急避孕的临床观察]. Chinese Journal of Family Planning2000;8:419‐20. ">Xu 2000b</a>; <a href="./references#CD001324-bbs2-0102" title="YeLQ . A study on the effect of mifepristone for emergency contraception. For all Health2013;7(1):12‐13. ">Ye 2013</a>; <a href="./references#CD001324-bbs2-0107" title="ZhangJQ . Emergency contraception in high‐land [高原地区紧急避孕临床应用]. Chinese Journal of Family Planning2000;8:552‐4. ">Zhang 2000</a>; <a href="./references#CD001324-bbs2-0112" title="ZhangLR . A comparative clinical study on mifepristone with levonorgestrel for emergency contraception [米非司酮与左炔诺孕酮用于紧急避孕的临床对比研究]. Modern Healthcare2014;7:67. ">Zhang 2014</a>), all conducted in China, compared levonorgestrel (2939 women), all used a 12‐hour split‐dose regimen with mid‐dose mifepristone (3113 women). </p> <section id="CD001324-sec-0097"> <h6 class="title">2.3.1 Observed number of pregnancies</h6> <p>Overall, the effectiveness of mid‐dose mifepristone was probably better than that of levonorgestrel, with lower pregnancy rates (RR 0.61, 95% CI 0.45 to 0.83, 27 RCTs, n = 6052, I<sup>2</sup> = 0%, moderate‐quality evidence) (<a href="./references#CD001324-fig-0017" title="">Analysis 4.1</a>; <a href="./full#CD001324-tbl-0002">summary of findings Table 2</a>). The evidence suggested that if the chance of pregnancy following levonorgestrel is assumed to be 35 per 1000 women, the chance of pregnancy following mid‐dose mifepristone would be between 16 to 29 per 1000 women. </p> <p><a href="./references#CD001324-bbs2-0068" title="SuW , ChuiJY , LiuP . A comparative study of IUCD with mifepristone and with levonorgestrel for emergency contraception [米非司酮、 左炔诺孕酮和IUCD用于紧急避孕的临床观察研究]. Journal of Baotou Medicine2001;25:24. ">Su 2001</a> reported a case of ectopic pregnancy in the levonorgestrel group. </p> <p>This result was confirmed with simulated ITT analyses. When we assumed that all missing participants had the event in the levonorgestrel group, but none in the mifepristone group, the estimated RR was 0.50 (95% CI 0.32 to 0.77) and when we assumed that no missing women had an event in the levonorgestrel group, but that all the women in the mifepristone group did, the estimated RR was 0.57 (95% CI 0.37 to 0.88). </p> <p>Funnel plots for the observed number of pregnancies between mid‐dose mifepristone and levonorgestrel did not suggest reporting bias. </p> </section> <section id="CD001324-sec-0098"> <h6 class="title">2.3.2. Side effects</h6> <p>Eighteen trials reported the overall side‐effect rate and suggested that mifepristone may be more tolerable than levonorgestrel (RR 0.55, 95% CI 0.40 to 0.74, 18 RCTs, n = 4352, I<sup>2</sup> = 72%, low‐quality evidence) (<a href="./references#CD001324-fig-0019" title="">Analysis 4.3</a>; <a href="./full#CD001324-tbl-0002">summary of findings Table 2</a>). </p> <p>The data were too imprecise to determine whether there was a difference between the groups for specific types of side effects, including nausea, headache, dizziness, breast tenderness or abdominal pain (<a href="./references#CD001324-fig-0020" title="">Analysis 4.4</a>, low‐quality evidence) except that spotting/bleeding after treatment appeared to be less common in the mifepristone group (RR 0.61, 95% CI 0.42 to 0.88, 9 RCTs, n = 1796, I<sup>2</sup> = 29%, low‐quality evidence) (<a href="./references#CD001324-fig-0020" title="">Analysis 4.4</a>; <a href="./full#CD001324-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD001324-sec-0099"> <h6 class="title">2.3.3. Effects on menses</h6> <p>Women who took mifepristone were probably more likely to have a delay in menses than those who took levonorgestrel (RR 1.29, 95% CI 1.09 to 1.54, 17 RCTs, n = 3615, I<sup>2</sup> = 31%, moderate‐quality evidence) (<a href="./references#CD001324-fig-0021" title="">Analysis 4.5</a>). There was no clear evidence of a difference between the groups in rates of early menses (RR 0.72, 95% CI 0.50 to 1.03, 7 RCTs, n = 1324, low‐quality evidence) (<a href="./full#CD001324-tbl-0002">summary of findings Table 2</a>). </p> </section> </section> <section id="CD001324-sec-0100"> <h5 class="title">2.4 Low‐dose mifepristone (less than 25 mg) versus levonorgestrel</h5> <p>Twelve Chinese studies (<a href="./references#CD001324-bbs2-0004" title="Bu GY ,  Yang MY ,  Cao XL . Clinical study on administration of low dose of mifepristone and levonorgestrel in urgent postcoital contraception [小剂量米非司酮和左炔诺孕酮用于紧急避孕的临床研究]. Progress in Modern Biomedicine2006;6(2):53‐4. ">Bu 2006</a>; <a href="./references#CD001324-bbs2-0020" title="Dong JF . Two different methods for emergency contraception [两种不同方法用作紧急避孕的临床研究]. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine2009;9(1):58‐9. ">Dong 2009</a>; <a href="./references#CD001324-bbs2-0046" title="LiW . A comparative study of mifepristone with levonorgestrel for emergency contraception [米非司酮与左炔诺酮用于紧急避孕的临床效果观察]. Guizhou Journal of Medicine2002;5:457. ">Li 2002a</a>; <a href="./references#CD001324-bbs2-0042" title="LeiX , YangG . A comparative observation on mifepristone with levonorgestrel for emergency contraception [米非司酮与左炔诺孕酮用于紧急避孕的效果比较]. Medical Information2013;26(15):486. ">Lei 2013</a>; <a href="./references#CD001324-bbs2-0050" title="LinN , ChengW , YangY , ShaoL . A comparative study of mifepristone and LNG for emergency contraception [小剂量米非司酮与左旋18‐甲基炔诺酮单方用于紧急避孕的比较研究]. Tianjing Medical Journal2000;28:601‐3. ">Lin 2000</a>; <a href="./references#CD001324-bbs2-0051" title="LiuJL , LiuLH , LiKZ , LiuHL . Comparative study of the efficacy of low‐dose mifepristone and levonorgestrel on the emergency contraception [低剂量米非司酮与左旋18甲基炔谱酮紧急避孕临床效果观察]. Practical Preventive Medicine2000;7:126‐7. ">Liu 2000</a>; <a href="./references#CD001324-bbs2-0059" title="PeiJH , WangZX . A randomised comparative study of mifepristone in small doses and levonorgestrel for emergency contraception [小剂量米非司酮与左炔诺孕酮用于紧急避孕的临床观察]. Haerbin Medicine2001;21:32‐3. ">Pei 2001</a>; <a href="./references#CD001324-bbs2-0066" title="ShengA . Clinical observation of the efficacy of mifepristone and levonorgestrel on the emergency contraception [小剂量米非司酮和左炔诺酮用于紧急避孕的疗效观察]. Academic Journal of Jiangsu University (Medicine)2002;12:246‐9. ">Sheng 2002</a>; <a href="./references#CD001324-bbs2-0086" title="WangCL . A comparative clinical study on mifepristone with levonorgestrel for emergency contraception [左炔诺孕酮和米非司酮用于紧急避孕的临床观察]. Guide of China Medicine2012;10(5):102‐3. ">Wang 2012</a>; <a href="./references#CD001324-bbs2-0079" title="WangC , TianM , ChangY , ShaoM . A clinical comparative observation among copper IUD, lower dose mifepristone and levonorgestrel for emergency contraception [含铜IUD、小剂量米非司酮与左炔诺孕酮用于紧急避孕的临床比较观察]. Journal of Chinese Physician2000;2:271‐3. ">Wang 2000a</a>; <a href="./references#CD001324-bbs2-0092" title="WuS , WangC , WangY , ChengW , ZuoS , LiH , et al. A randomized, double‐blind, multicentre study on comparing levonorgestrel and mifepristone for emergency contraception [左炔诺孕酮和小剂量米非司酮用于紧急避孕的临床观察]. Chinese Journal of Obstetrics and Gynaecology1999;34:327‐30. ">Wu 1999a</a>; <a href="./references#CD001324-bbs2-0111" title="ZhangH . A comparative clinical study on mifepristone with levonorgestrel for emergency contraception [左炔诺孕酮和米非司酮用于紧急避孕的临床观察]. Guide of China Medicine2012;10(26):576‐7. ">Zhang 2012</a>), one UK study (<a href="./references#CD001324-bbs2-0030" title="HamodaH , AshokPW , StalderC , FlettGMM , KennedyE , TempletonA . A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraception. Obstetrics &amp; Gynecology2004;104:1307‐13. ">Hamoda 2004</a>) and one multinational WHO study (<a href="./references#CD001324-bbs2-0077" title="vonHertzenH , PiaggioG , DingJ , ChenJ , SongS , BartfaiG , et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception. Lancet2002;360:1803‐10. ">von Hertzen 2002</a>) compared low‐dose mifepristone (3688 women) versus levonorgestrel (5064 women). </p> <section id="CD001324-sec-0101"> <h6 class="title">2.4.1 Observed number of pregnancies</h6> <p>When we pooled all the studies, there was evidence that there was a difference in effectiveness between low‐dose mifepristone regimens and levonorgestrel, with fewer pregnancies in the low‐dose mifepristone group (RR 0.72, 95% CI 0.52 to 0.99, 14 RCTs, n = 8752, I<sup>2</sup> = 0%, high‐quality evidence) (<a href="./references#CD001324-fig-0024" title="">Analysis 5.1</a>; <a href="./full#CD001324-tbl-0003">summary of findings Table 3</a>). Funnel plots for the primary outcomes (observed number of pregnancies) showed asymmetry, suggesting possible reporting bias (<a href="#CD001324-fig-0005">Figure 5</a>). The evidence suggested that if the chance of pregnancy following levonorgestrel is assumed to be 20 per 1000 women, the chance of pregnancy following low‐dose mifepristone would be between 10 to 20 per 1000 women. </p> <div class="figure" id="CD001324-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison 2.4: Low‐dose mifepristone (&lt; 25 mg) versus levonorgestrel 1.5 mg, outcome 2.4.1 Observed number of pregnancies (all women)" data-id="CD001324-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison 2.4: Low‐dose mifepristone (&lt; 25 mg) versus levonorgestrel 1.5 mg, outcome 2.4.1 Observed number of pregnancies (all women) </p> </div> </div> </div> <p>Additional analysis of data from one trial (<a href="./references#CD001324-bbs2-0077" title="vonHertzenH , PiaggioG , DingJ , ChenJ , SongS , BartfaiG , et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception. Lancet2002;360:1803‐10. ">von Hertzen 2002</a>) indicated that the above conclusions were not modified by whether women abstained from further acts of intercourse or not (P = 0.14 for the interaction test), or by the time elapsed (within or after 72 hours) from intercourse to treatment administration (P = 0.99 for the interaction test) (<a href="./references#CD001324-bbs2-0030" title="HamodaH , AshokPW , StalderC , FlettGMM , KennedyE , TempletonA . A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraception. Obstetrics &amp; Gynecology2004;104:1307‐13. ">Hamoda 2004</a>; <a href="./references#CD001324-bbs2-0077" title="vonHertzenH , PiaggioG , DingJ , ChenJ , SongS , BartfaiG , et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception. Lancet2002;360:1803‐10. ">von Hertzen 2002</a>). When we assumed that all women lost to follow‐up in the levonorgestrel group became pregnant, whereas none of those lost to follow‐up in the mifepristone group did, results indicated that mifepristone was associated with significantly lower risk of pregnancy than levonorgestrel (RR 0.70; 95% CI 0.50 to 0.98) (<a href="#CD001324-fig-0006">Figure 6</a>; <a href="./references#CD001324-fig-0030" title="">Analysis 5.7</a>). However, there was no evidence of a difference between the groups when we assumed that none of the women lost to follow‐up in the levonorgestrel group became pregnant but all those in the mifepristone group did (RR 0.90, 95% CI 0.76 to 1.05) (<a href="./references#CD001324-fig-0031" title="">Analysis 5.8</a>). </p> <div class="figure" id="CD001324-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison 2.4: Low‐dose mifepristone (&lt; 25 mg) versus levonorgestrel 1.5 mg, outcome 2.4.1 ITT (all loss follow‐up as pregnancy in levonorgestrel, and no pregnancy in mifepristone)" data-id="CD001324-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison 2.4: Low‐dose mifepristone (&lt; 25 mg) versus levonorgestrel 1.5 mg, outcome 2.4.1 ITT (all loss follow‐up as pregnancy in levonorgestrel, and no pregnancy in mifepristone) </p> </div> </div> </div> </section> <section id="CD001324-sec-0102"> <h6 class="title">2.4.2 Side effects</h6> <p>The low‐dose mifepristone group appeared to have fewer overall side effects than the levonorgestrel group (RR 0.26, 95% CI 0.17 to 0.38, 3 RCTs, n = 609, I<sup>2</sup> = 0%, low‐quality evidence) (<a href="./references#CD001324-fig-0027" title="">Analysis 5.4</a>; <a href="./full#CD001324-tbl-0003">summary of findings Table 3</a>). There was no evidence of a difference between the groups in rates of nausea or abdominal pain (<a href="./references#CD001324-fig-0028" title="">Analysis 5.5</a>; <a href="./full#CD001324-tbl-0003">summary of findings Table 3</a>). There was insufficient evidence to determine whether there was a difference between the groups for other specific side effects such as vomiting, headache, dizziness, fatigue, breast tenderness, diarrhoea, or hot flushes, but low‐dose mifepristone was associated with a lower risk of spotting or bleeding after treatment (RR 0.61, 95% CI 0.54 to 0.69, 5 RCTs, n = 4598, I<sup>2</sup> = 0%, high‐quality evidence) (<a href="./references#CD001324-fig-0028" title="">Analysis 5.5</a>, <a href="./full#CD001324-tbl-0003">summary of findings Table 3</a>). </p> </section> <section id="CD001324-sec-0103"> <h6 class="title">2.4.3 Effects on menses</h6> <p>Early return of menstruation was probably less frequent in the mifepristone group than in the levonorgestrel group (RR 0.45, 95% CI 0.35 to 0.59, 5 RCTs, n = 1800, I<sup>2</sup> = 0%, low‐quality evidence). Delay in menstruation was probably more frequent in the mifepristone group (RR 1.70, 95% CI 1.48 to 1.97, 9 RCTs, n = 7520, I<sup>2</sup> = 51%, low‐quality evidence) (<a href="./references#CD001324-fig-0029" title="">Analysis 5.6</a>, <a href="./full#CD001324-tbl-0003">summary of findings Table 3</a>). </p> <p>There were no trials that compared high‐dose (more than 50 mg) mifepristone with levonorgestrel.</p> </section> </section> <section id="CD001324-sec-0104"> <h5 class="title">2.5 Mifepristone versus Yuzpe regimen</h5> <p>Three trials conducted in the UK compared high‐dose mifepristone (100 mg and 600 mg) with the Yuzpe regimen (<a href="./references#CD001324-bbs2-0002" title="AshokPW , StalderC , WagaarachchiPT , FlettGM , MelvinL , TempletonA . A randomised study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception. BJOG2002;109:553‐60. ">Ashok 2002</a> (100 mg); <a href="./references#CD001324-bbs2-0028" title="GlasierA , ThongKJ , DewarM , MackieM , BairdD . Postcoital contraception with mifepristone (letter). Lancet1991;337:1414‐5. GlasierA , ThongKJ , DewarM , MackieM , BairdDT . Mifepristone (RU 486) compared with high‐dose estrogen and progestogen for emergency postcoital contraception. New England Journal of Medicine1992;327:1041‐4. ">Glasier 1992</a> (600 mg); and <a href="./references#CD001324-bbs2-0087" title="WebbAM . Alternative treatments in oral postcoital contraception: interim results. Advances in Contraception1991;7:271‐9. WebbAMC , RussellJ , ElsteinM . Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. BMJ1992;305:927‐31. ">Webb 1992</a> (600 mg)). <a href="./references#CD001324-bbs2-0087" title="WebbAM . Alternative treatments in oral postcoital contraception: interim results. Advances in Contraception1991;7:271‐9. WebbAMC , RussellJ , ElsteinM . Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. BMJ1992;305:927‐31. ">Webb 1992</a> included danazol as a third arm. This trial was stopped early because mifepristone showed higher effectiveness than the Yuzpe regimen and danazol (number of pregnancies: 0/195 with mifepristone vs 5/191 with Yuzpe and 9/193 with danazol). One trial investigated whether the effectiveness was influenced by high‐ or low‐risk behaviour (<a href="./references#CD001324-bbs2-0028" title="GlasierA , ThongKJ , DewarM , MackieM , BairdD . Postcoital contraception with mifepristone (letter). Lancet1991;337:1414‐5. GlasierA , ThongKJ , DewarM , MackieM , BairdDT . Mifepristone (RU 486) compared with high‐dose estrogen and progestogen for emergency postcoital contraception. New England Journal of Medicine1992;327:1041‐4. ">Glasier 1992</a>). No pregnancy was observed among women who abstained from further intercourse, but the sample size of this study was relatively small. </p> <section id="CD001324-sec-0105"> <h6 class="title">2.5.1 Observed number of pregnancies</h6> <p>The risk of pregnancy among mifepristone users was significantly lower than that among the Yuzpe users (RR 0.14; 95% CI 0.05 to 0.41, 3 RCTs, n = 2144 , I<sup>2</sup> = 0%, high‐quality evidence) (<a href="./references#CD001324-fig-0032" title="">Analysis 6.1</a>; <a href="./full#CD001324-tbl-0004">summary of findings Table 4</a>). This suggests that if the chance of pregnancy following Yuzpe is assumed to be 25 per 1000 women, the chance following mifepristone would be between 1 to 10 per 1000 women. </p> </section> <section id="CD001324-sec-0106"> <h6 class="title">2.5.2 Side effects</h6> <p>Overall side effects were less common in the mifepristone group (RR 0.83, 95% CI 0.77 to 0.88, 2 RCTs, n = 1693, I<sup>2</sup> = 94%, moderate‐quality evidence). Heterogeneity was very high, but the direction of effect was consistent. </p> <p>Women receiving mifepristone reported fewer complaints of nausea (RR 0.63, 95% CI 0.53 to 0.76, 3 RCTs, n = 2186, I<sup>2</sup> = 59%, moderate‐quality evidence), vomiting (RR 0.12, 95% CI 0.07 to 0.20, 3 RCTs, n = 2186, I<sup>2</sup> = 0%, high‐quality evidence), headache (RR 0.75, 95% CI 0.61 to 0.91, 2 RCTs, n = 1800, I<sup>2</sup> = 48%), dizziness (RR 0.58, 95% CI 0.42 to 0.80), fatigue (RR 0.81, 95% CI 0.68 to 0.95 ), hot flushes RR 0.58, 95% CI 0.40 to 0.83) or abdominal pain (RR 0.76, 95% CI 0.61 to 0.95, 1 RCT, n = 1000, moderate‐quality evidence) (<a href="./references#CD001324-fig-0037" title="">Analysis 6.6</a>; <a href="./full#CD001324-tbl-0004">summary of findings Table 4</a>). There was no clear evidence of a difference between the groups in rates of breast tenderness or lethargy. </p> </section> <section id="CD001324-sec-0107"> <h6 class="title">2.5.3 Effects on menses</h6> <p>Delay in menses appeared to be more frequent in women receiving mifepristone than in those who used the Yuzpe regimen (RR 2.83; 95% CI 2.30 to 3.47, 3 RCTs, n = 1924, I<sup>2</sup> = 85%, moderate‐quality evidence) (<a href="./references#CD001324-fig-0038" title="">Analysis 6.7</a>; <a href="./full#CD001324-tbl-0004">summary of findings Table 4</a>). </p> </section> </section> <section id="CD001324-sec-0108"> <h5 class="title">2.6 Mifepristone versus anordrin</h5> <p>Seven trials (<a href="./references#CD001324-bbs2-0008" title="ChenG . Mifepristone for emergency contraception [米非司酮用于紧急避孕的临床观察]. Journal of Guangxi Traditional Chinese Medical University2001;4:22‐4. ">Chen 2001</a>; <a href="./references#CD001324-bbs2-0026" title="FuX , WangL , JiangQ , YangX . Anordrin and mifepristone for emergency contraception [双炔失碳酯或米非司酮用于紧急避孕临床观察]. Journal of Qinghai Medical College2000;21:43‐4. ">Fu 2000</a>; <a href="./references#CD001324-bbs2-0031" title="HanX , WengL , ZhangL , ZengT , XiaoB . Clinical trial of mifepristone and anordrin for emergency contraception [米非司酮,双炔失碳酯单独或联合应用于紧急避孕的临床观察]. Journal of Reproductive Medicine (China)1995;4:206‐11. ">Han 1995</a>; <a href="./references#CD001324-bbs2-0052" title="LiuL , WangZ , LiL . Mifepristone and anordrin for emergency contraception [米非司酮、双炔失碳酯用于紧急避孕的临床观察]. Zhong Guo Yiu Sheng Yu Yi Chuan Zha Zi2001;9:108‐11. ">Liu 2001</a>; <a href="./references#CD001324-bbs2-0078" title="WangZ , LiuL , LiuQ , ZhangH . A clinical comparative study of mifepristone with anordrin for emergency contraception [米非司酮,双炔失碳酯用于紧急避孕临床效果观察]. Chinese Journal of Family Planning1999;7:320‐1. ">Wang 1999</a>; <a href="./references#CD001324-bbs2-0098" title="XuZ . A comparative study of mifepristone, anordrin and levonorgestrel for emergency contraception [米非司酮、双炔失碳酯、左炔诺孕酮用于紧急避孕的临床观察]. Journal of Yichun Medical College2000;12:248‐9. ">Xu 2000a</a><a href="./references#CD001324-bbs2-0100" title="YangLJ . A comparative study on mifepristone, anordrin and danazol for emergency contraception [米非司酮双炔失碳酯丹那唑紧急避孕的临床研究]. Guangzhou Medical Journal2001;32:12‐3. ">Yang 2001</a>) compared mid‐dose mifepristone with anordrin in different regimens (the total dosage ranging from 15 mg to 90 mg). </p> <section id="CD001324-sec-0109"> <h6 class="title">2.6.1 Observed number of pregnancies</h6> <p>Mifepristone may be more effective in preventing pregnancy than anordrin (RR 0.26, 95% CI 0.11 to 0.63, 7 RCTs, n = 1035, I<sup>2</sup> = 0%, <a href="./references#CD001324-fig-0039" title="">Analysis 7.1</a>). This suggests that if the risk of pregnancy following anordrin is assumed to be 40 per 1000 women, the risk of pregnancy following mifepristone would be between 4 to 25 per 1000 women. </p> </section> <section id="CD001324-sec-0110"> <h6 class="title">2.6.2 Side effects</h6> <p>Mifepristone may have fewer overall side effects than anordrin (RR 0.62, 95% CI 0.43 to 0.91, 4 RCTs, n = 746, I<sup>2</sup> = 66%) (<a href="./references#CD001324-fig-0040" title="">Analysis 7.2</a>). There was insufficient evidence to determine whether there was a difference between the groups in rates of spotting/bleeding (RR 1.82, 95% CI 0.69 to 4.77, 2 RCTs, n = 331, I<sup>2</sup> = 0%) (<a href="./references#CD001324-fig-0041" title="">Analysis 7.3</a>). </p> </section> <section id="CD001324-sec-0111"> <h6 class="title">2.6.3 Effects on menses</h6> <p>There was no clear evidence of a difference in menses' changes between mifepristone and anordrin (RR 1.14, 95% CI 0.78 to 1.68, 4 RCTs, n = 667, I<sup>2</sup> = 85%) (<a href="./references#CD001324-fig-0042" title="">Analysis 7.4</a>). </p> </section> </section> <section id="CD001324-sec-0112"> <h5 class="title">2.7 Low‐or mid‐dose mifepristone versus mifepristone with anordrin</h5> <p>Five trials (<a href="./references#CD001324-bbs2-0031" title="HanX , WengL , ZhangL , ZengT , XiaoB . Clinical trial of mifepristone and anordrin for emergency contraception [米非司酮,双炔失碳酯单独或联合应用于紧急避孕的临床观察]. Journal of Reproductive Medicine (China)1995;4:206‐11. ">Han 1995</a>; <a href="./references#CD001324-bbs2-0032" title="HanX , WengL , XiaoB . Emergency contraception with mifepristone and anordrin [米非司酮用于紧急避孕的临床观察]. Chinese Journal of Obstetrics and Gynecology1996;9:526‐9. ">Han 1996</a>; <a href="./references#CD001324-bbs2-0056" title="LouX , MaL , YangY . Mifepristone and C53 contraceptive in postcoital contraception [米非司酮与双炔失碳酯联合用于紧急避孕的临床观察]. Journal of Chinese Modern Gynaecology and Obstetrics2005;2:405‐6. ">Lou 2005</a>; <a href="./references#CD001324-bbs2-0064" title="SangGW , ShaoQ , ZhangJ , ZhangM , ChenS , SongS , et al. A randomized multicentre clinical trial on different doses of mifepristone alone and in combination with anordrin as emergency contraception [不同剂量米非司酮及合并双炔失碳酯用于紧急避孕的多中心随机临床研究]. Chinese Journal of Obstetrics and Gynaecology1999;34(6):331‐4. ">Sang 1999</a>; <a href="./references#CD001324-bbs2-0108" title="ZhangY , ZhangW , WangL . Low‐dose of mifepristone and anordrin for emergency contraception: observation of 116 cases [低剂量米非司酮并用双炔失碳酯用于紧急避孕116例分析]. Journal of Qiqihar Medical College2002;4:415. ">Zhang 2002a</a>) compared low‐ or mid‐dose mifepristone versus mifepristone combined with anordrin. </p> <section id="CD001324-sec-0113"> <h6 class="title">2.7.1 Observed number of pregnancies</h6> <p>It was unclear whether there was a difference between the groups in the risk of pregnancy (RR 1.32, 95% CI 0.73 to 2.41, 5 RCTs, n = 3038, I<sup>2</sup> = 0%) (<a href="./references#CD001324-fig-0043" title="">Analysis 8.1</a>). This suggests that if the chance of pregnancy using mifepristone and anordrin is assumed to be 12 per 1000 women, the chance by using mifepristone alone would be between 9 to 30 per 1000 women. </p> </section> <section id="CD001324-sec-0114"> <h6 class="title">2.7.2 Side effects</h6> <p>There was no clear evidence of a difference between the groups in overall rates of side‐effects (RR 0.83, 95% CI 0.49 to 1.41, 2 RCTs, n = 442, I<sup>2</sup> = 0%) (<a href="./references#CD001324-fig-0044" title="">Analysis 8.2</a>). </p> <p>The mifepristone‐only regimen was associated with lower rates of nausea (RR 0.53; , CI 0.44 to 0.65, 1 RCT, n = 2387) (<a href="./references#CD001324-fig-0045" title="">Analysis 8.3</a>), vomiting (RR 0.26, 95% CI 0.14 to 0.50, 1 RCT, n = 2387) and fatigue (RR 0.66, 95% CI 0.49 to 0.89, 1 RCT, n = 2387) , but higher rates of spotting/bleeding (RR 1.80; 95% CI 1.33 to 2.43, 5 RCTs, n = 3038) than the combination regimen (<a href="./references#CD001324-fig-0045" title="">Analysis 8.3</a>). There was no clear evidence of any difference between the groups in rates of headache, dizziness, breast tenderness or abdominal pain. </p> </section> <section id="CD001324-sec-0115"> <h6 class="title">2.7.3 Effects on menses</h6> <p>The mifepristone‐only regimen was associated with a lower risk of menstrual delay (RR 0.79, 95% CI 0.65 to 0.97, 3 RCTs, n = 2781, I<sup>2</sup> = 3%) (<a href="./references#CD001324-fig-0046" title="">Analysis 8.4</a>). </p> </section> </section> <section id="CD001324-sec-0116"> <h5 class="title">2.8 Low‐dose mifepristone versus mifepristone with misoprostol (200 μg)</h5> <p><a href="./references#CD001324-bbs2-0093" title="WuXZ , SaoJY , ChenCQ , YanY , FaYY , LiuJH , et al. A comparative study on methods for emergency contraception [两种紧急避孕方法比较性研究]. Reproduction &amp; Contraception (China)2002;22:152‐5. ">Wu 2002</a> compared low‐dose mifepristone with mifepristone combined with misoprostol (200 μg). </p> <section id="CD001324-sec-0117"> <h6 class="title">2.8.1. Observed number of pregnancies</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in pregnancy rates (RR 3.49, 95% CI 0.73 to 16.65; n = 599) (<a href="./references#CD001324-fig-0047" title="">Analysis 9.1</a>). </p> </section> <section id="CD001324-sec-0118"> <h6 class="title">2.8.2 Side effects</h6> <p>This study did not report overall rates of side effects.</p> <p>With regard to specific side effects, there was no clear evidence of a difference between the groups in rates of nausea, vomiting, headache, dizziness, fatigue, breast tenderness, diarrhoea or spotting/bleeding after treatment, but the mifepristone‐alone regimen is probably associated with a lower risk of abdominal pain than the combination regimen (RR 0.31, 95% CI 0.10 to 0.93) (<a href="./references#CD001324-fig-0048" title="">Analysis 9.2</a>). </p> </section> <section id="CD001324-sec-0119"> <h6 class="title">2.8.3 Effects on menses</h6> <p>No studies reported on this outcome.</p> </section> </section> <section id="CD001324-sec-0120"> <h5 class="title">2.9 Low‐dose mifepristone versus mifepristone with tamoxifen (20 mg)</h5> <p>One double‐blind trial (<a href="./references#CD001324-bbs2-0035" title="HeCH , GuiYL , YangJ , WangBS , ZhengE , GaoES , et al. A randomized comparative study on mifepristone alone and in combination with tamoxifen for emergency contraception. Contraception2002;66:221‐4. ">He 2002</a>) compared low‐dose mifepristone with mifepristone combined with tamoxifen (20 mg). </p> <section id="CD001324-sec-0121"> <h6 class="title">2.9.1. Observed number of pregnancies</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in the risk of pregnancy (RR 3.00, 95% CI 0.31 to 28.60, 1 RCT, n = 400) (<a href="./references#CD001324-fig-0049" title="">Analysis 10.1</a>). </p> </section> <section id="CD001324-sec-0122"> <h6 class="title">2.9.2 Side effects</h6> <p>Rates of overall side‐effects were not reported by this study.</p> <p>With regard to specific side‐effects, there was no clear evidence of a difference between the groups in rates of nausea, vomiting, headache, dizziness, fatigue, breast tenderness, diarrhoea, spotting/bleeding after treatment, or abdominal pain (<a href="./references#CD001324-fig-0050" title="">Analysis 10.2</a>). </p> </section> <section id="CD001324-sec-0123"> <h6 class="title">2.9.3 Effects on menses</h6> <p>Heavy menses was more common in the mifepristone‐only group (RR 5.56, 95% CI 1.25 to 24.74, 1 RCT, n = 396) (<a href="./references#CD001324-fig-0050" title="">Analysis 10.2</a>). </p> <p>There was no evidence of a difference between the groups in the rate of delayed menses (RR 1.79, 95% CI 0.93 to 3.43, 1 RCT, n = 396) (<a href="./references#CD001324-fig-0051" title="">Analysis 10.3</a>). </p> </section> </section> <section id="CD001324-sec-0124"> <h5 class="title">2.10 Mifepristone (25 mg) versus mifepristone with methotrexate (5 mg)</h5> <p>Two tr<b>i</b>als (<a href="./references#CD001324-bbs2-0010" title="ChenH , MinX . Mifepristone in combination with MTX for emergency contraception [米非司酮加用氨甲喋呤用于紧急避孕的研究]. Strait Pharmaceutical Journal2002;3:51‐2. ">Chen 2002b</a>; <a href="./references#CD001324-bbs2-0103" title="Zeng XY . A clinical study of Mifepristone in combination with MTX for emergency contraception. Practical Clinical Journal of Integrated Chinese and Western Medicine2007;7(3):62‐3. ">Zeng 2007</a>) compared a mid‐dose mifepristone (25 mg) regimen with a regimen of mifepristone combined with methotrexate (5 mg). </p> <section id="CD001324-sec-0125"> <h6 class="title">2.10.1. Observed number of pregnancies</h6> <p>Two women were pregnant in the mifepristone‐alone group, and none in the combination group. There was insufficient evidence to determine whether there was a difference between mifepristone alone and mifepristone with methotrexate (RR 3.00, 95% CI 0.32 to 28.36, 2 RCTs, n = 200, I<sup>2</sup> = 0%) (<a href="./references#CD001324-fig-0052" title="">Analysis 11.1</a>). Since only 100 women were recruited in each arm, the non‐significant result may be due partly to the small sample sizes of these two trials (<a href="./references#CD001324-fig-0052" title="">Analysis 11.1</a>). </p> </section> <section id="CD001324-sec-0126"> <h6 class="title">2.10.2 Side effects</h6> <p>There was insufficient evidence to determine whether there was a difference between the groups in the overall incidence of side effects (RR 0.75, 95% CI 0.33 to 1.70, 2 RCTs, n = 200, I<sup>2</sup> = 0%, <a href="./references#CD001324-fig-0053" title="">Analysis 11.2</a>). </p> </section> <section id="CD001324-sec-0127"> <h6 class="title">2.10.3 Effects on menses</h6> <p>There was insufficient evidence to determine whether there was a difference between two regimens in rates of early menses (RR 1.50, 95% CI 0.26 to 8.60, 1 RCT, n = 100) or menstrual delay (RR 0.91, 95% CI 0.60 to 1.39, 2 RCTs, n = 199, I<sup>2</sup> = 0%) (<a href="./references#CD001324-fig-0054" title="">Analysis 11.3</a>). </p> </section> </section> <section id="CD001324-sec-0128"> <h5 class="title">2.11 Mifepristone versus danazol</h5> <p>Two trials (<a href="./references#CD001324-bbs2-0087" title="WebbAM . Alternative treatments in oral postcoital contraception: interim results. Advances in Contraception1991;7:271‐9. WebbAMC , RussellJ , ElsteinM . Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. BMJ1992;305:927‐31. ">Webb 1992</a>; <a href="./references#CD001324-bbs2-0100" title="YangLJ . A comparative study on mifepristone, anordrin and danazol for emergency contraception [米非司酮双炔失碳酯丹那唑紧急避孕的临床研究]. Guangzhou Medical Journal2001;32:12‐3. ">Yang 2001</a>) compared mifepristone (50 mg or 600 mg) with danazol (400 mg or 600 mg, repeated after 12 hours). </p> <section id="CD001324-sec-0129"> <h6 class="title">2.11.1 Observed number of pregnancies</h6> <p>Mifepristone is probably associated with a lower risk of pregnancy than danazol (RR 0.10, 95% CI 0.02 to 0.55, 2 RCTs, n = 629, I<sup>2</sup> = 0%) (<a href="./references#CD001324-fig-0055" title="">Analysis 12.1</a>). This suggests that if the chance of pregnancy using danazol is assumed to be 45 per 1000 women, the chance of pregnancy using mifepristone would be between 1 to 25 per 1000 women. </p> </section> <section id="CD001324-sec-0130"> <h6 class="title">2.11.2 Side effects</h6> <p>Mifepristone was associated with fewer overall side effects than danazol (RR 0.35, 95% CI 0.13 to 0.95, 1 RCT, n = 241) (<a href="./references#CD001324-fig-0056" title="">Analysis 12.2</a>). </p> <p>With respect to specific side‐effects, there was no clear evidence of a difference between the groups in rates of nausea, vomiting, breast tenderness or other (unspecified) side effects (<a href="./references#CD001324-fig-0057" title="">Analysis 12.3</a>). </p> </section> <section id="CD001324-sec-0131"> <h6 class="title">2.11.3 Effects on menses</h6> <p>It was unclear whether there was a difference between the groups in rates of delayed menses (RR 2.39, 0.56 to 10.27, 2 RCTs, n = 621, I<sup>2</sup> = 91%) (<a href="./references#CD001324-fig-0058" title="">Analysis 12.4</a>). Heterogeneity was very high, but the direction of effect was consistent. </p> </section> </section> <section id="CD001324-sec-0132"> <h5 class="title">2.12 Mifepristone versus gestrinone</h5> <p><a href="./references#CD001324-bbs2-0094" title="WuS , DongJ , CongJ , WangCP , vonHertzenH , GodfreyEM . Gestrinone compared with mifepristone for emergency contraception: a randomized controlled trial. Obstetrics and Gynecology2010;115(4):740‐4. ">Wu 2010</a> conducted a randomized, double‐blind, multicentre clinical trial (996 women) comparing mifepristone 10 mg with gestrinone 10 mg (a 19‐nortestosterone derivative with anti‐progestagenic, anti‐oestrogenic and anti‐gonadotropic properties). </p> <section id="CD001324-sec-0133"> <h6 class="title">2.12.1. Observed number of pregnancies</h6> <p>It was unclear whether there was a difference between the groups in pregnancy rates (RR 0.75, 95% CI 0.32 to 1.76, 1 RCT, n = 996) (<a href="./references#CD001324-fig-0059" title="">Analysis 13.1</a>). </p> </section> <section id="CD001324-sec-0134"> <h6 class="title">2.12.2 Side effects</h6> <p>Overall rates of side‐effects were not reported.</p> <p>With regard to specific side‐effects, there was no clear evidence of a difference between the groups in rates of nausea, vomiting, headache, dizziness, fatigue, breast tenderness, diarrhoea, spotting/bleeding after treatment, or lower abdominal pain (<a href="./references#CD001324-fig-0060" title="">Analysis 13.2</a>). </p> </section> <section id="CD001324-sec-0135"> <h6 class="title">2.12.3 Effects on menses</h6> <p>Mifepristone was probably associated with higher risk of menstrual delay than gestrinone (RR 1.37, 95% CI 1.03 to 1.82, 1 RCT, n = 975) (<a href="./references#CD001324-fig-0061" title="">Analysis 13.3</a>) and a lower risk of early return to next menses (RR 0.37, 95% CI 0.20 to 0.69, 1 RCT, n = 975) (<a href="./references#CD001324-fig-0061" title="">Analysis 13.3</a>). </p> </section> </section> <section id="CD001324-sec-0136"> <h5 class="title">2.13 High‐dose oestrogen versus Yuzpe regimen</h5> <p>One trial conducted in the early 1980s compared a five‐day ethinyl oestradiol 5 mg regimen (standard treatment at that time) versus Yuzpe in a double‐blind trial (<a href="./references#CD001324-bbs2-0076" title="VanSantenMR , HaspelsAA . A comparison of high‐dose estrogens versus low‐dose ethinylestradiol and norgestrel combination in postcoital interception: a study in 493 women. Fertility and Sterility1985;43:206‐13. VanSantenMR , HaspelsAA . Comparative randomized double‐blind study of high dosage ethinylestradiol versus ethinylestradiol and norgestrel combination in postcoital contraception. Acta Endocrinologica1982;99(suppl 246):2. ">Van Santen 1985a</a>). </p> <section id="CD001324-sec-0137"> <h6 class="title">2.13.1. Observed number of pregnancies</h6> <p>There was insufficient evidence to determine whether there was any difference between the groups in the risk of pregnancy (RR 2.17, 95% CI 0.20 to 23.77, 1 RCT, n = 384) (<a href="./references#CD001324-fig-0062" title="">Analysis 14.1</a>). </p> </section> <section id="CD001324-sec-0138"> <h6 class="title">2.13.2 Side effects</h6> <p>No studies reported this outcome.</p> </section> <section id="CD001324-sec-0139"> <h6 class="title">2.13.3 Effects on menses</h6> <p>No studies reported this outcome.</p> </section> </section> <section id="CD001324-sec-0140"> <h5 class="title">2.14 Danazol versus Yuzpe regimen</h5> <p>Danazol was compared to the Yuzpe regimen in one trial (<a href="./references#CD001324-bbs2-0063" title="RowlandsS , GuillebaudJ , BoundsW , BoothM . Side effects of danazol compared with an ethinyloestradiol/norgestrel combination when used for postcoital contraception. Contraception1983;27:39‐49. RowlandsS , KubbaAA , GuillebaudJ , BoundsW . A possible mechanism of action of danazol and an ethinylestradiol/norgestrel combination used as postcoital contraceptive agents. Contraception1986;33:539‐45. ">Rowlands 1983</a>) and to the Yuzpe regimen and mifepristone (600 mg) in a three‐arm trial (<a href="./references#CD001324-bbs2-0087" title="WebbAM . Alternative treatments in oral postcoital contraception: interim results. Advances in Contraception1991;7:271‐9. WebbAMC , RussellJ , ElsteinM . Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. BMJ1992;305:927‐31. ">Webb 1992</a>). </p> <section id="CD001324-sec-0141"> <h6 class="title">2.14.1. Observed number of pregnancies</h6> <p>There was insufficient evidence to determine whether there was any difference in risk of pregnancy between danazol and the Yuzpe regimen (RR 1.78, 95% CI 0.61 to 5.22, 2 RCTs, n = 485) (<a href="./references#CD001324-fig-0063" title="">Analysis 15.1</a>). </p> </section> <section id="CD001324-sec-0142"> <h6 class="title">2.14.2 Side effects</h6> <p>Overall rates of side effects were not reported.</p> <p>With regard to specific side effects, danazol is probably associated with lower rates of nausea (RR 0.38, 95% CI 0.30 to 0.47, 2 RCTs, n = 538, I<sup>2</sup> = 81%) and vomiting (RR 0.13, 95% CI 0.06 to 0.27, 2 RCTs, n = 538, I<sup>2</sup> = 0%). There was very high heterogeneity for the outcome of nausea, but the direction of effect was consistent. There was insufficient evidence to determine whether there was any difference between the groups in rates of breast tenderness (RR 1.14, 95% CI 0.75 to 1.72, 1 RCT, n = 384) (<a href="./references#CD001324-fig-0064" title="">Analysis 15.2</a>). </p> </section> <section id="CD001324-sec-0143"> <h6 class="title">2.14.3 Effects on menses</h6> <p>There was insufficient evidence to determine whether there was any difference between the groups in rates of delay of menses (RR 1.53, 95% CI 0.74 to 3.18, 1 RCT, n = 384) (<a href="./references#CD001324-fig-0065" title="">Analysis 15.3</a>). </p> </section> </section> <section id="CD001324-sec-0144"> <h5 class="title">2.15 UPA (all doses) versus levonorgestrel</h5> <p>UPA is a second‐generation progesterone receptor modulator. <a href="./references#CD001324-bbs2-0017" title="CreininMD , SchlaffW , ArcherDF , WanL , FrezieresR , TomasM , et al. Progesterone receptor modulator for emergency contraception. A randomized controlled trial. Obstetrics &amp; Gynecology2006;108:1089‐97. ">Creinin 2006</a> compared levonorgestrel split‐dose regimen with UPA unmicronised, 50 mg single‐dose, orally within 72 hours of unprotected intercourse. <a href="./references#CD001324-bbs2-0029" title="GlasierAF , CameronST , FinePM , LoganSJ , CasaleW , VanHornJ , et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non‐inferiority trial and meta‐analysis. Lancet2010;375(9714):555‐62. ">Glasier 2010</a> compared levonorgestrel single‐dose regimen with UPA micronised, 30 mg, single‐dose, orally within 120 hours of unprotected intercourse. Since both the European Medicines Agency (EMA) and the Food and Drug Administration (FDA, USA) accepted the bioequivalence of the two regimens, we combined data from the two trials for meta‐analysis in this review. </p> <section id="CD001324-sec-0145"> <h6 class="title">2.15.1 Observed number of pregnancies</h6> <p>UPA was associated with fewer pregnancies than levonorgestrel within 120 hours after unprotected intercourse (RR 0.59, 95% CI 0.35 to 0.99, 2 RCTs, n = 3448, I<sup>2</sup> = 0%, high‐quality evidence) (<a href="./references#CD001324-fig-0066" title="">Analysis 16.1</a>; <a href="./full#CD001324-tbl-0005">summary of findings Table 5</a>). The evidence suggests that if the chance of pregnancy using levonorgestrel is assumed to be 22 per 1000 women, the chance of pregnancy using UPA would be between 8 to 22 per 1000 women. </p> </section> <section id="CD001324-sec-0146"> <h6 class="title">2.15.2 Side effects</h6> <p>Overall rates of side effects were not reported.</p> <p>With regard to specific side effects, there was no evidence of a difference between the groups in rates of nausea, vomiting, headache, dizziness, fatigue, breast tenderness, diarrhoea, spotting/bleeding after treatment, overall abdominal pain, lower abdominal pain, upper abdominal pain, back pain or dysmenorrhoea. (<a href="./references#CD001324-fig-0070" title="">Analysis 16.5</a>, moderate‐quality evidence, <a href="./full#CD001324-tbl-0005">summary of findings Table 5</a>). </p> </section> <section id="CD001324-sec-0147"> <h6 class="title">2.15.3 Effects on menses</h6> <p>Women who took UPA were less likely to have earlier return of menses, compared with those who received levonorgestrel (RR 0.43, 95% CI 0.37 to 0.50, 2 RCTs, n = 3593, I<sup>2</sup> = 72%, moderate‐quality evidence) and UPA users were more likely to have delayed return of next menses than those who received levonorgestrel (RR 1.65, 95% CI 1.42 to 1.92, 2 RCTs, n = 3593, I<sup>2</sup> = 0%, high‐quality evidence) (<a href="./references#CD001324-fig-0071" title="">Analysis 16.6</a>; <a href="./full#CD001324-tbl-0005">summary of findings Table 5</a>). </p> </section> </section> <section id="CD001324-sec-0148"> <h5 class="title">2.16 Split‐dose levonorgestrel: 24 hours versus 12 hours</h5> <p>One double‐blind, randomized, multicenter trial conducted in China (<a href="./references#CD001324-bbs2-0058" title="NgaiSW , FanS , LiS , ChengL , DingJ , JingX , et al. A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraception. Human Reproduction2005;20:307‐11. ">Ngai 2005</a>) compared levonorgestrel split‐dose in two different regimens (24 hours versus 12 hours apart). </p> <section id="CD001324-sec-0149"> <h6 class="title">2.16.1. Observed number of pregnancies</h6> <p>There was no clear evidence of any difference between the two regimens (RR 0.98, 95% CI 0.53 to 1.82, 1 RCT, n = 2060) (<a href="./references#CD001324-fig-0072" title="">Analysis 17.1</a>). This conclusion was not modified by whether or not the women abstained from further acts of intercourse (<a href="./references#CD001324-fig-0073" title="">Analysis 17.2</a>). </p> </section> <section id="CD001324-sec-0150"> <h6 class="title">2.16.2 Side effects</h6> <p>Overall rates of side effects were not reported.</p> <p>With regard to specific side effects, there was no clear evidence of a difference between the groups in rates of nausea, vomiting, headache, dizziness, breast tenderness, or lower abdominal pain (<a href="./references#CD001324-fig-0074" title="">Analysis 17.3</a>). </p> </section> <section id="CD001324-sec-0151"> <h6 class="title">2.16.3. Effects on menses</h6> <p>There was no clear evidence of a difference between the two regimens in rates of delayed menses (RR 0.79, 95% CI 0.53 to 1.17, 1 RCT, n = 1978) (<a href="./references#CD001324-fig-0075" title="">Analysis 17.4</a>). </p> </section> </section> <section id="CD001324-sec-0152"> <h5 class="title">2.17 Single‐dose levonorgestrel versus split‐dose levonorgestrel</h5> <p>Three trials compared regimens of levonorgestrel 1.5 mg single dose with levonorgestrel 0.75 mg two doses, 12 hours apart. <a href="./references#CD001324-bbs2-0001" title="ArowojoluAO , OkewoleLA , AdekunleAO . Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians. Contraception2002;66:269‐73. ">Arowojolu 2002</a> recruited 1160 women who had a single act of unprotected intercourse within 72 hours, and <a href="./references#CD001324-bbs2-0077" title="vonHertzenH , PiaggioG , DingJ , ChenJ , SongS , BartfaiG , et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception. Lancet2002;360:1803‐10. ">von Hertzen 2002</a> recruited 4136 and <a href="./references#CD001324-bbs2-0018" title="DadaOA , GodfreyEM , PiaggioG , vonHertzenH , Nigerian Network for Reproductive Health Research and Training. A randomized, double‐blind, noninferiority study to compare two regimens of levonorgestrel for emergency contraception in Nigeria. Contraception2010;82(4):373‐8. ">Dada 2010</a> recruited 3022 women attending clinics within 120 hours of unprotected intercourse. </p> <section id="CD001324-sec-0153"> <h6 class="title">2.17.1 Observed number of pregnancies</h6> <p>There was no evidence of a difference between the groups in pregnancy rates (RR 0.84; 95% CI 0.53 to 1.33, 3 RCTs, n = 6653, I<sup>2</sup> = 0%, moderate‐quality evidence) (<a href="./references#CD001324-fig-0076" title="">Analysis 18.1</a>; <a href="./full#CD001324-tbl-0006">summary of findings Table 6</a>). Additional analysis of the <a href="./references#CD001324-bbs2-0077" title="vonHertzenH , PiaggioG , DingJ , ChenJ , SongS , BartfaiG , et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception. Lancet2002;360:1803‐10. ">von Hertzen 2002</a> trial data indicated that this conclusion was not modified by whether the women abstained from further acts of intercourse or not (P = 0.18 for the interaction test), or by the time elapsed (within or after 72 hours) from intercourse to treatment administration (P = 0.90 for the interaction test). </p> <p><a href="./references#CD001324-bbs2-0077" title="vonHertzenH , PiaggioG , DingJ , ChenJ , SongS , BartfaiG , et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception. Lancet2002;360:1803‐10. ">von Hertzen 2002</a> reported one case of ectopic pregnancy in the split‐dose group. </p> </section> <section id="CD001324-sec-0154"> <h6 class="title">2.17.2 Side effects</h6> <p>Overall rates of side‐effects were not reported.</p> <p>With regard to specific side‐effects, there was no clear evidence of a difference between the groups in rates of nausea, vomiting, dizziness, fatigue, breast tenderness, diarrhoea, spotting/bleeding after treatment, or lower abdominal pain (<a href="./references#CD001324-fig-0079" title="">Analysis 18.4</a>, moderate‐quality evidence, <a href="./full#CD001324-tbl-0006">summary of findings Table 6</a>). Headache was more common in the single‐dose group (RR 1.14, 95% CI 1.01 to 1.30, 3 RCTs, n = 6804, I<sup>2</sup> = 57%). </p> </section> <section id="CD001324-sec-0155"> <h6 class="title">2.17.3. Effects on menses</h6> <p>Those who took single‐dose levonorgestrel were probably more likely to experience heavy menses (RR 1.48, 95% CI 1.08 to 2.04, 1 RCT, n = 1062) (<a href="./references#CD001324-fig-0079" title="">Analysis 18.4</a>) and delayed menses (RR 1.18, 95% CI 0.96 to 1.46, 2 RCTs, n = 3784, I<sup>2</sup> = 50%, low‐quality evidence) (<a href="./references#CD001324-fig-0080" title="">Analysis 18.5</a>; <a href="./full#CD001324-tbl-0006">summary of findings Table 6</a>). </p> </section> </section> <section id="CD001324-sec-0156"> <h5 class="title">2.18 Low‐dose mifepristone (10 mg) versus low‐dose mifepristone (5 mg)</h5> <p>Two Chinese trials (<a href="./references#CD001324-bbs2-0041" title="Lan XL ,  Chen LP , Ye QH . Clinical study of low‐dose mifepristone for emergency contraception [小剂量米非司酮用于紧急避孕的临床观察]. Clinical Medicine2006;26(11):68‐9. ">Lan 2006</a>; <a href="./references#CD001324-bbs2-0105" title="ZhangY , QiaoG , ZhuP , ZhangS , ZhangJ , ZhuN . Clinical observation of three lower doses of mifepristone for emergency contraception [三种低剂量米非司酮用于紧急避孕的临床观察]. Chinese Journal of Family Planning1998;6:343‐5. ">Zhang 1998</a>) and two Cuban trials (<a href="./references#CD001324-bbs2-0007" title="CarbonellJL , GarciaR , GonzalezA . Mifepristone 5 mg versus 10 mg for emergency contraception: double‐blinded randomized clinical trial. International Journal of Women's Health2015;7:95‐102. ">Carbonell 2015</a>; <a href="./references#CD001324-bbs2-0057" title="MirasRG , SanchezAG , MirasLG , Llibre GuerraJJ , deJesus Delgado GonzálezM , Penalver CruzAM . Mifepristone efficacy for emergency contraception when comparing 5 and 10 milligrams doses [Eficacia de la mifepristona como comtraceptivo de emergencia al comparar dosis de 5 y 10 miligramos]. Revista Cubana de Obstetricia y Ginecologia2014;40(3):326‐35. ">Miras 2014</a>) compared the effectiveness of mifepristone 10 mg to that of mifepristone 5 mg, among 3110 women. </p> <section id="CD001324-sec-0157"> <h6 class="title">2.18.1 Observed number of pregnancies</h6> <p>There was no clear evidence of a difference between the groups (RR 0.65, 95% CI 0.33 to 1.31, 4 RCTs, n = 3110, I<sup>2</sup> = 0%) (<a href="./references#CD001324-fig-0081" title="">Analysis 19.1</a>). </p> </section> <section id="CD001324-sec-0158"> <h6 class="title">2.18.2 Side effects</h6> <p>Overall rates of side‐effects were not reported.</p> <p>With regard to specific side‐effects, there was no clear evidence of a difference between the groups in rates of nausea, headache, dizziness, fatigue, breast tenderness, or lower abdominal pain (<a href="./references#CD001324-fig-0082" title="">Analysis 19.2</a>). </p> </section> <section id="CD001324-sec-0159"> <h6 class="title">2.18.3 Effects on menses</h6> <p>Those who took 10 mg mifepristone were more likely to experience delayed menses (RR 2.91, 95% CI 2.51 to 3.38, 1 RCT, n = 2418) and less likely to experience early menses (RR 0.62, 95% CI 0.50 to 0.76, 1 RCT, n = 2418) (<a href="./references#CD001324-fig-0083" title="">Analysis 19.3</a>) </p> </section> </section> <section id="CD001324-sec-0160"> <h5 class="title">2.19 Low dose mifepristone (10 mg) versus split low dose mifepristone (10 mg x2)</h5> <p>One Chinese trial (<a href="./references#CD001324-bbs2-0110" title="ZhangL , LaiL , DengX . Single and small dose of Mifepristone for emergency contraception of curative effect observe [单次小剂量米非司酮用于紧急避孕的疗效观察]. Journal of Gannan Medical College2005;3:328‐30. ">Zhang 2005</a>) compared regimens of mifepristone 10mg single dose with mifepristone 10mg two doses, 12 hours apart. </p> <section id="CD001324-sec-0161"> <h6 class="title">2.19.1 Observed number of pregnancies</h6> <p>There was no clear evidence of a difference between the groups in the risk of pregnancy (RR 0.96, 95% CI 0.06 to 15.22; 1 RCT, n= 220) (<a href="./references#CD001324-fig-0084" title="">Analysis 20.1</a>) </p> </section> <section id="CD001324-sec-0162"> <h6 class="title">2.19.2 Side effects</h6> <p>There was no conclusive evidence of a difference between the groups in rates of overall side effects. (RR 1.48, 95% CI 0.82 to 2.68; 1 RCT,n = 220) (<a href="./references#CD001324-fig-0085" title="">Analysis 20.2</a>) </p> <p>Specific side‐effects were not reported.</p> </section> <section id="CD001324-sec-0163"> <h6 class="title">2.19.3 Effects on menses</h6> <p>There was insufficient evidence to determine whether there was a difference between two regimens in rates of early menses (RR 1.29, 95% CI 0.29 to 5.61; 1 RCT, n = 220) or menstrual delay (RR 0.58, 95% CI 0.22 to 1.54; RCT,n = 220) (<a href="./references#CD001324-fig-0086" title="">Analysis 20.3</a>) </p> </section> </section> <section id="CD001324-sec-0164"> <h5 class="title">2.20 Mid‐dose mifepristone (25 mg to 50 mg) versus low‐dose mifepristone (less than 25 mg) </h5> <p>Twenty‐five trials were included in this comparison. Seventeen trials were two‐arm comparisons of mifepristone 25 mg versus mifepristone 10 mg (<a href="./references#CD001324-bbs2-0012" title="Chen S ,  An HB ,  Wang D ,  Jin FB . Different dose of mifepristone for emergency contraception [不同剂量米非司酮用于紧急避孕的临床观察]. China Health Care Nutrition ‐ Clinical Medicine Journal2009;2:28‐9. ">Chen 2009</a>; <a href="./references#CD001324-bbs2-0021" title="DuJ . Low dose of mifepristone for emergency contraception [小剂量米非司酮用于紧急避孕的临床观察]. Henan Yi Yao Xin Xi2002;11:14‐5. ">Du 2002</a>; <a href="./references#CD001324-bbs2-0023" title="FanH , ChengY , GuoF , WuS , TanY , ChenX , et al. Low dose of mifepristone for emergency contraception. Hubei Yu Fang Yi Xue Zha Zi2001;23:52. ">Fan 2001a</a>; <a href="./references#CD001324-bbs2-0034" title="HanL , MaY , LiH . Low doses of mifepristone for emergency contraception [低剂量米非司酮用于紧急避孕]. Fudan University Journal of Medical Sciences2001;2:176‐7. ">Han 2001a</a>; <a href="./references#CD001324-bbs2-0040" title="LaiZ , WangJ , ZhouZ , LuH , SongX , SunJ . A comparative study of low‐dose mifepristone for emergency contraception [低剂量米非司酮用于紧急避孕的临床观察]. Maternal and Child Health Care of China2004;19(2):36‐8. ">Lai 2004</a>; <a href="./references#CD001324-bbs2-0060" title="QiY , ZhangJ , CaoY , ZhangZ . A comparative clinical trial on two low doses of mifepristone for emergency contraception [两种低剂量米非司酮用于紧急避孕随机对比临床观察]. Maternal and Child Health Care of China2000;15:701‐4. ">Qi 2000a</a>; <a href="./references#CD001324-bbs2-0064" title="SangGW , ShaoQ , ZhangJ , ZhangM , ChenS , SongS , et al. A randomized multicentre clinical trial on different doses of mifepristone alone and in combination with anordrin as emergency contraception [不同剂量米非司酮及合并双炔失碳酯用于紧急避孕的多中心随机临床研究]. Chinese Journal of Obstetrics and Gynaecology1999;34(6):331‐4. ">Sang 1999</a>; <a href="./references#CD001324-bbs2-0081" title="WangSZ , HuangZK , LiS . Clinical trial of mifepristone in different dose for emergency contraception [不同剂量米非司酮用于紧急避孕的临床比较观察]. Chinese Journal of Practical Gynaecology and Obstetrics2001;9:534‐6. ">Wang 2001</a>; <a href="./references#CD001324-bbs2-0083" title="WangL , LvY , GuanD , ZhangH , YaoL . 12.5 mg mifepristone for emergency contraception [12.5 mg 米非司酮用于紧急避孕的临床研究]. Chinese General Practice2004;7:1477‐8. ">Wang 2004</a>; <a href="./references#CD001324-bbs2-0084" title="WangJ . A comparative study on different doses of mifepristone for emergency contraception [不同剂量米非司酮用于紧急避孕的临床疗效研究]. Journal Huaihai Medicine2006;24:19‐20. ">Wang 2006a</a>; <a href="./references#CD001324-bbs2-0085" title="Wang ZW ,  Qu HW . Two different doses of mifepristone for emergency contraception [两种剂量米非司酮进行紧急避孕比较分析]. Chinese Journal of Misdiagnosis2008;20:4819‐20. ">Wang 2008</a>; <a href="./references#CD001324-bbs2-0088" title="WeiRH . Low dose of mifepristone for emergency contraception ‐ 200 cases report [小剂量米非司酮用于紧急避孕200例的临床观察]. Shanghai Sheng Wu Yi Xue Gong Cheng Zha Zi2002;23:39‐42. ">Wei 2002a</a>; <a href="./references#CD001324-bbs2-0089" title="WeiH , HeCB , LiuJ . Low dose mifepristone for emergency contraception [小剂量米非司酮用于紧急避孕的临床研究]. Chinese and Foreign Women Health2011;19(3):70. ">Wei 2011</a>; <a href="./references#CD001324-bbs2-0095" title="XiaoBL , vonHertzenH , PiaggioG . A randomized double‐blind comparison of two single doses of mifepristone for emergency contraception. Human Reproduction2002;17:3084‐9. ">Xiao 2002</a>; <a href="./references#CD001324-bbs2-0097" title="Xie HH , Shang XM ,  Dai WY . Analysis of emergency contraception use mifepristone by different doses [不同剂量米非司酮用于紧急避孕的疗效分析]. Guide of China Medicine2010;8(14):34‐5. ">Xie 2010</a>; <a href="./references#CD001324-bbs2-0104" title="Zeng MY ,  Zhu LF ,  Huang Y . A comparative study of low‐dose mifepristone for emergency contraception [小剂量米非司酮用于紧急避孕的临床观察]. International Medicine Health Guidance News2008;14:68‐70. ">Zeng 2008</a>; <a href="./references#CD001324-bbs2-0115" title="ZuoSH , WuJ , LiuL , LiuJ , GaoY . A clinical trial on two low doses of mifepristone for emergency contraception [两种低剂量米非司酮用于房事后紧急避孕的临床研究]. Reproduction &amp; Contraception (China)1999;6:352‐6. ">Zuo 1999</a>). Seven trials had three arms (<a href="./references#CD001324-bbs2-0015" title="ChengL , TongCH , XiaoZH . Low doses of mifepristone for emergency postcoital contraception [不同剂量米非司酮用于紧急避孕的临床多中心研究]. Chinese Journal of Obstetrics and Gynaecology1999;6:335‐8. ">Cheng 1999a</a>; <a href="./references#CD001324-bbs2-0019" title="DingG . Different doses of mifepristone for emergency contraception [不同剂量米非司酮用于紧急避孕的临床观察]. Journal of Practical Diagnosis and Therapy2005;19:226‐7. ">Ding 2005</a>; <a href="./references#CD001324-bbs2-0073" title="TanL , ZhengG , LiJ . Mifepristone for emergency contraception ‐ 150 cases report [150例米非司酮用于紧急避孕的临床观察]. Health Vocational Education2003;21:138‐9. ">Tan 2003</a>; <a href="./references#CD001324-bbs2-0091" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet1999;353:697‐702. ">WHO 1999</a>; <a href="./references#CD001324-bbs2-0105" title="ZhangY , QiaoG , ZhuP , ZhangS , ZhangJ , ZhuN . Clinical observation of three lower doses of mifepristone for emergency contraception [三种低剂量米非司酮用于紧急避孕的临床观察]. Chinese Journal of Family Planning1998;6:343‐5. ">Zhang 1998</a>; <a href="./references#CD001324-bbs2-0109" title="ZhangY , WenL , LiS , WangY . Mifepristone for emergency contraception [米非司酮用于紧急避孕的临床研究]. Henan YI Yao Xin XI2002;8:20‐1. ">Zhang 2002b</a>; <a href="./references#CD001324-bbs2-0113" title="ZhaoJ , LiuR , LiH , ZhangY . Different doses of mifepristone for emergency contraception [不同剂量米非司酮用于紧急避孕的临床观察]. Journal of Shandong University (Health Sciences)2003;41:468. ">Zhao 2003</a>) and one trial had four comparisons (<a href="./references#CD001324-bbs2-0005" title="CaoP , LiM , XuJ , LiQ . Different doses of mifepristone for emergency contraception [不同剂量米非司酮用于紧急避孕效果的观察与分析]. Journal of Practical Obstetrics and Gynecology1999;15:295‐6. ">Cao 1999</a>). Except for the WHO trial (<a href="./references#CD001324-bbs2-0091" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet1999;353:697‐702. ">WHO 1999</a>), all trials were conducted in China. </p> <section id="CD001324-sec-0165"> <h6 class="title">2.20.1 Observed number of pregnancies</h6> <p>The pooled data showed that the mid‐dose regimen was more effective than the low‐dose regimen (RR 0.73, 95% CI 0.55 to 0.97, 25 RCTs, n = 11,914, I<sup>2</sup> = 0%, high‐quality evidence) (<a href="./references#CD001324-fig-0087" title="">Analysis 21.1</a>; <a href="./full#CD001324-tbl-0007">summary of findings Table 7</a>). This suggests that if the chance of pregnancy following low‐dose mifepristone is assumed to 17 per 1000 women, that chance following mid‐dose would be between 9 to 16 per 1000 women. </p> <p><a href="./references#CD001324-bbs2-0091" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet1999;353:697‐702. ">WHO 1999</a> reported two cases of ectopic pregnancy in the 50 mg mifepristone group and <a href="./references#CD001324-bbs2-0064" title="SangGW , ShaoQ , ZhangJ , ZhangM , ChenS , SongS , et al. A randomized multicentre clinical trial on different doses of mifepristone alone and in combination with anordrin as emergency contraception [不同剂量米非司酮及合并双炔失碳酯用于紧急避孕的多中心随机临床研究]. Chinese Journal of Obstetrics and Gynaecology1999;34(6):331‐4. ">Sang 1999</a> reported one ectopic pregnancy in the 10 mg mifepristone group. </p> <p>Funnel plots for the primary outcomes (live birth and ongoing pregnancy) did not suggest reporting bias. </p> </section> <section id="CD001324-sec-0166"> <h6 class="title">2.20.2 Side effects</h6> <p>Mid‐dose mifepristone was associated with a higher overall rate of side effects than low‐dose mifepristone (RR 1.31, 95% CI 1.01 to 1.70, 11 RCTs, n =2464 , I<sup>2</sup> = 9%, moderate‐quality evidence) (<a href="./references#CD001324-fig-0089" title="">Analysis 21.3</a>). </p> <p>With regard to specific side effects, there was no clear evidence of a difference between the groups in rates of nausea, vomiting, headache, dizziness, fatigue, breast tenderness, diarrhoea, or abdominal pain, but mid‐dose mifepristone was associated with higher risks of spotting/bleeding (RR 1.85, 95% CI 1.55 to 2.20, 11 RCTs, n = 5078 , I<sup>2</sup> = 41%, high‐quality evidence) (<a href="./references#CD001324-fig-0090" title="">Analysis 21.4</a>; <a href="./full#CD001324-tbl-0007">summary of findings Table 7</a>). </p> </section> <section id="CD001324-sec-0167"> <h6 class="title">2.20.3 Effects on menses</h6> <p>Women in the mid‐dose group may be more likely to experience menstrual delay (RR 1.28; 95% CI 1.11 to 1.47, 21 RCTs, n = 11,282, I<sup>2</sup> = 56%, moderate‐quality evidence) than low‐dose mifepristone (<a href="./references#CD001324-fig-0091" title="">Analysis 21.5</a>; <a href="./full#CD001324-tbl-0007">summary of findings Table 7</a>). There was no clear evidence of a difference between the groups in rates of early menses (RR 1.09, 95% CI 0.87 to 1.36, 7 RCTs, n = 2136, I<sup>2</sup> = 0%, low‐quality evidence). </p> </section> </section> <section id="CD001324-sec-0168"> <h5 class="title">2.21 Mid‐dose mifepristone (50 mg) versus mid‐dose mifepristone (25 mg)</h5> <p>Thirteen Chinese trials (<a href="./references#CD001324-bbs2-0005" title="CaoP , LiM , XuJ , LiQ . Different doses of mifepristone for emergency contraception [不同剂量米非司酮用于紧急避孕效果的观察与分析]. Journal of Practical Obstetrics and Gynecology1999;15:295‐6. ">Cao 1999</a>; <a href="./references#CD001324-bbs2-0009" title="ChenR , LiQ , ZhangY , HuangM , ChenY , ZhongX , et al. A comparative study of low‐dose mifepristone for emergency contraception [两种不同小剂量米非司酮用于紧急避孕的临床研究]. Shi Yong Yi Xue Zha Zi2002;10:1028‐9. ">Chen 2002a</a>; <a href="./references#CD001324-bbs2-0015" title="ChengL , TongCH , XiaoZH . Low doses of mifepristone for emergency postcoital contraception [不同剂量米非司酮用于紧急避孕的临床多中心研究]. Chinese Journal of Obstetrics and Gynaecology1999;6:335‐8. ">Cheng 1999a</a>; <a href="./references#CD001324-bbs2-0024" title="FangQ , GuoX , PanJ , XiaoJ , LiY . A comparative study on different doses of mifepristone for emergency contraception [不同剂量米非司酮用于紧急避孕的临床观察]. Maternal and Child Health Care of China2000;15:48‐9. ">Fang 2000</a>; <a href="./references#CD001324-bbs2-0032" title="HanX , WengL , XiaoB . Emergency contraception with mifepristone and anordrin [米非司酮用于紧急避孕的临床观察]. Chinese Journal of Obstetrics and Gynecology1996;9:526‐9. ">Han 1996</a>; <a href="./references#CD001324-bbs2-0044" title="LiQ , ChenR , ZhangY , HuangM , ChenRX , ZhongX . A comparative study of mifepristone 50 mg and 25 mg for emergency contraception [50mg与25mg米非司酮用于紧急避孕的临床效果比较]. Guangdon Medical Journal2000;22:884‐5. ">Li 2000b</a>; <a href="./references#CD001324-bbs2-0045" title="LiH , ChangJP , LiJ . A study of low‐dose mifepristone for emergency contraception [小剂量米非司酮用于紧急避孕的临床观察]. Heilongjiang Medical Journal2000;23:90. ">Li 2000c</a>; <a href="./references#CD001324-bbs2-0055" title="LouC . Low‐dose mifepristone for emergency contraception [低剂量米非司酮用于紧急避孕的效果]. Xian Dai Shi Yong YI Xue2002;14:485. ">Lou 2002</a>; <a href="./references#CD001324-bbs2-0072" title="TanK , MaiT , HeP , LinH , LiS . Low doses of mifepristone for emergency contraception [分两次服用小剂量米非司酮用于紧急避孕]. Chinese Journal of Family Planning1999;7:470‐1. ">Tan 1999</a>; <a href="./references#CD001324-bbs2-0096" title="XieX , LiuY , LinX . A clinical study on 600 cases of mifepristone for emergency contraception [米非司酮用于紧急避孕600例临床观察]. Reproduction &amp; Contraception (China)1998;18:224‐6. ">Xie 1998</a>; <a href="./references#CD001324-bbs2-0101" title="YangF . A comparative study on two low doses of mifepristone for emergency contraception. Journal of Clinical Research2003;20:630‐1. ">Yang 2003</a>; <a href="./references#CD001324-bbs2-0107" title="ZhangJQ . Emergency contraception in high‐land [高原地区紧急避孕临床应用]. Chinese Journal of Family Planning2000;8:552‐4. ">Zhang 2000</a>; <a href="./references#CD001324-bbs2-0113" title="ZhaoJ , LiuR , LiH , ZhangY . Different doses of mifepristone for emergency contraception [不同剂量米非司酮用于紧急避孕的临床观察]. Journal of Shandong University (Health Sciences)2003;41:468. ">Zhao 2003</a> ) compared mifepristone 50 mg with mifepristone 25 mg. </p> <section id="CD001324-sec-0169"> <h6 class="title">2.21.1 Observed number of pregnancies</h6> <p>There was no conclusive evidence of a difference in pregnancies between the groups receiving 50 mg mifepristone and 25 mg mifepristone (RR 0.72, 95% CI 0.41 to 1.27, 13 RCTs, n = 3123, I<sup>2</sup> = 0%) (<a href="./references#CD001324-fig-0092" title="">Analysis 22.1</a>). </p> <p>Funnel plots for the primary outcomes (observed number of pregnancies) did not suggest reporting bias. </p> </section> <section id="CD001324-sec-0170"> <h6 class="title">2.21.2 Side effects</h6> <p>The 50 mg dose of mifepristone was associated with a higher overall rate of side effects than the 25 mg dose (RR 1.79, 95% CI 1.39 to 2.31, 6 RCTs, n = 1465, I<sup>2</sup> = 5%) (<a href="./references#CD001324-fig-0093" title="">Analysis 22.2</a>). </p> <p>With regard to specific side effects, there was no clear evidence of a difference between the groups in rates of nausea, vomiting, headache, dizziness, fatigue, breast tenderness, abdominal pain, or spotting/bleeding after treatment (<a href="./references#CD001324-fig-0094" title="">Analysis 22.3</a>). </p> </section> <section id="CD001324-sec-0171"> <h6 class="title">2.21.3 Effects on menses</h6> <p>There was evidence that the 50 mg regimen may be associated with a higher probability of menstrual delay than the 25 mg regimen (RR 1.32, 95% CI 1.12 to 1.56, 8 RCTs, n = 1945 , I<sup>2</sup> = 0%) (<a href="./references#CD001324-fig-0095" title="">Analysis 22.4</a>). </p> </section> </section> <section id="CD001324-sec-0172"> <h5 class="title">2.22 Mid dose mifepristone split dose comparisons</h5> <p>One trial (<a href="./references#CD001324-bbs2-0106" title="ZhangX , GaoG , ShiJ , QuC , LengY . A clinical study on low doses of mifepristone for emergency contraception [低剂量米非司酮用于紧急避孕的临床效果观察]. Chinese Journal of Family Planning1999;4:175‐6. ">Zhang 1999b</a>) compared three different regimens of mifepristone (1) mifepristone 25 mg orally two doses 12 hours apart; (2) mifepristone 10 mg/day for five days and (3) mifepristone 10mg/day for three days. </p> <section id="CD001324-sec-0173"> <h6 class="title">2.22.1 Observed number of pregnancies</h6> <p>There was no conclusive evidence of a difference in pregnancies between the groups receiving 50 mg mifepristone (25 mg orally two doses ) versus 30 mg mifepristone (10mg/day for three days) (RR 1.93, 95% CI 0.18 to 21.03; 1 RCT,n= 236); the groups receiving 50 mg mifepristone (25 mg orally two doses ) versus 50 mg mifepristone (10mg/day for five days) (RR 4.92, 95% CI 0.24 to 101.35; 1 RCT, n = 238); or the groups receiving 30 mg mifepristone (10mg/day for three days) versus 50 mg mifepristone (10mg/day for five days) (RR 3.05, 95% CI 0.13 to 74.14; 1 RCT, n = 234) (<a href="./references#CD001324-fig-0096" title="">Analysis 23.1</a>). </p> </section> <section id="CD001324-sec-0174"> <h6 class="title">2.22.2 Side effects</h6> <p>There were only 14 events in this trial, all of which occurred in the group receiving the 50 mg dose split into two 25 mg doses, suggesting that this regimen was associated with a higher risk of side effects than the 50 mg dose split into five 10 mg doses (RR 28.52, 95% CI 1.72 to 472.69; 1 RCT, n = 238), or the 30 mg dose (10mg/day for three days) (RR 28.04, 95% CI 1.69 to 464.70; 1 RCT, n = 236) (<a href="./references#CD001324-fig-0097" title="">Analysis 23.2</a>). </p> </section> <section id="CD001324-sec-0175"> <h6 class="title">2.22.3 Effects on menses</h6> <p>There was no clear evidence of a difference in rates of early menses between the groups receiving 50 mg mifepristone (25 mg orally two doses ) versus 30 mg mifepristone (10mg/day for three days) (RR 1.05, 95% CI 0.63 to 1.77; 1 RCT,n= 236); the groups receiving 50 mg mifepristone (25 mg orally two doses ) versus 50 mg mifepristone (10mg/day for five days) (RR 1.07, 95% CI 0.64 to 1.80; 1 RCT, n = 238); or the groups receiving 30 mg mifepristone (10mg/day for three days) versus 50 mg mifepristone (10mg/day for five days) (RR 1.02, 95% CI 0.60 to 1.73; 1 RCT, n = 234) (<a href="./references#CD001324-fig-0098" title="">Analysis 23.3</a>). </p> <p>Delay of subsequent menses was more common in the group receiving 50 mg mifepristone (25 mg orally two doses ) than in those receiving 30 mg mifepristone (10mg/day for three days) (RR 1.86, 95% CI 1.03 to 3.37; 1 RCT, n = 236). There was no clear evidence of a difference in rates of delayed menses between the groups receiving 50 mg mifepristone (25 mg orally two doses ) versus 50 mg mifepristone (10mg/day for five days) (RR 1.15 95% CI 0.70 to 1.89; 1 RCT, n = 238); or the groups receiving 30 mg mifepristone (10mg/day for three days) versus 50 mg mifepristone (10mg/day for five days) (RR 0.62, 95% CI 0.34 to 1.14; 1 RCT, n = 234) (<a href="./references#CD001324-fig-0099" title="">Analysis 23.4</a>). </p> </section> </section> <section id="CD001324-sec-0176"> <h5 class="title">2.23 High‐dose mifepristone (more than 50 mg) versus low‐dose mifepristone (less than 25 mg) </h5> <p>Five trials compared high‐ versus low‐dose mifepristone, one with four treatment arms (<a href="./references#CD001324-bbs2-0005" title="CaoP , LiM , XuJ , LiQ . Different doses of mifepristone for emergency contraception [不同剂量米非司酮用于紧急避孕效果的观察与分析]. Journal of Practical Obstetrics and Gynecology1999;15:295‐6. ">Cao 1999</a>; 100 mg, 50 mg, 25 mg, 10 mg) and four with three (<a href="./references#CD001324-bbs2-0091" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet1999;353:697‐702. ">WHO 1999</a>: 600 mg, 50 mg, 10 mg; <a href="./references#CD001324-bbs2-0019" title="DingG . Different doses of mifepristone for emergency contraception [不同剂量米非司酮用于紧急避孕的临床观察]. Journal of Practical Diagnosis and Therapy2005;19:226‐7. ">Ding 2005</a>: 75 mg, 50 mg, 10 mg; <a href="./references#CD001324-bbs2-0073" title="TanL , ZhengG , LiJ . Mifepristone for emergency contraception ‐ 150 cases report [150例米非司酮用于紧急避孕的临床观察]. Health Vocational Education2003;21:138‐9. ">Tan 2003</a>: 150 mg, 50 mg, 12.5 mg; <a href="./references#CD001324-bbs2-0109" title="ZhangY , WenL , LiS , WangY . Mifepristone for emergency contraception [米非司酮用于紧急避孕的临床研究]. Henan YI Yao Xin XI2002;8:20‐1. ">Zhang 2002b</a>: 100 mg, 50 mg, 10 mg). </p> <section id="CD001324-sec-0177"> <h6 class="title">2.23.1 Observed number of pregnancies</h6> <p>There was no conclusive evidence of a difference in the risk of pregnancy between high‐dose and low‐dose mifepristone (RR 0.52, 95% CI 0.23 to 1.17; 5 RCTs, n = 1726 , I<sup>2</sup> = 20%, <a href="./references#CD001324-fig-0100" title="">Analysis 24.1</a> ). This suggests that if the risk of pregnancy following low‐dose mifepristone is assumed to be 19 per 1000 women, the risk following high‐dose would be between 4 and 23 per 1000 women. </p> </section> <section id="CD001324-sec-0178"> <h6 class="title">2.23.2 Side effects</h6> <p>High‐dose mifepristone was associated with a higher overall rate of side effects than low‐dose mifepristone (RR 13.04, 95% CI 5.13 to 33.15, 3 RCTs, n = 512, I<sup>2</sup> = 55%) (<a href="./references#CD001324-fig-0102" title="">Analysis 24.3</a>). </p> <p>With regard to specific side effects, there was no clear evidence of a difference between the groups in rates of nausea, dizziness, fatigue, breast tenderness or diarrhoea. There was evidence that spotting/bleeding is probably more frequent with use of the high‐dose mifepristone (RR 2.36, 95% CI 1.89 to 2.95, 2 RCTs, n = 1224, I<sup>2</sup> = 0%) (<a href="./references#CD001324-fig-0103" title="">Analysis 24.4</a>). </p> </section> <section id="CD001324-sec-0179"> <h6 class="title">2.23.3 Effects on menses</h6> <p>Delay of subsequent menses (RR 1.98, 95% CI 1.66 to 2.37, 4 RCTs, n = 1574 , I<sup>2</sup> = 47%) (<a href="./references#CD001324-fig-0104" title="">Analysis 24.5</a>) appeared to be more frequent in the high‐dose mifepristone group. </p> </section> </section> <section id="CD001324-sec-0180"> <h5 class="title">2.24 High‐dose mifepristone (more than 50 mg) versus mid‐dose mifepristone (25 mg to 50 mg) </h5> <p>Eight Chinese trials (<a href="./references#CD001324-bbs2-0005" title="CaoP , LiM , XuJ , LiQ . Different doses of mifepristone for emergency contraception [不同剂量米非司酮用于紧急避孕效果的观察与分析]. Journal of Practical Obstetrics and Gynecology1999;15:295‐6. ">Cao 1999</a>; <a href="./references#CD001324-bbs2-0019" title="DingG . Different doses of mifepristone for emergency contraception [不同剂量米非司酮用于紧急避孕的临床观察]. Journal of Practical Diagnosis and Therapy2005;19:226‐7. ">Ding 2005</a>; <a href="./references#CD001324-bbs2-0045" title="LiH , ChangJP , LiJ . A study of low‐dose mifepristone for emergency contraception [小剂量米非司酮用于紧急避孕的临床观察]. Heilongjiang Medical Journal2000;23:90. ">Li 2000c</a>; <a href="./references#CD001324-bbs2-0062" title="QianL . Three doses of mifepristone for emergency contraception [三种剂量米非司酮用于紧急避孕的临床观察]. Chinese Journal of Family Planning1999;7:322‐3. ">Qian 1999</a>; <a href="./references#CD001324-bbs2-0073" title="TanL , ZhengG , LiJ . Mifepristone for emergency contraception ‐ 150 cases report [150例米非司酮用于紧急避孕的临床观察]. Health Vocational Education2003;21:138‐9. ">Tan 2003</a>; <a href="./references#CD001324-bbs2-0096" title="XieX , LiuY , LinX . A clinical study on 600 cases of mifepristone for emergency contraception [米非司酮用于紧急避孕600例临床观察]. Reproduction &amp; Contraception (China)1998;18:224‐6. ">Xie 1998</a>;<a href="./references#CD001324-bbs2-0109" title="ZhangY , WenL , LiS , WangY . Mifepristone for emergency contraception [米非司酮用于紧急避孕的临床研究]. Henan YI Yao Xin XI2002;8:20‐1. ">Zhang 2002b</a>; <a href="./references#CD001324-bbs2-0114" title="ZhengA . Low‐dose of mifepristone for emergency contraception [小剂量米非司酮用于紧急避孕的临床观察]. Youjiang Medical Journal2005;4:375‐6. ">Zheng 2005</a>) and one WHO trial (<a href="./references#CD001324-bbs2-0091" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet1999;353:697‐702. ">WHO 1999</a>) were included in this comparison. The WHO trial had three study arms (600 mg, 50 mg, 10 mg). </p> <section id="CD001324-sec-0181"> <h6 class="title">2.24.1 Observed number of pregnancies</h6> <p>There was no conclusive evidence of a difference between the high‐ and mid‐dose groups in the risk of pregnancy (RR 0.93, 95% CI 0.50 to 1.72, 9 RCTs, n = 3009, I<sup>2</sup> = 0%) (<a href="./references#CD001324-fig-0105" title="">Analysis 25.1</a>). Funnel plots for this outcome did not suggest reporting bias. </p> </section> <section id="CD001324-sec-0182"> <h6 class="title">2.24.2 Side effects</h6> <p>High dose mifepristone was associated with a higher overall rate of side‐effects than mid dose mifepristone (RR 2.64 95% CI 1.57 to 4.43, 5 RCTs, n = 1310, I<sup>2</sup> = 58%) (<a href="./references#CD001324-fig-0106" title="">Analysis 25.2</a>). </p> <p>With regard to specific side effects, there was no clear evidence of a difference between the groups in rates of nausea, dizziness, fatigue, breast tenderness or diarrhoea. Bleeding episodes appear to be more frequent with the high‐dose regimen (RR 1.32, 95% CI 1.12 to 1.56, 4 RCTs, n = 1509, I<sup>2</sup> = 78%, <a href="./references#CD001324-fig-0107" title="">Analysis 25.3</a>). There was high heterogeneity, but the direction of effect was consistent. </p> </section> <section id="CD001324-sec-0183"> <h6 class="title">2.24.3 Effects on menses</h6> <p>Delays in subsequent menses (RR 1.53, 95% CI 1.34 to 1.75, 8 RCTs, n = 2854, I<sup>2</sup> = 0%) were probably more frequent in the high‐dose regimen group. Evidence suggested that the high‐dose regimen was also associated with a higher rate of early menses (RR 10.00, 95% CI 1.30 to 76.66, 2 RCTs, n = 290) (<a href="./references#CD001324-fig-0108" title="">Analysis 25.4</a>). </p> </section> </section> <section id="CD001324-sec-0184"> <h5 class="title">2.25 Half‐dose Yuzpe regimen versus standard Yuzpe regimen</h5> <p><a href="./references#CD001324-bbs2-0022" title="EllertsonC , WebbA , BlanchardK , BigriggA , HaskellS , ShochetT , et al. Modifying the Yuzpe regimen of emergency contraception: a multicenter randomized controlled trial. Obstetrics and Gynecology2003;101:1160‐7. ">Ellertson 2003a</a> compared the standard Yuzpe regimen (of two doses, 12 hours apart) to a half dose given only once, and to a standard regimen replacing norgestrel with norethindrone in a three‐arm trial. </p> <section id="CD001324-sec-0185"> <h6 class="title">2.25.1. Observed number of pregnancies</h6> <p>It was unclear whether there was a difference between the groups in the risk of pregnancy (RR 1.41, 95% CI 0.76 to 2.61, 1 RCT, n = 1323) (<a href="./references#CD001324-fig-0109" title="">Analysis 26.1</a>). </p> </section> <section id="CD001324-sec-0186"> <h6 class="title">2.25.2 Side effects</h6> <p>The side‐effect profile was improved with the half dose (any side effect: RR 0.85, 95% CI 0.77 to 0.93, 1 RCT, n = 1288; nausea: RR 0.86, 95% CI 0.77 to 0.97, 1 RCT, n = 1288; vomiting: RR 0.50, 95% CI 0.36 to 0.69, 1 RCT, n = 1288), though there was no evidence of a difference between the groups in rates of headache, dizziness or abdominal pain (<a href="./references#CD001324-fig-0111" title="">Analysis 26.3</a>). </p> </section> <section id="CD001324-sec-0187"> <h6 class="title">2.25.3 Effects on menses</h6> <p>No studies reported this outcome.</p> </section> </section> </section> <section id="CD001324-sec-0188"> <h4 class="title">3. IUD versus emergency contraceptive pills</h4> <section id="CD001324-sec-0189"> <h5 class="title">3.1 Cu‐IUD versus mifepristone</h5> <p>Two Chinese trials (<a href="./references#CD001324-bbs2-0053" title="LiuL , ChenA . A comparative study of mifepristone with Cu‐IUD for emergency contraception [米非司酮与带铜宫内节育器（IUD）用于紧急避孕方法的对比观察]. Journal of Changzhi Medical College2002;61:198‐9. ">Liu 2002b</a>, <a href="./references#CD001324-bbs2-0075" title="TianZM . A clinical comparative observation among copper IUD and mifepristone for emergency contraception [Cu‐IUD和米非司酮用于紧急避孕的效果比较]. China Health Care &amp; Nutrition2013;9:5238. ">Tian 2013</a>) compared Cu‐IUD with mifepristone 50 mg. </p> <section id="CD001324-sec-0190"> <h6 class="title">3.1.1. Observed number of pregnancies</h6> <p>There was insufficient evidence to determine whether there was a difference in the risk of pregnancy between the Cu‐IUD group and the mifepristone group (RR 0.33, 95% CI 0.04 to 2.74; 2 RCTs, n = 395, I<sup>2</sup> = 0%, low‐quality evidence) (<a href="./references#CD001324-fig-0112" title="">Analysis 27.1</a>; <a href="./full#CD001324-tbl-0008">summary of findings Table 8</a>). </p> </section> <section id="CD001324-sec-0191"> <h6 class="title">3.1.2 Side effects</h6> <p>The evidence suggested that the overall risk of side effects was lower in the Cu‐IUD group (RR 0.06, 95% CI 0.00, 0.99, 1 RCT, n = 285), but the risk of abdominal pain was higher (RR 73.61, 95% CI 4.48 to 1208.50; 1 RCT, n = 285, low‐quality evidence) (<a href="./references#CD001324-fig-0114" title="">Analysis 27.3</a>). </p> </section> <section id="CD001324-sec-0192"> <h6 class="title">3.1.3 Effects on menses</h6> <p>Cu‐IUD users may be more likely to experience delay of menses than mifepristone users (RR 0.23, 95% CI 0.09 to 0.64, 1 RCT, n = 284, low‐quality evidence) (<a href="./references#CD001324-fig-0115" title="">Analysis 27.4</a>; <a href="./full#CD001324-tbl-0008">summary of findings Table 8</a>). </p> </section> </section> </section> <section id="CD001324-sec-0193"> <h4 class="title">Subgroup analyses</h4> <section id="CD001324-sec-0194"> <h5 class="title">Time elapsed since intercourse</h5> <p>In comparisons of shorter versus longer time elapsed between intercourse and treatment, times compared varied from a minimum of under 24 hours to a maximum of over 72 hours. </p> <p> <ol id="CD001324-list-0021"> <li> <p>For levonorgestrel there were seven relevant studies. The risk of pregnancy was lower if levonorgestrel was given within 72 hours of intercourse than if it was given later than this (RR 0.51, 95% CI 0.31 to 0.84, 4 RCTs, n = 7453, I<sup>2</sup> = 59%). There was moderate heterogeneity, but the direction of effect was consistent. </p> </li> <li> <p>For mifepristone there were three relevant studies, but there were insufficient data to determine whether there was a difference between the groups. </p> </li> <li> <p>For the Yuzpe regimen there were three relevant studies. The risk of pregnancy was lower in women receiving treatment within 24 hours than in those who received treatment at 24 hours to 48 hours (RR 0.47, 95% CI 0.26 to 0.88, 3 studies, n = 1527, I<sup>2</sup> = 0%) or at 48 hours to 72 hours (RR 0.41, 95% CI 0.18 to 0.89, 2 studies, n = 863, I<sup>2</sup> = 0%). Findings were inconclusive in the comparison of treatment between 24 hours and 48 hours after intercourse versus between 48 hours and 72 hours. </p> </li> <li> <p>For UPA there were two relevant studies, but there were insufficient data to determine whether there was a difference between the groups. </p> </li> </ol> </p> </section> <section id="CD001324-sec-0195"> <h5 class="title">High‐risk women versus low‐risk women</h5> <p>When we combined all studies of hormonal interventions, women defined as 'high risk' (who had further acts of intercourse during the same cycle in which EC was used) were at higher risk of pregnancy than women defined as 'low risk' (those without further acts of coitus during that cycle) (RR 2.67, 95% CI 2.11 to 3.39, 11 studies, n = 19,700, I<sup>2</sup> = 66%). There was moderate heterogeneity, but the direction of effect was consistent. </p> </section> <section id="CD001324-sec-0196"> <h5 class="title">BMI</h5> <p>No randomized data were reported by the included studies.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001324-sec-0197" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001324-sec-0197"></div> <section id="CD001324-sec-0198"> <h3 class="title" id="CD001324-sec-0198">Summary of main results</h3> <p>A total of 115 trials with 60,479 women met our inclusion criteria and were included in this review. Our main findings were as follows. </p> <p> <ol id="CD001324-list-0022"> <li> <p>Evidence from six trials in 4750 women showed that the levonorgestrel regimen is more effective in preventing pregnancy than the Yuzpe regimen. However, since the Yuzpe regimen is a well‐established method for emergency contraception, and in many countries is the only available emergency contraception method, Yuzpe should continue to be provided in these specific settings. </p> </li> <li> <p>Evidence from 27 studies in 6052 women showed that effectiveness of mid‐dose mifepristone regimens was probably better than that of levonorgestrel regimens to prevent unwanted pregnancy. Moreover, based on data from 14 trials in 8752 women, low‐dose mifepristone (less than 25 mg) regimens were more effective than levonorgestrel regimens. </p> </li> <li> <p>Evidence from 25 trials in 11,914 participants indicated that the mid‐dose mifepristone regimens are more effective than the low‐dose mifepristone regimens. </p> </li> <li> <p>Three trials compared a 1.5 mg, single‐dose levonorgestrel regimen with two doses of 0.75 mg levonorgestrel, 12 hours apart. The pooled data from 6653 women suggested that the effectiveness of the two regimens was similar. </p> </li> <li> <p>One double‐blinded, randomized, multicenter trial compared levonorgestrel split‐dose 24 hours apart with levonorgestrel split‐dose 12 hours apart. Findings from 2060 participants indicated that the effectiveness between the two split‐dose regimens was probably similar. </p> </li> <li> <p>Two trials compared effectiveness of UPA with that of levonorgestrel regimens. The UPA regimen was associated with fewer pregnancies than the levonorgestrel regimen. </p> </li> <li> <p>There was insufficient evidence (data from two trials in 395 women) to determine the relative effectiveness of Cu‐IUD compared with mifepristone. The evidence suggests that Cu‐IUD may be more effective, but more data are required for this comparison. </p> </li> <li> <p>Evidence from one trial in 300 women showed (as would be expected) that there was a higher number of pregnancies in the expectant management group than in the group of IUD users. This type of comparison is no longer considered ethical. </p> </li> </ol> </p> <p>Altogether there were five cases of ectopic pregnancy out of 1153 pregnancies reported overall in the included 115 trials (0.4%). These occurred as follows: <a href="./references#CD001324-bbs2-0091" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet1999;353:697‐702. ">WHO 1999</a> reported two cases after 50 mg mifepristone; <a href="./references#CD001324-bbs2-0064" title="SangGW , ShaoQ , ZhangJ , ZhangM , ChenS , SongS , et al. A randomized multicentre clinical trial on different doses of mifepristone alone and in combination with anordrin as emergency contraception [不同剂量米非司酮及合并双炔失碳酯用于紧急避孕的多中心随机临床研究]. Chinese Journal of Obstetrics and Gynaecology1999;34(6):331‐4. ">Sang 1999</a> reported one case after 10 mg mifepristone; and <a href="./references#CD001324-bbs2-0068" title="SuW , ChuiJY , LiuP . A comparative study of IUCD with mifepristone and with levonorgestrel for emergency contraception [米非司酮、 左炔诺孕酮和IUCD用于紧急避孕的临床观察研究]. Journal of Baotou Medicine2001;25:24. ">Su 2001</a> and <a href="./references#CD001324-bbs2-0077" title="vonHertzenH , PiaggioG , DingJ , ChenJ , SongS , BartfaiG , et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception. Lancet2002;360:1803‐10. ">von Hertzen 2002</a> reported one case each after split‐dose of levonorgestrel. Eleven healthy infants were reported to be delivered following the use of ECPs (<a href="./references#CD001324-bbs2-0001" title="ArowojoluAO , OkewoleLA , AdekunleAO . Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in Nigerians. Contraception2002;66:269‐73. ">Arowojolu 2002</a>; <a href="./references#CD001324-bbs2-0029" title="GlasierAF , CameronST , FinePM , LoganSJ , CasaleW , VanHornJ , et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non‐inferiority trial and meta‐analysis. Lancet2010;375(9714):555‐62. ">Glasier 2010</a>; <a href="./references#CD001324-bbs2-0087" title="WebbAM . Alternative treatments in oral postcoital contraception: interim results. Advances in Contraception1991;7:271‐9. WebbAMC , RussellJ , ElsteinM . Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. BMJ1992;305:927‐31. ">Webb 1992</a>): seven mothers used levonorgestrel, two used the Yuzpe regimen, one used danazol and one used mifepristone. </p> <p>Nausea and vomiting occurred with oestrogen‐containing EC methods. Progestogen and anti‐progestogen methods caused changes in subsequent menses. All methods of EC appeared safe, and no serious adverse events were identified among EC users. </p> </section> <section id="CD001324-sec-0199"> <h3 class="title" id="CD001324-sec-0199">Overall completeness and applicability of evidence</h3> <p>We have added 13 trials to the previous version of the review (<a href="./references#CD001324-bbs2-0249" title="ChengL , CheY , GülmezogluAM . Interventions for emergency contraception. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD001324.pub4] ">Cheng 2012</a>), and the number of included women in these studies has increased to 60,479 from 55,666 in <a href="./references#CD001324-bbs2-0249" title="ChengL , CheY , GülmezogluAM . Interventions for emergency contraception. Cochrane Database of Systematic Reviews2012, Issue 8. [DOI: 10.1002/14651858.CD001324.pub4] ">Cheng 2012</a>. All the included studies reported observed pregnancies as their primary outcome. However, studies often failed to report important secondary outcomes such as breast tenderness, headache, dizziness, fatigue, lower abdominal pain, diarrhoea, and spotting or bleeding after treatment. </p> <p>We only identified three trials evaluating the effects of Cu‐IUD to prevent unwanted pregnancy, and we rated their data quality as low. As pregnancy appears to be rare among women using Cu‐IUD for EC and the side effects of Cu‐IUD are well documented, Cu‐IUD would seem to be particularly appropriate for women presenting too late for ECPs, provided they are not at risk of sexually transmitted diseases and prefer long‐term contraception. Nevertheless, we need more well‐designed studies to enable us to make a solid conclusion with regard to this. </p> <p>We decided to exclude trials comparing emergency contraception pills with lactational amenorrhoea method (LAM). In practice, women who are breastfeeding are a unique group who are at high risk of unplanned pregnancy. Several trials have been undertaken that compare emergency contraception pills with LAM and that were excluded from our review. This comparison could be a useful topic for a future Cochrane Review. </p> <p>We aim for the findings of this review to be applicable to women seeking services for EC following a single act of unprotected intercourse, and the included studies include women with wide range of ages, and ethnicities, from countries including Egypt, Italy, UK, Cuba and China. But there is a problem in that the methods and pills for emergency contraception were provided in differing manners by different countries and regions, and not all methods are universally available. In many countries and regions, the traditional Yuzpe regimen is still the only option available for emergency contraception. Problems with the availability and distribution of emergency contraception pills are the main factors limiting the applicability of our findings. </p> <p>With respect to the influence of BMI on the effectiveness of EC, no data were reported by the primary studies. However, secondary analyses of randomized data from two RCTs included in our review (<a href="./references#CD001324-bbs2-0017" title="CreininMD , SchlaffW , ArcherDF , WanL , FrezieresR , TomasM , et al. Progesterone receptor modulator for emergency contraception. A randomized controlled trial. Obstetrics &amp; Gynecology2006;108:1089‐97. ">Creinin 2006</a>; <a href="./references#CD001324-bbs2-0029" title="GlasierAF , CameronST , FinePM , LoganSJ , CasaleW , VanHornJ , et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non‐inferiority trial and meta‐analysis. Lancet2010;375(9714):555‐62. ">Glasier 2010</a>) suggested a fourfold increased risk of pregnancy after use of levonorgestrel ECP among obese women, compared with normal or underweight women (<a href="./references#CD001324-bbs2-0221" title="GlasierA , CameronST , BlitheD , ScherrerB , MatheH , LevyD , et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception2011;84:363‐7. ">Glasier 2011</a>). In women weighing about 80 kg, the rate of pregnancy rose above 6%, which is the estimated pregnancy probability without contraception (<a href="./references#CD001324-bbs2-0233" title="KappN , AbitbolJL , MatheH , ScherrerB , GuillardH , GainerE , et al. Effect of body weight and BMI on the efficacy of levonorgestrel emergency contraception. Contraception2015;91(2):97‐104. ">Kapp 2015</a>). However secondary analysis of data from three other trials in our review (<a href="./references#CD001324-bbs2-0018" title="DadaOA , GodfreyEM , PiaggioG , vonHertzenH , Nigerian Network for Reproductive Health Research and Training. A randomized, double‐blind, noninferiority study to compare two regimens of levonorgestrel for emergency contraception in Nigeria. Contraception2010;82(4):373‐8. ">Dada 2010</a>; <a href="./references#CD001324-bbs2-0077" title="vonHertzenH , PiaggioG , DingJ , ChenJ , SongS , BartfaiG , et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception. Lancet2002;360:1803‐10. ">von Hertzen 2002</a>; <a href="./references#CD001324-bbs2-0090" title="WHO Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet1998;352:428‐33. ">WHO 1998</a>) did not confirm that the efficacy of levonorgestrel decreased with increasing BMI (<a href="./references#CD001324-bbs2-0219" title="Gemzell‐DanielssonK , KardosL , vonHertzenH . Impact of bodyweight/body mass index on the effectiveness of emergency contraception with levonorgestrel: a pooled‐analysis of three randomized controlled trials. Curr Med Res Opin2015;31:2241‐8. ">Gemzell‐Danielsson 2015</a>). With respect to ulipristal, a secondary analysis (<a href="./references#CD001324-bbs2-0163" title="MoreauC , TrussellJ . Results from pooled phase III studies of ulipristal scetate for emergency contraception. Contraception2012;86:673‐80. ">Moreau 2012</a>), which pooled data from one of the RCTs in our review (<a href="./references#CD001324-bbs2-0029" title="GlasierAF , CameronST , FinePM , LoganSJ , CasaleW , VanHornJ , et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non‐inferiority trial and meta‐analysis. Lancet2010;375(9714):555‐62. ">Glasier 2010</a>), and a non‐randomised study (<a href="./references#CD001324-bbs2-0217" title="FineP , MatheH , GindeS , CullinsV , MorfesisJ , GainerE . Ulipristal acetate taken 48–120 hours after intercourse for emergency contraception.. Obstet Gynecol2010;115:257‐63. ">Fine 2010a</a>), suggested that pregnancy rates in obese women might be double those in non‐obese women, though confidence intervals were wide and the findings were not statistically significant. The findings of all these secondary analyses are discussed in a recent systematic review (<a href="./references#CD001324-bbs2-0231" title="JatlaouiTC , CurtisKM . Safety and effectiveness data for emergency contraceptive pills among women with obesity: a systematic review. Contraception2016;94:605‐11. ">Jatlaoui 2016a</a>). </p> <p>For this current update, we searched trials registers in order to identify new ongoing trials. We scrutinised reference lists of the new trials, only to find two trials that we had already included and three ongoing trials awaiting classification. Two of the ongoing trials compare ulipristal acetate with levonorgestrel IUS; and one compares Cu‐IUD versus levonorgestrel IUD (see <a href="./references#CD001324-bbs2-0210" title="NCT01539720 . Levonorgestrel intrauterine system for emergency contraception (LIFE). clinicaltrials.gov/show/NCT01539720 first received: 21 February, 2012. ">NCT01539720</a>; <a href="./references#CD001324-bbs2-0211" title="NCT02175030 . RAPID EC ‐ RCT assessing pregnancy with intrauterine devices for EC. clinicaltrials.gov/show/NCT02175030 first received: 23 June , 2014. ">NCT02175030</a>). </p> </section> <section id="CD001324-sec-0200"> <h3 class="title" id="CD001324-sec-0200">Quality of the evidence</h3> <p>We assessed the primary outcome and secondary outcomes with <a href="./references#CD001324-bbs2-0222" title="GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 15 March 2017. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a> criteria. All the included trials were RCTs, which minimises the risk of bias associated with study design. The quality of the evidence for the primary outcome ranged from moderate to high, and for other outcomes ranged from very low to high. The main limitations were risk of bias (associated with poor reporting of randomization methods), imprecision and inconsistency. </p> <p>For details of the quality of the evidence for each comparison, see <a href="./full#CD001324-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD001324-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD001324-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD001324-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD001324-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD001324-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD001324-tbl-0007">summary of findings Table 7</a>; and <a href="./full#CD001324-tbl-0008">summary of findings Table 8</a>. </p> <p>We graded fewer than 15% of the studies (14/115) as being at low risk of bias randomization methods: these studies had detailed description of methods of sequence generation and allocation concealment. Moreover, we have included 92 Chinese trials. However, most of the trials only mentioned 'randomization' and did not report randomization methods in detail, making us uncertain about the possible risk of bias, which caused us to downgrade the quality of the evidence. </p> <p>Another potentially important source of bias in these studies was loss to follow‐up and missing outcome data. Only 31 studies, with an attrition of about 30%, clearly reported the reasons for attrition. Poor reporting of losses to follow‐up is problematic, even with lower levels of attrition, particularly where loss is not balanced across different arms of trials. </p> <p>We included a large number of trials (115) with a wide array of comparisons (26). The availability of several recent large multicenter trials was helpful in increasing the power and the generalisability of the study findings. However, RCTs with large sample sizes were relatively few. In addition, most of the included trials were conducted in China, in particular those evaluating the effects of mifepristone regimens. This is probably because few countries have approved mifepristone for use as EC, and China is the largest one. Since it was evident that ECs were effective, most recent studies on EC aimed to reduce dosage or times of medication administration so that clients' compliance or cost of treatment, or both, could be improved. Because of this reason, most recent EC trials were designed as equivalence rather than superiority studies (trying to show that two treatments are as good as each other rather than one is more effective than the other). It is common to claim an equivalent effectiveness when the difference between two treatment groups is not statistically significant. Nevertheless, few trials in this review calculated their sample sizes on the basis of an equivalence approach that usually requires a large study sample. </p> <p>As noted above, for comparisons in which most of the studies failed to provide adequate details of their randomization methods, we did not downgrade the evidence for risk of bias if the analysis also included a large study at low risk of bias which had findings consistent with the smaller studies. </p> <p>We did not downgrade the evidence for the primary outcome (pregnancy) for lack of blinding. Since pregnancy is an objective outcome, lack of blindness probably has little influence on evaluation of this outcome. We extracted information from the trials about other potential sources of bias in line with the Cochrane 'Risk of bias' tool. </p> </section> <section id="CD001324-sec-0201"> <h3 class="title" id="CD001324-sec-0201">Potential biases in the review process</h3> <p>There may be potential biases at any stage of the review process. In order to minimise the risk of bias, two review authors independently screened studies for inclusion and any disagreements were resolved by a third review author. One review author performed data extraction and assessed risk of bias and a second review author checked them. Again, any discrepancies were resolved by a third review author. In this updated review, we assessed risk of bias for all the included 115 trials. </p> <p>The key strengths of this review include exhaustive searches for literature about EC trials (including searches of the Chinese databases) and restriction to RCTs. Limiting the review to RCTs reduced the number of studies available, because, except for some regions where women have no alternatives for emergency contraception pills because of poor availability, most women do have a choice, and this tends to increase the difficulties of randomization. Hence, we found many observational trials, comparing the effectiveness of different ECPs. If this review had had broader inclusion criteria in relation to the type of study design, we would have included additional studies. However, we decided not to change our previous decision to exclude observational trials trials, to minimise the risk of bias in our review. Observational trials are at high risk of selection bias, which could influence the applicability of the result. </p> <p>Another strength of this review is that we conducted additional analyses in order to assess problems associated with attrition. This consisted of simulated ITT analyses for the comparison of mid‐dose mifepristone (25 mg to 50 mg) with levonorgestrel, assuming on the one hand that all women lost to follow‐up in the levonorgestrel group had had an event, but none in the mifepristone group; or on the other hand assuming that the opposite was the case. </p> </section> <section id="CD001324-sec-0202"> <h3 class="title" id="CD001324-sec-0202">Agreements and disagreements with other studies or reviews</h3> <p>The main conclusions about emergency contraception in our review are similar to those of other published articles and reviews (<a href="./references#CD001324-bbs2-0232" title="JatlaouiTC . Safety data for levonorgestrel, ulipristal acetate and Yuzpe regimens for emergency contraception.. Contraception 93;2:93‐112. ">Jatlaoui 2016b</a>; <a href="./references#CD001324-bbs2-0234" title="LalitkumarPGL . Emergency contraception. Best Practice and Research: Clinical Endocrinology and Metabolism 27;1:91‐101. ">Lalitkumar 2013</a>; <a href="./references#CD001324-bbs2-0236" title="MilosavljevicJ . Mechanism of action, efficacy and safety of emergency hormonal contraception (levonorgestrel and ulipristal acetate) and attitudes of pharmacists. Acta Facultatis Medicae Naissensis 31;3:155‐61. ">Milosavljevic 2014</a>; <a href="./references#CD001324-bbs2-0237" title="MozzanegaB . Ulipristal acetate: critical review about endometrial and ovulatory effects in emergency contraception. Reproductive Sciences 21;6:678‐85. ">Mozzanega 2014</a>; <a href="./references#CD001324-bbs2-0242" title="ShohelM , RahmanMM , ZamanA , UddinMMN , Al‐AminMM , RezaHM . A systematic review of effectiveness and safety of different regimens of levonorgestrel oral tablets for emergency contraception. BMC Women's Health 14;1:54. ">Shohel 2014</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001324-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD001324-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD001324-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD001324-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 2.1: levonorgestrel versus Yuzpe, outcome 2.1.1 Observed number of pregnancies (all women)" data-id="CD001324-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison 2.1: levonorgestrel versus Yuzpe, outcome 2.1.1 Observed number of pregnancies (all women) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison 2.4: Low‐dose mifepristone (&lt; 25 mg) versus levonorgestrel 1.5 mg, outcome 2.4.1 Observed number of pregnancies (all women)" data-id="CD001324-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison 2.4: Low‐dose mifepristone (&lt; 25 mg) versus levonorgestrel 1.5 mg, outcome 2.4.1 Observed number of pregnancies (all women) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison 2.4: Low‐dose mifepristone (&lt; 25 mg) versus levonorgestrel 1.5 mg, outcome 2.4.1 ITT (all loss follow‐up as pregnancy in levonorgestrel, and no pregnancy in mifepristone)" data-id="CD001324-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison 2.4: Low‐dose mifepristone (&lt; 25 mg) versus levonorgestrel 1.5 mg, outcome 2.4.1 ITT (all loss follow‐up as pregnancy in levonorgestrel, and no pregnancy in mifepristone) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intrauterine contraceptive device versus control (expectant management), Outcome 1 Observed number of pregnancies." data-id="CD001324-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Intrauterine contraceptive device versus control (expectant management), Outcome 1 Observed number of pregnancies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Levonorgestrel versus Yuzpe, Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Levonorgestrel versus Yuzpe, Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Levonorgestrel versus Yuzpe, Outcome 2 Observed number of pregnancies (by risk status)." data-id="CD001324-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Levonorgestrel versus Yuzpe, Outcome 2 Observed number of pregnancies (by risk status). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Levonorgestrel versus Yuzpe, Outcome 3 Observed number of pregnancies (time from intercourse)." data-id="CD001324-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Levonorgestrel versus Yuzpe, Outcome 3 Observed number of pregnancies (time from intercourse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Levonorgestrel versus Yuzpe, Outcome 4 Need for extra dose." data-id="CD001324-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Levonorgestrel versus Yuzpe, Outcome 4 Need for extra dose.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Levonorgestrel versus Yuzpe, Outcome 5 Any side effect." data-id="CD001324-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Levonorgestrel versus Yuzpe, Outcome 5 Any side effect.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Levonorgestrel versus Yuzpe, Outcome 6 Specific side effects." data-id="CD001324-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Levonorgestrel versus Yuzpe, Outcome 6 Specific side effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Levonorgestrel versus Yuzpe, Outcome 7 Menses." data-id="CD001324-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Levonorgestrel versus Yuzpe, Outcome 7 Menses.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Levonorgestrel (all doses) versus anordrin (all doses), Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Levonorgestrel (all doses) versus anordrin (all doses), Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Levonorgestrel (all doses) versus anordrin (all doses), Outcome 2 Any side effect." data-id="CD001324-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Levonorgestrel (all doses) versus anordrin (all doses), Outcome 2 Any side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mifepristone mid‐dose (25 mg‐50 mg) versus levonorgestrel 1.5 mg, Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Mifepristone mid‐dose (25 mg‐50 mg) versus levonorgestrel 1.5 mg, Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mifepristone mid‐dose (25 mg‐50 mg) versus levonorgestrel 1.5 mg, Outcome 2 Observed number of pregnancies (by risk status)." data-id="CD001324-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Mifepristone mid‐dose (25 mg‐50 mg) versus levonorgestrel 1.5 mg, Outcome 2 Observed number of pregnancies (by risk status). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mifepristone mid‐dose (25 mg‐50 mg) versus levonorgestrel 1.5 mg, Outcome 3 Any side effect." data-id="CD001324-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Mifepristone mid‐dose (25 mg‐50 mg) versus levonorgestrel 1.5 mg, Outcome 3 Any side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mifepristone mid‐dose (25 mg‐50 mg) versus levonorgestrel 1.5 mg, Outcome 4 Specific side effect." data-id="CD001324-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Mifepristone mid‐dose (25 mg‐50 mg) versus levonorgestrel 1.5 mg, Outcome 4 Specific side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mifepristone mid‐dose (25 mg‐50 mg) versus levonorgestrel 1.5 mg, Outcome 5 Menses." data-id="CD001324-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Mifepristone mid‐dose (25 mg‐50 mg) versus levonorgestrel 1.5 mg, Outcome 5 Menses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mifepristone mid‐dose (25 mg‐50 mg) versus levonorgestrel 1.5 mg, Outcome 6 ITT (all loss follow‐up as pregnancy in LNG, and no preg in Mife)." data-id="CD001324-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Mifepristone mid‐dose (25 mg‐50 mg) versus levonorgestrel 1.5 mg, Outcome 6 ITT (all loss follow‐up as pregnancy in LNG, and no preg in Mife). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Mifepristone mid‐dose (25 mg‐50 mg) versus levonorgestrel 1.5 mg, Outcome 7 ITT (all loss follow‐up as no pregnancy in LNG, and preg in Mife)." data-id="CD001324-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Mifepristone mid‐dose (25 mg‐50 mg) versus levonorgestrel 1.5 mg, Outcome 7 ITT (all loss follow‐up as no pregnancy in LNG, and preg in Mife). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-005-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Mifepristone low dose (&lt; 25 mg) versus levonorgestrel 1.5 mg, Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Mifepristone low dose (&lt; 25 mg) versus levonorgestrel 1.5 mg, Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Mifepristone low dose (&lt; 25 mg) versus levonorgestrel 1.5 mg, Outcome 2 Observed number of pregnancies (by risk status)." data-id="CD001324-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Mifepristone low dose (&lt; 25 mg) versus levonorgestrel 1.5 mg, Outcome 2 Observed number of pregnancies (by risk status). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Mifepristone low dose (&lt; 25 mg) versus levonorgestrel 1.5 mg, Outcome 3 Observed number of pregnancies (time from intercourse)." data-id="CD001324-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Mifepristone low dose (&lt; 25 mg) versus levonorgestrel 1.5 mg, Outcome 3 Observed number of pregnancies (time from intercourse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Mifepristone low dose (&lt; 25 mg) versus levonorgestrel 1.5 mg, Outcome 4 Any side effect." data-id="CD001324-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Mifepristone low dose (&lt; 25 mg) versus levonorgestrel 1.5 mg, Outcome 4 Any side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Mifepristone low dose (&lt; 25 mg) versus levonorgestrel 1.5 mg, Outcome 5 Specific side effect." data-id="CD001324-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Mifepristone low dose (&lt; 25 mg) versus levonorgestrel 1.5 mg, Outcome 5 Specific side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Mifepristone low dose (&lt; 25 mg) versus levonorgestrel 1.5 mg, Outcome 6 Menses." data-id="CD001324-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Mifepristone low dose (&lt; 25 mg) versus levonorgestrel 1.5 mg, Outcome 6 Menses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-005-07.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Mifepristone low dose (&lt; 25 mg) versus levonorgestrel 1.5 mg, Outcome 7 ITT (all loss follow‐up as pregnancy in LNG, and no preg in Mifepristone)." data-id="CD001324-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Mifepristone low dose (&lt; 25 mg) versus levonorgestrel 1.5 mg, Outcome 7 ITT (all loss follow‐up as pregnancy in LNG, and no preg in Mifepristone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Mifepristone low dose (&lt; 25 mg) versus levonorgestrel 1.5 mg, Outcome 8 ITT (all loss follow‐up as no pregnancy in LNG, and preg in Mifepristone)." data-id="CD001324-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Mifepristone low dose (&lt; 25 mg) versus levonorgestrel 1.5 mg, Outcome 8 ITT (all loss follow‐up as no pregnancy in LNG, and preg in Mifepristone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Mifepristone (all doses) versus Yuzpe, Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0032" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Mifepristone (all doses) versus Yuzpe, Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Mifepristone (all doses) versus Yuzpe, Outcome 2 Observed number of pregnancies (by risk status)." data-id="CD001324-fig-0033" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Mifepristone (all doses) versus Yuzpe, Outcome 2 Observed number of pregnancies (by risk status). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Mifepristone (all doses) versus Yuzpe, Outcome 3 Observed number of pregnancies (time from intercourse)." data-id="CD001324-fig-0034" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Mifepristone (all doses) versus Yuzpe, Outcome 3 Observed number of pregnancies (time from intercourse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Mifepristone (all doses) versus Yuzpe, Outcome 4 Need for extra dose." data-id="CD001324-fig-0035" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Mifepristone (all doses) versus Yuzpe, Outcome 4 Need for extra dose.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Mifepristone (all doses) versus Yuzpe, Outcome 5 Any side effect." data-id="CD001324-fig-0036" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Mifepristone (all doses) versus Yuzpe, Outcome 5 Any side effect.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Mifepristone (all doses) versus Yuzpe, Outcome 6 Specific side effects." data-id="CD001324-fig-0037" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Mifepristone (all doses) versus Yuzpe, Outcome 6 Specific side effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Mifepristone (all doses) versus Yuzpe, Outcome 7 Menses." data-id="CD001324-fig-0038" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Mifepristone (all doses) versus Yuzpe, Outcome 7 Menses.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Mifepristone (all doses) versus anordrin (all doses), Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0039" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Mifepristone (all doses) versus anordrin (all doses), Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Mifepristone (all doses) versus anordrin (all doses), Outcome 2 Any side effect." data-id="CD001324-fig-0040" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Mifepristone (all doses) versus anordrin (all doses), Outcome 2 Any side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Mifepristone (all doses) versus anordrin (all doses), Outcome 3 Specific side effects." data-id="CD001324-fig-0041" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Mifepristone (all doses) versus anordrin (all doses), Outcome 3 Specific side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Mifepristone (all doses) versus anordrin (all doses), Outcome 4 Menses." data-id="CD001324-fig-0042" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Mifepristone (all doses) versus anordrin (all doses), Outcome 4 Menses.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Mifepristone alone (low or mid dose) versus mifepristone + anordrin (all doses), Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0043" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Mifepristone alone (low or mid dose) versus mifepristone + anordrin (all doses), Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Mifepristone alone (low or mid dose) versus mifepristone + anordrin (all doses), Outcome 2 Any side effect." data-id="CD001324-fig-0044" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Mifepristone alone (low or mid dose) versus mifepristone + anordrin (all doses), Outcome 2 Any side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Mifepristone alone (low or mid dose) versus mifepristone + anordrin (all doses), Outcome 3 Specific side effects." data-id="CD001324-fig-0045" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Mifepristone alone (low or mid dose) versus mifepristone + anordrin (all doses), Outcome 3 Specific side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Mifepristone alone (low or mid dose) versus mifepristone + anordrin (all doses), Outcome 4 Delay in menses." data-id="CD001324-fig-0046" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Mifepristone alone (low or mid dose) versus mifepristone + anordrin (all doses), Outcome 4 Delay in menses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Mifepristone versus mifepristone + misoprostol (all doses), Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0047" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Mifepristone versus mifepristone + misoprostol (all doses), Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Mifepristone versus mifepristone + misoprostol (all doses), Outcome 2 Specific side effect." data-id="CD001324-fig-0048" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Mifepristone versus mifepristone + misoprostol (all doses), Outcome 2 Specific side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Mifepristone alone (all doses) versus mifepristone + tamoxifen (all doses), Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0049" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Mifepristone alone (all doses) versus mifepristone + tamoxifen (all doses), Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Mifepristone alone (all doses) versus mifepristone + tamoxifen (all doses), Outcome 2 Specific side effect." data-id="CD001324-fig-0050" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Mifepristone alone (all doses) versus mifepristone + tamoxifen (all doses), Outcome 2 Specific side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Mifepristone alone (all doses) versus mifepristone + tamoxifen (all doses), Outcome 3 Menses." data-id="CD001324-fig-0051" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Mifepristone alone (all doses) versus mifepristone + tamoxifen (all doses), Outcome 3 Menses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Mifepristone alone (all doses) versus mifepristone + methotrexate (all doses), Outcome 1 Observed number of pregnancy (all women)." data-id="CD001324-fig-0052" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Mifepristone alone (all doses) versus mifepristone + methotrexate (all doses), Outcome 1 Observed number of pregnancy (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Mifepristone alone (all doses) versus mifepristone + methotrexate (all doses), Outcome 2 Any side effect." data-id="CD001324-fig-0053" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Mifepristone alone (all doses) versus mifepristone + methotrexate (all doses), Outcome 2 Any side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-011-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-011-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Mifepristone alone (all doses) versus mifepristone + methotrexate (all doses), Outcome 3 Menses." data-id="CD001324-fig-0054" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-011-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 Mifepristone alone (all doses) versus mifepristone + methotrexate (all doses), Outcome 3 Menses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-011-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Mifepristone (all doses) versus danazol (all doses), Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0055" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Mifepristone (all doses) versus danazol (all doses), Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Mifepristone (all doses) versus danazol (all doses), Outcome 2 Any side effect." data-id="CD001324-fig-0056" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Mifepristone (all doses) versus danazol (all doses), Outcome 2 Any side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-012-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-012-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Mifepristone (all doses) versus danazol (all doses), Outcome 3 Specific side effect." data-id="CD001324-fig-0057" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-012-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12 Mifepristone (all doses) versus danazol (all doses), Outcome 3 Specific side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-012-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-012-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-012-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Mifepristone (all doses) versus danazol (all doses), Outcome 4 Menses." data-id="CD001324-fig-0058" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-012-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12 Mifepristone (all doses) versus danazol (all doses), Outcome 4 Menses.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-012-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Mifepristone versus gestrinone, Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0059" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Mifepristone versus gestrinone, Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-013-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-013-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Mifepristone versus gestrinone, Outcome 2 Side effects." data-id="CD001324-fig-0060" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-013-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13 Mifepristone versus gestrinone, Outcome 2 Side effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-013-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-013-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-013-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Mifepristone versus gestrinone, Outcome 3 Menses." data-id="CD001324-fig-0061" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-013-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13 Mifepristone versus gestrinone, Outcome 3 Menses.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-013-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 High‐dose oestrogens versus Yuzpe, Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0062" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 High‐dose oestrogens versus Yuzpe, Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Danazol (all doses) versus Yuzpe, Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0063" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 Danazol (all doses) versus Yuzpe, Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-015-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-015-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Danazol (all doses) versus Yuzpe, Outcome 2 Specific side effects." data-id="CD001324-fig-0064" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-015-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15 Danazol (all doses) versus Yuzpe, Outcome 2 Specific side effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-015-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-015-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-015-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Danazol (all doses) versus Yuzpe, Outcome 3 Menses." data-id="CD001324-fig-0065" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-015-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15 Danazol (all doses) versus Yuzpe, Outcome 3 Menses.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-015-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-016-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-016-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Ulipristal acetate (all doses) versus levonorgestrel, Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0066" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-016-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16 Ulipristal acetate (all doses) versus levonorgestrel, Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-016-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-016-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-016-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Ulipristal acetate (all doses) versus levonorgestrel, Outcome 2 Observed number of pregnancies (by risk status)." data-id="CD001324-fig-0067" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-016-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16 Ulipristal acetate (all doses) versus levonorgestrel, Outcome 2 Observed number of pregnancies (by risk status). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-016-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-016-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-016-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Ulipristal acetate (all doses) versus levonorgestrel, Outcome 3 Observed number of pregnancies (time from intercourse)." data-id="CD001324-fig-0068" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-016-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16 Ulipristal acetate (all doses) versus levonorgestrel, Outcome 3 Observed number of pregnancies (time from intercourse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-016-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-016-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-016-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Ulipristal acetate (all doses) versus levonorgestrel, Outcome 4 Observed number of pregnancies within 0‐72 h." data-id="CD001324-fig-0069" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-016-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.4</div> <div class="figure-caption"> <p>Comparison 16 Ulipristal acetate (all doses) versus levonorgestrel, Outcome 4 Observed number of pregnancies within 0‐72 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-016-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-016-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-016-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Ulipristal acetate (all doses) versus levonorgestrel, Outcome 5 Specific side effects." data-id="CD001324-fig-0070" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-016-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.5</div> <div class="figure-caption"> <p>Comparison 16 Ulipristal acetate (all doses) versus levonorgestrel, Outcome 5 Specific side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-016-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-016-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-016-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Ulipristal acetate (all doses) versus levonorgestrel, Outcome 6 Menses." data-id="CD001324-fig-0071" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-016-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.6</div> <div class="figure-caption"> <p>Comparison 16 Ulipristal acetate (all doses) versus levonorgestrel, Outcome 6 Menses.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-016-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-017-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-017-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Levonorgestrel split dose, 24 hours versus 12 hours, Outcome 1 Observed number of pregnancy (all women)." data-id="CD001324-fig-0072" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-017-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17 Levonorgestrel split dose, 24 hours versus 12 hours, Outcome 1 Observed number of pregnancy (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-017-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-017-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-017-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Levonorgestrel split dose, 24 hours versus 12 hours, Outcome 2 Observed number of pregnancies (by risk status)." data-id="CD001324-fig-0073" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-017-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17 Levonorgestrel split dose, 24 hours versus 12 hours, Outcome 2 Observed number of pregnancies (by risk status). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-017-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-017-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-017-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Levonorgestrel split dose, 24 hours versus 12 hours, Outcome 3 Specific side effects." data-id="CD001324-fig-0074" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-017-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17 Levonorgestrel split dose, 24 hours versus 12 hours, Outcome 3 Specific side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-017-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-017-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-017-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Levonorgestrel split dose, 24 hours versus 12 hours, Outcome 4 Menses." data-id="CD001324-fig-0075" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-017-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.4</div> <div class="figure-caption"> <p>Comparison 17 Levonorgestrel split dose, 24 hours versus 12 hours, Outcome 4 Menses.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-017-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-018-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-018-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Levonorgestrel single dose versus split dose, Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0076" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-018-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18 Levonorgestrel single dose versus split dose, Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-018-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-018-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-018-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Levonorgestrel single dose versus split dose, Outcome 2 Observed number of pregnancies (by risk status)." data-id="CD001324-fig-0077" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-018-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.2</div> <div class="figure-caption"> <p>Comparison 18 Levonorgestrel single dose versus split dose, Outcome 2 Observed number of pregnancies (by risk status). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-018-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-018-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-018-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Levonorgestrel single dose versus split dose, Outcome 3 Observed number of pregnancies (time from intercourse)." data-id="CD001324-fig-0078" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-018-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.3</div> <div class="figure-caption"> <p>Comparison 18 Levonorgestrel single dose versus split dose, Outcome 3 Observed number of pregnancies (time from intercourse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-018-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-018-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-018-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Levonorgestrel single dose versus split dose, Outcome 4 Specific side effects." data-id="CD001324-fig-0079" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-018-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.4</div> <div class="figure-caption"> <p>Comparison 18 Levonorgestrel single dose versus split dose, Outcome 4 Specific side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-018-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-018-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-018-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Levonorgestrel single dose versus split dose, Outcome 5 Menses." data-id="CD001324-fig-0080" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-018-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.5</div> <div class="figure-caption"> <p>Comparison 18 Levonorgestrel single dose versus split dose, Outcome 5 Menses.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-018-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-019-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-019-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Mifepristone low dose (10 mg) versus low dose (5 mg), Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0081" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-019-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19 Mifepristone low dose (10 mg) versus low dose (5 mg), Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-019-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-019-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-019-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Mifepristone low dose (10 mg) versus low dose (5 mg), Outcome 2 Specific side effects." data-id="CD001324-fig-0082" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-019-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19 Mifepristone low dose (10 mg) versus low dose (5 mg), Outcome 2 Specific side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-019-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-019-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-019-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Mifepristone low dose (10 mg) versus low dose (5 mg), Outcome 3 Delay of menses." data-id="CD001324-fig-0083" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-019-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.3</div> <div class="figure-caption"> <p>Comparison 19 Mifepristone low dose (10 mg) versus low dose (5 mg), Outcome 3 Delay of menses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-019-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-020-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-020-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Low dose mifepristone (10 mg) versus split low dose mifepristone (10 mg x2), Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0084" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-020-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20 Low dose mifepristone (10 mg) versus split low dose mifepristone (10 mg x2), Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-020-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-020-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-020-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Low dose mifepristone (10 mg) versus split low dose mifepristone (10 mg x2), Outcome 2 Any side effect." data-id="CD001324-fig-0085" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-020-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.2</div> <div class="figure-caption"> <p>Comparison 20 Low dose mifepristone (10 mg) versus split low dose mifepristone (10 mg x2), Outcome 2 Any side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-020-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-020-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-020-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Low dose mifepristone (10 mg) versus split low dose mifepristone (10 mg x2), Outcome 3 Menses." data-id="CD001324-fig-0086" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-020-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.3</div> <div class="figure-caption"> <p>Comparison 20 Low dose mifepristone (10 mg) versus split low dose mifepristone (10 mg x2), Outcome 3 Menses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-020-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-021-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-021-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Mifepristone mid dose (25‐50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0087" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-021-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21 Mifepristone mid dose (25‐50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-021-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-021-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-021-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Mifepristone mid dose (25‐50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 2 Observed number of pregnancies (by risk status)." data-id="CD001324-fig-0088" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-021-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.2</div> <div class="figure-caption"> <p>Comparison 21 Mifepristone mid dose (25‐50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 2 Observed number of pregnancies (by risk status). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-021-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-021-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-021-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Mifepristone mid dose (25‐50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 3 Any side effect." data-id="CD001324-fig-0089" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-021-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.3</div> <div class="figure-caption"> <p>Comparison 21 Mifepristone mid dose (25‐50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 3 Any side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-021-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-021-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-021-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Mifepristone mid dose (25‐50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 4 Specific side effects." data-id="CD001324-fig-0090" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-021-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.4</div> <div class="figure-caption"> <p>Comparison 21 Mifepristone mid dose (25‐50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 4 Specific side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-021-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-021-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-021-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Mifepristone mid dose (25‐50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 5 Menses." data-id="CD001324-fig-0091" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-021-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.5</div> <div class="figure-caption"> <p>Comparison 21 Mifepristone mid dose (25‐50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 5 Menses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-021-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-022-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-022-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Mifepristone mid dose (50 mg) versus mifepristone mid dose (25 mg), Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0092" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-022-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22 Mifepristone mid dose (50 mg) versus mifepristone mid dose (25 mg), Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-022-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-022-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-022-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Mifepristone mid dose (50 mg) versus mifepristone mid dose (25 mg), Outcome 2 Any side effect." data-id="CD001324-fig-0093" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-022-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.2</div> <div class="figure-caption"> <p>Comparison 22 Mifepristone mid dose (50 mg) versus mifepristone mid dose (25 mg), Outcome 2 Any side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-022-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-022-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-022-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Mifepristone mid dose (50 mg) versus mifepristone mid dose (25 mg), Outcome 3 Specific side effects." data-id="CD001324-fig-0094" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-022-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.3</div> <div class="figure-caption"> <p>Comparison 22 Mifepristone mid dose (50 mg) versus mifepristone mid dose (25 mg), Outcome 3 Specific side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-022-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-022-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-022-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Mifepristone mid dose (50 mg) versus mifepristone mid dose (25 mg), Outcome 4 Delay in menses." data-id="CD001324-fig-0095" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-022-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.4</div> <div class="figure-caption"> <p>Comparison 22 Mifepristone mid dose (50 mg) versus mifepristone mid dose (25 mg), Outcome 4 Delay in menses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-022-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-023-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-023-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Mid dose mifepristone split dose comparisons, Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0096" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-023-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23 Mid dose mifepristone split dose comparisons, Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-023-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-023-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-023-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Mid dose mifepristone split dose comparisons, Outcome 2 Any side effect." data-id="CD001324-fig-0097" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-023-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.2</div> <div class="figure-caption"> <p>Comparison 23 Mid dose mifepristone split dose comparisons, Outcome 2 Any side effect.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-023-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-023-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-023-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Mid dose mifepristone split dose comparisons, Outcome 3 Early menses." data-id="CD001324-fig-0098" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-023-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.3</div> <div class="figure-caption"> <p>Comparison 23 Mid dose mifepristone split dose comparisons, Outcome 3 Early menses.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-023-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-023-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-023-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Mid dose mifepristone split dose comparisons, Outcome 4 Delay menses." data-id="CD001324-fig-0099" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-023-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.4</div> <div class="figure-caption"> <p>Comparison 23 Mid dose mifepristone split dose comparisons, Outcome 4 Delay menses.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-023-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-024-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-024-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Mifepristone high dose (&gt; 50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0100" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-024-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.1</div> <div class="figure-caption"> <p>Comparison 24 Mifepristone high dose (&gt; 50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-024-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-024-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-024-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Mifepristone high dose (&gt; 50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 2 Observed number of pregnancies (by risk status)." data-id="CD001324-fig-0101" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-024-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.2</div> <div class="figure-caption"> <p>Comparison 24 Mifepristone high dose (&gt; 50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 2 Observed number of pregnancies (by risk status). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-024-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-024-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-024-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Mifepristone high dose (&gt; 50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 3 Any side effect." data-id="CD001324-fig-0102" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-024-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.3</div> <div class="figure-caption"> <p>Comparison 24 Mifepristone high dose (&gt; 50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 3 Any side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-024-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-024-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-024-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Mifepristone high dose (&gt; 50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 4 Specific side effects." data-id="CD001324-fig-0103" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-024-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.4</div> <div class="figure-caption"> <p>Comparison 24 Mifepristone high dose (&gt; 50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 4 Specific side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-024-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-024-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-024-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Mifepristone high dose (&gt; 50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 5 Menses." data-id="CD001324-fig-0104" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-024-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.5</div> <div class="figure-caption"> <p>Comparison 24 Mifepristone high dose (&gt; 50 mg) versus mifepristone low dose (&lt; 25 mg), Outcome 5 Menses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-024-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-025-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-025-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 25 Mifepristone high dose (&gt; 50 mg) versus mifepristone mid dose (25‐50 mg), Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0105" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-025-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.1</div> <div class="figure-caption"> <p>Comparison 25 Mifepristone high dose (&gt; 50 mg) versus mifepristone mid dose (25‐50 mg), Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-025-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-025-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-025-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 25 Mifepristone high dose (&gt; 50 mg) versus mifepristone mid dose (25‐50 mg), Outcome 2 Any side effect." data-id="CD001324-fig-0106" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-025-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.2</div> <div class="figure-caption"> <p>Comparison 25 Mifepristone high dose (&gt; 50 mg) versus mifepristone mid dose (25‐50 mg), Outcome 2 Any side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-025-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-025-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-025-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 25 Mifepristone high dose (&gt; 50 mg) versus mifepristone mid dose (25‐50 mg), Outcome 3 Specific side effects." data-id="CD001324-fig-0107" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-025-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.3</div> <div class="figure-caption"> <p>Comparison 25 Mifepristone high dose (&gt; 50 mg) versus mifepristone mid dose (25‐50 mg), Outcome 3 Specific side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-025-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-025-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-025-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 25 Mifepristone high dose (&gt; 50 mg) versus mifepristone mid dose (25‐50 mg), Outcome 4 Menses." data-id="CD001324-fig-0108" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-025-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.4</div> <div class="figure-caption"> <p>Comparison 25 Mifepristone high dose (&gt; 50 mg) versus mifepristone mid dose (25‐50 mg), Outcome 4 Menses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-025-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-026-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-026-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 Half‐dose Yuzpe versus standard Yuzpe, Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0109" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-026-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.1</div> <div class="figure-caption"> <p>Comparison 26 Half‐dose Yuzpe versus standard Yuzpe, Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-026-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-026-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-026-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 Half‐dose Yuzpe versus standard Yuzpe, Outcome 2 Any side effect." data-id="CD001324-fig-0110" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-026-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.2</div> <div class="figure-caption"> <p>Comparison 26 Half‐dose Yuzpe versus standard Yuzpe, Outcome 2 Any side effect.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-026-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-026-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-026-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 Half‐dose Yuzpe versus standard Yuzpe, Outcome 3 Specific side effects." data-id="CD001324-fig-0111" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-026-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.3</div> <div class="figure-caption"> <p>Comparison 26 Half‐dose Yuzpe versus standard Yuzpe, Outcome 3 Specific side effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-026-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-027-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-027-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 27 Copper intrauterine device versus mifepristone (all doses), Outcome 1 Observed number of pregnancies (all women)." data-id="CD001324-fig-0112" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-027-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.1</div> <div class="figure-caption"> <p>Comparison 27 Copper intrauterine device versus mifepristone (all doses), Outcome 1 Observed number of pregnancies (all women). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-027-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-027-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-027-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 27 Copper intrauterine device versus mifepristone (all doses), Outcome 2 Any side effect." data-id="CD001324-fig-0113" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-027-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.2</div> <div class="figure-caption"> <p>Comparison 27 Copper intrauterine device versus mifepristone (all doses), Outcome 2 Any side effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-027-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-027-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-027-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 27 Copper intrauterine device versus mifepristone (all doses), Outcome 3 Specific side effects." data-id="CD001324-fig-0114" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-027-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.3</div> <div class="figure-caption"> <p>Comparison 27 Copper intrauterine device versus mifepristone (all doses), Outcome 3 Specific side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-027-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-027-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-027-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 27 Copper intrauterine device versus mifepristone (all doses), Outcome 4 Menses." data-id="CD001324-fig-0115" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-027-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.4</div> <div class="figure-caption"> <p>Comparison 27 Copper intrauterine device versus mifepristone (all doses), Outcome 4 Menses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-027-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-028-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-028-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 28 Time elapsed since intercourse in levonorgestrel, Outcome 1 ≤ 24 h vs &gt; 24‐48 h." data-id="CD001324-fig-0116" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-028-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.1</div> <div class="figure-caption"> <p>Comparison 28 Time elapsed since intercourse in levonorgestrel, Outcome 1 ≤ 24 h vs &gt; 24‐48 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-028-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-028-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-028-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 28 Time elapsed since intercourse in levonorgestrel, Outcome 2 ≤ 24 h vs &gt; 48‐72 h." data-id="CD001324-fig-0117" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-028-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.2</div> <div class="figure-caption"> <p>Comparison 28 Time elapsed since intercourse in levonorgestrel, Outcome 2 ≤ 24 h vs &gt; 48‐72 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-028-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-028-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-028-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 28 Time elapsed since intercourse in levonorgestrel, Outcome 3 &gt; 24‐48 h vs &gt; 48‐72 h." data-id="CD001324-fig-0118" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-028-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.3</div> <div class="figure-caption"> <p>Comparison 28 Time elapsed since intercourse in levonorgestrel, Outcome 3 &gt; 24‐48 h vs &gt; 48‐72 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-028-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-028-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-028-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 28 Time elapsed since intercourse in levonorgestrel, Outcome 4 &lt; 72 h vs &gt; 72 h." data-id="CD001324-fig-0119" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-028-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.4</div> <div class="figure-caption"> <p>Comparison 28 Time elapsed since intercourse in levonorgestrel, Outcome 4 &lt; 72 h vs &gt; 72 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-028-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-029-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-029-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 29 Time elapsed since intercourse (coitus‐treatment interval) in mifepristone, Outcome 1 ≤ 24 h vs &gt; 24‐48 h." data-id="CD001324-fig-0120" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-029-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.1</div> <div class="figure-caption"> <p>Comparison 29 Time elapsed since intercourse (coitus‐treatment interval) in mifepristone, Outcome 1 ≤ 24 h vs &gt; 24‐48 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-029-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-029-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-029-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 29 Time elapsed since intercourse (coitus‐treatment interval) in mifepristone, Outcome 2 ≤ 24 h vs &gt; 48‐72 h." data-id="CD001324-fig-0121" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-029-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.2</div> <div class="figure-caption"> <p>Comparison 29 Time elapsed since intercourse (coitus‐treatment interval) in mifepristone, Outcome 2 ≤ 24 h vs &gt; 48‐72 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-029-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-029-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-029-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 29 Time elapsed since intercourse (coitus‐treatment interval) in mifepristone, Outcome 3 &gt; 24‐48 h vs &gt; 48‐72 h." data-id="CD001324-fig-0122" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-029-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.3</div> <div class="figure-caption"> <p>Comparison 29 Time elapsed since intercourse (coitus‐treatment interval) in mifepristone, Outcome 3 &gt; 24‐48 h vs &gt; 48‐72 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-029-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-029-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-029-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 29 Time elapsed since intercourse (coitus‐treatment interval) in mifepristone, Outcome 4 &lt; 72 h vs &gt; 72 h." data-id="CD001324-fig-0123" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-029-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.4</div> <div class="figure-caption"> <p>Comparison 29 Time elapsed since intercourse (coitus‐treatment interval) in mifepristone, Outcome 4 &lt; 72 h vs &gt; 72 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-029-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-030-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-030-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 Time elapsed since intercourse in Yuzpe, Outcome 1 ≤ 24 h vs &gt; 24‐48 h." data-id="CD001324-fig-0124" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-030-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.1</div> <div class="figure-caption"> <p>Comparison 30 Time elapsed since intercourse in Yuzpe, Outcome 1 ≤ 24 h vs &gt; 24‐48 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-030-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-030-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-030-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 Time elapsed since intercourse in Yuzpe, Outcome 2 ≤ 24 h vs &gt; 48‐72 h." data-id="CD001324-fig-0125" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-030-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.2</div> <div class="figure-caption"> <p>Comparison 30 Time elapsed since intercourse in Yuzpe, Outcome 2 ≤ 24 h vs &gt; 48‐72 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-030-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-030-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-030-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 Time elapsed since intercourse in Yuzpe, Outcome 3 &gt; 24‐48 h vs &gt; 48‐72 h." data-id="CD001324-fig-0126" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-030-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.3</div> <div class="figure-caption"> <p>Comparison 30 Time elapsed since intercourse in Yuzpe, Outcome 3 &gt; 24‐48 h vs &gt; 48‐72 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-030-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-031-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-031-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 31 Time elapsed since intercourse in ulipristal acetate, Outcome 1 ≤ 24 h vs &gt; 24‐48 h." data-id="CD001324-fig-0127" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-031-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.1</div> <div class="figure-caption"> <p>Comparison 31 Time elapsed since intercourse in ulipristal acetate, Outcome 1 ≤ 24 h vs &gt; 24‐48 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-031-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-031-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-031-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 31 Time elapsed since intercourse in ulipristal acetate, Outcome 2 ≤ 24 h vs &gt; 48‐72 h." data-id="CD001324-fig-0128" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-031-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.2</div> <div class="figure-caption"> <p>Comparison 31 Time elapsed since intercourse in ulipristal acetate, Outcome 2 ≤ 24 h vs &gt; 48‐72 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-031-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-031-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-031-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 31 Time elapsed since intercourse in ulipristal acetate, Outcome 3 &gt; 24‐48 h vs &gt; 48‐72 h." data-id="CD001324-fig-0129" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-031-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.3</div> <div class="figure-caption"> <p>Comparison 31 Time elapsed since intercourse in ulipristal acetate, Outcome 3 &gt; 24‐48 h vs &gt; 48‐72 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-031-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-031-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-031-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 31 Time elapsed since intercourse in ulipristal acetate, Outcome 4 &lt; 72 h vs &gt; 72 h." data-id="CD001324-fig-0130" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-031-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.4</div> <div class="figure-caption"> <p>Comparison 31 Time elapsed since intercourse in ulipristal acetate, Outcome 4 &lt; 72 h vs &gt; 72 h. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-031-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001324-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/urn:x-wiley:14651858:media:CD001324:CD001324-CMP-032-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_t/tCD001324-CMP-032-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 32 High‐risk women versus low‐risk women (all hormonal methods), Outcome 1 Observed number of pregnancies." data-id="CD001324-fig-0131" src="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-032-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.1</div> <div class="figure-caption"> <p>Comparison 32 High‐risk women versus low‐risk women (all hormonal methods), Outcome 1 Observed number of pregnancies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/media/CDSR/CD001324/image_n/nCD001324-CMP-032-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001324-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Levonorgestrel compared to Yuzpe for emergency contraception</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Levonorgestrel compared to Yuzpe for emergency contraception</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population: W</b> omen seeking emergency contraception<br/> <b>Setting:</b> China (3), Italy (2), multinational (1); family planning clinics<br/> <b>Intervention:</b> Levonorgestrel<br/> <b>Comparison:</b> Yuzpe </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Yuzpe</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Levonorgestrel</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observed number of pregnancies (all women)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1,000<br/> (11 to 24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.57<br/> (0.39 to 0.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4750<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any side effect</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>681 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>545 per 1,000<br/> (511 to 586) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.80<br/> (0.75 to 0.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1955<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ Nausea</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>447 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1,000<br/> (161 to 197) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.40<br/> (0.36 to 0.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4750<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ Vomiting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>254 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1,000<br/> (61 to 89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.29<br/> (0.24 to 0.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3640<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ Spotting/bleeding after treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1,000<br/> (119 to 210) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.82<br/> (1.37 to 2.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1614<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ Early</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>119 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>137 per 1,000<br/> (103 to 182) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.15<br/> (0.86 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1310<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ Delay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>103 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>127 per 1,000<br/> (99 to 162) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.23<br/> (0.96 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1988<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The quality of evidence was downgraded by one level for “inconsistency” because of high heterogeneity in the meta‐analysis </p> <p><sup>2</sup> The quality of evidence was downgraded by one level for “imprecision” because the 95% CI overlaps no effect and CI fails to exclude important benefit or important harm. </p> <p><sup>3</sup> The quality of evidence was downgraded by one level for “ serious risk of bias” associated with poor reporting of randomization methods </p> <p><sup>4</sup> The quality of evidence was downgraded by one level for “imprecision” because the total (cumulative) sample size is lower than the calculated optimal information size (OIS) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Levonorgestrel compared to Yuzpe for emergency contraception</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001324-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Mid‐dose mifepristone (25 mg‐50 mg) versus levonorgestrel 1.5 mg for emergency contraception</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mid‐dose mifepristone (25 mg‐50 mg) compared to levonorgestrel 1.5 mg for emergency contraception</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women seeking emergency contraception<br/> <b>Setting:</b> China (27); family planning clinics<br/> <b>Intervention:</b> mifepristone, mid‐dose (25 mg‐50 mg)<br/> <b>Comparison:</b> levonorgestrel 1.5 mg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with levonorgestrel 1.5 mg</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with mid‐dose mifepristone (25 mg‐50 mg)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observed number of pregnancies (all women)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/> (16 to 29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.61<br/> (0.45 to 0.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6052<br/> (27 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any side effect</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>202 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000<br/> (81 to 150) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.55<br/> (0.40 to 0.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4352<br/> (18 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effect ‐ nausea</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000<br/> (39 to 109) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.81<br/> (0.48 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>713<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effect ‐ vomiting</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effect ‐ spotting/bleeding after treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000<br/> (32 to 68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.61<br/> (0.42 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1796<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ early</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<br/> (47 to 97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.72<br/> (0.50 to 1.03) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1324<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ delay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>108 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000<br/> (117 to 166) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.29<br/> (1.09 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3615<br/> (17 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level for serious risk of bias associated with poor reporting of randomization methods.<br/> <sup>2</sup>We downgraded the quality of evidence by one level for inconsistency because of high heterogeneity in the meta‐analysis.<br/> <sup>3</sup>We downgraded the quality of evidence by one level for imprecision because the total (cumulative) sample size was lower than the calculated optimal information size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Mid‐dose mifepristone (25 mg‐50 mg) versus levonorgestrel 1.5 mg for emergency contraception</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001324-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Low‐dose mifepristone (&lt; 25 mg) versus levonorgestrel 1.5 mg for emergency contraception</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Low‐dose mifepristone (&lt; 25 mg) versus levonorgestrel 1.5 mg for emergency contraception</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women seeking emergency contraception<br/> <b>Setting:</b> China (12), UK (1), multinational (1); family planning clinics<br/> <b>Intervention:</b> mifepristone, low dose (&lt; 25 mg)<br/> <b>Comparison:</b> levonorgestrel 1.5 mg </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with levonorgestrel 1.5 mg</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with low‐dose mifepristone (&lt; 25 mg)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observed number of pregnancies (all women)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<br/> (10 to 20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.72<br/> (0.52 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8752<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any side effect</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>342 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1000<br/> (58 to 130) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.26<br/> (0.17 to 0.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>609<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effect ‐ nausea</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>133 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000<br/> (112 to 145) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95<br/> (0.84 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6384<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effect ‐ vomiting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000<br/> (8 to 41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.22<br/> (0.55 to 2.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6085<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effect ‐ spotting/bleeding after treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>284 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>173 per 1000<br/> (153 to 196) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.61<br/> (0.54 to 0.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4598<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ early</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>182 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000<br/> (64 to 108) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.45<br/> (0.35 to 0.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1800<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ delay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1000<br/> (98 to 131) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.70<br/> (1.48 to 1.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7520<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level for serious risk of bias associated with poor reporting of randomization methods.<br/> <sup>2</sup>We downgraded the quality of evidence by one level for imprecision because the total (cumulative) sample size was lower than the calculated optimal information size.<br/> <sup>3</sup>We downgraded the quality of evidence by one level for imprecision because the 95% CI overlaps no effect and CI fails to exclude important benefit or important harm.<br/> <sup>4</sup>We downgraded the quality of evidence by one level for inconsistency because of high heterogeneity in the meta‐analysis. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Low‐dose mifepristone (&lt; 25 mg) versus levonorgestrel 1.5 mg for emergency contraception</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001324-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Mifepristone (all doses) versus Yuzpe for emergency contraception</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mifepristone (all doses) versus Yuzpe for emergency contraception</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women seeking emergency contraception<br/> <b>Setting:</b> UK (3); family planning clinics<br/> <b>Intervention:</b> mifepristone (all doses)<br/> <b>Comparison:</b> Yuzpe </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Yuzpe</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with mifepristone (all doses)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observed number of pregnancies (all women)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/> (1 to 10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.14<br/> (0.05 to 0.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2144<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any side effect</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>735 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>610 per 1000<br/> (566 to 647) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.83<br/> (0.77 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1693<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ nausea</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>424 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>267 per 1000<br/> (225 to 322) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.63<br/> (0.53 to 0.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2186<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ vomiting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>135 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/> (9 to 27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.12<br/> (0.07 to 0.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2186<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ abdominal pain</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>276 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>210 per 1000<br/> (168 to 262) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.76<br/> (0.61 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ spotting/bleeding after treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ delay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>311 per 1000<br/> (253 to 381) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.83<br/> (2.30 to 3.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1924<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level for inconsistency because of high heterogeneity in the meta‐analysis.<br/> <sup>2</sup>We downgraded the quality of evidence by one level for imprecision because the total (cumulative) sample size was lower than the calculated optimal information size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Mifepristone (all doses) versus Yuzpe for emergency contraception</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001324-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Ulipristal acetate (all doses) versus levonorgestrel for emergency contraception</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ulipristal acetate (all doses) versus levonorgestrel for emergency contraception</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women seeking emergency contraception<br/> <b>Setting:</b> multinational (2); family planning clinics<br/> <b>Intervention:</b> ulipristal acetate (all doses)<br/> <b>Comparison:</b> levonorgestrel </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with levonorgestrel</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with ulipristal acetate (all doses)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observed number of pregnancies (all women)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000<br/> (8 to 22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.59<br/> (0.35 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3448<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any side effect</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ nausea</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>90 per 1000<br/> (74 to 112) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.14<br/> (0.93 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3770<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ vomiting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/> (0 to 18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/> (0.14 to 7.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1549<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ spotting/bleeding after treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/> (2 to 20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.71<br/> (0.23 to 2.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1549<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ early</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>256 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000<br/> (95 to 128) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.43<br/> (0.37 to 0.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3593<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ delay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>208 per 1000<br/> (179 to 241) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.65<br/> (1.42 to 1.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3593<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level for imprecision because the 95% CI overlaps no effect and CI fails to exclude important benefit or important harm.<br/> <sup>2</sup>We downgraded the quality of evidence by one level for imprecision because the total (cumulative) sample size is lower than the calculated optimal information size.<br/> <sup>3</sup>We downgraded the quality of evidence by one level for inconsistency because of high heterogeneity in the meta‐analysis. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Ulipristal acetate (all doses) versus levonorgestrel for emergency contraception</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001324-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Single‐dose levonorgestrel versus split‐dose levonorgestrel for emergency contraception</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Single‐dose levonorgestrel versus split‐dose levonorgestrel for emergency contraception</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women seeking emergency contraception<br/> <b>Setting:</b> multinational (3); family planning clinics<br/> <b>Intervention</b> : levonorgestrel, single‐dose<br/> <b>Comparison</b>: levonorgestrel, split‐dose </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with split‐dose levonorgestrel</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with single‐dose levonorgestrel</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observed number of pregnancies (all women)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (6 to 16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.84<br/> (0.53 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6653<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any side effect</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ nausea</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>195 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>189 per 1000<br/> (171 to 208) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.97<br/> (0.88 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6804<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ vomiting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000<br/> (48 to 70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01<br/> (0.83 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6804<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ spotting/bleeding after treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>313 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>313 per 1000<br/> (282 to 351) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/> (0.90 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2720<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ early</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>299 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000<br/> (162 to 245) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.67<br/> (0.54 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1118<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ delay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>77 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000<br/> (74 to 112) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.18<br/> (0.96 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3784<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level for imprecision because the 95% CI overlaps no effect and CI fails to exclude important benefit or important harm.<br/> <sup>2</sup>We downgraded the quality of evidence by one level for inconsistency because of high heterogeneity in the meta‐analysis. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Single‐dose levonorgestrel versus split‐dose levonorgestrel for emergency contraception</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001324-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Mid‐dose mifepristone (25 mg‐50 mg) versus low‐dose mifepristone (&lt; 25 mg) for emergency contraception</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Mid‐dose mifepristone (25 mg‐50 mg) versus low‐dose mifepristone (&lt; 25 mg) for emergency contraception</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> women seeking emergency contraception<br/> <b>Setting:</b> China (25); family planning clinics<br/> <b>Intervention:</b> mifepristone, mid‐dose (25 mg‐50 mg)<br/> <b>Comparison:</b> mifepristone, low‐doses (&lt; 25 mg) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with low‐dose mifepristone<br/> (&lt; 25 mg)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with mid‐dose mifepristone<br/> (25 mg‐50 mg)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observed number of pregnancies (all women)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/> (9 to 16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.73<br/> (0.55 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11914<br/> (25 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any side effect</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>115 per 1000<br/> (89 to 149) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.31<br/> (1.01 to 1.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2464<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ nausea</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>114 per 1000<br/> (100 to 128) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.10<br/> (0.97 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7948<br/> (13 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ vomiting</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (4 to 13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.22<br/> (0.68 to 2.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6082<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ spotting/bleeding after treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>69 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>127 per 1000<br/> (107 to 151) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.85<br/> (1.55 to 2.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5078<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ early</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 per 1000<br/> (103 to 160) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.09<br/> (0.87 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2136<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ delay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>117 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>150 per 1000<br/> (130 to 172) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.28<br/> (1.11 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11282<br/> (21 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level for risk of bias because we judged allocation concealment to be inadequate in the meta‐analysis.<br/> <sup>2</sup>We downgraded the quality of evidence by one level for imprecision because the 95% CI overlaps no effect and CI fails to exclude important benefit or important harm.<br/> <sup>3</sup>We downgraded the quality of evidence by one level for inconsistency because of high heterogeneity in the meta‐analysis. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Mid‐dose mifepristone (25 mg‐50 mg) versus low‐dose mifepristone (&lt; 25 mg) for emergency contraception</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001324-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Copper intrauterine device versus mifepristone (all doses) for emergency contraception</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Copper intrauterine device versus mifepristone (all doses) for emergency contraception</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population: w</b> omen seeking emergency contraception<br/> <b>Setting:</b> China (2); family planning clinics<br/> <b>Intervention:</b> copper intrauterine device<br/> <b>Comparison:</b> mifepristone (all doses) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with mifepristone<br/> (all doses)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with copper intrauterine device</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Observed number of pregnancies (all women)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/> (0 to 34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.33<br/> (0.04 to 2.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>395<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any side effect</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000<br/> (0 to 83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.06<br/> (0.00 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ nausea</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ vomiting</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ lower abdominal pain</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 73.61<br/> (4.48 to 1208.50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific side effects ‐ spotting/bleeding after treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menses ‐ delay</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000<br/> (16 to 115) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.23<br/> (0.09 to 0.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>284<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence by one level for serious risk of bias associated with poor reporting of randomization method.<br/> <sup>2</sup>We downgraded the quality of evidence by one level for imprecision because the total (cumulative) sample size was lower than the calculated optimal information size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Copper intrauterine device versus mifepristone (all doses) for emergency contraception</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/full#CD001324-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intrauterine contraceptive device versus control (expectant management)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.03, 0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intrauterine contraceptive device versus control (expectant management)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Levonorgestrel versus Yuzpe</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.39, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Observed number of pregnancies (by risk status) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.31, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 High‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.19, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Low‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1893</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.32, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Observed number of pregnancies (time from intercourse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.28, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Within 24 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.19, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 25‐48 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>952</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.19, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 49‐72 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>337</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.19, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Need for extra dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1955</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.38, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1955</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.75, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Specific side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.36, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.24, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.71, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.65, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4750</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.60, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.76, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.66, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8 Spotting/bleeding after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.37, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1955</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.70, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.10 Hot flushes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.09, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.11 Stomach pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.81, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.12 Nose spot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.80, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.99, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Early</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.86, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.96, 1.57]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Levonorgestrel versus Yuzpe</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Levonorgestrel (all doses) versus anordrin (all doses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.11, 3.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.27, 2.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Levonorgestrel (all doses) versus anordrin (all doses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Mifepristone mid‐dose (25 mg‐50 mg) versus levonorgestrel 1.5 mg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.45, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Observed number of pregnancies (by risk status) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.26, 10.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 High‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.11, 12.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Low‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.12, 53.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.40, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Specific side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>713</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.48, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.22, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.26, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>713</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.52, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.11, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Spotting/bleeding after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1796</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.42, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Early</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.50, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [1.09, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 ITT (all loss follow‐up as pregnancy in LNG, and no preg in Mife) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.32, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 ITT (all loss follow‐up as no pregnancy in LNG, and preg in Mife) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.37, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Mifepristone mid‐dose (25 mg‐50 mg) versus levonorgestrel 1.5 mg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Mifepristone low dose (&lt; 25 mg) versus levonorgestrel 1.5 mg</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8752</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.52, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Observed number of pregnancies (by risk status) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.55, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 High‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.67, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Low‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2836</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.25, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Observed number of pregnancies (time from intercourse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6074</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.56, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Within 72 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.53, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Later than 72 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.35, 3.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.17, 0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Specific side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.55, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.83, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.79, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.94, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6084</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.88, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.93, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 Spotting/bleeding after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.54, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9 Low abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10 Hot flushes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.65, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Early</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.35, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7520</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.48, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 ITT (all loss follow‐up as pregnancy in LNG, and no preg in Mifepristone) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.50, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 ITT (all loss follow‐up as no pregnancy in LNG, and preg in Mifepristone) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.76, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Mifepristone low dose (&lt; 25 mg) versus levonorgestrel 1.5 mg</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Mifepristone (all doses) versus Yuzpe</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.05, 0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Observed number of pregnancies (by risk status) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 High‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Low‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Observed number of pregnancies (time from intercourse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.06, 0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 within 24 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 25‐48 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.02, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 49‐72 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.05, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Need for extra dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>958</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.03, 0.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.77, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Specific side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.53, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.07, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.61, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.42, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.68, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.54, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Spotting/bleeding after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.61, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9 Hot flushes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.40, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.10 Lethargy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.59, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Early</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1924</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [2.30, 3.47]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Mifepristone (all doses) versus Yuzpe</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Mifepristone (all doses) versus anordrin (all doses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1035</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.11, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.43, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Specific side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Spotting/bleeding after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [0.69, 4.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.78, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.78, 1.68]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Mifepristone (all doses) versus anordrin (all doses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Mifepristone alone (low or mid dose) versus mifepristone + anordrin (all doses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.73, 2.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.49, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Specific side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.44, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.14, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.53, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.54, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.65, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.49, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Spotting/bleeding after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.33, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.83, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Delay in menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Early</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2781</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.65, 0.97]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Mifepristone alone (low or mid dose) versus mifepristone + anordrin (all doses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Mifepristone versus mifepristone + misoprostol (all doses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.49 [0.73, 16.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Specific side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.48, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.09, 2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 15.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Spotting/bleeding after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.35, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.10, 0.93]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Mifepristone versus mifepristone + misoprostol (all doses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Mifepristone alone (all doses) versus mifepristone + tamoxifen (all doses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.31, 28.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Specific side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.38, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.18, 21.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.12, 73.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.24, 103.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.40, 3.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.05, 5.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.12, 73.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Spotting/bleeding after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.35, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.31, 28.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10 Heavy menses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.56 [1.25, 24.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [0.93, 3.43]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Mifepristone alone (all doses) versus mifepristone + tamoxifen (all doses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Mifepristone alone (all doses) versus mifepristone + methotrexate (all doses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancy (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.32, 28.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.33, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.63, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Early</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.26, 8.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.60, 1.39]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Mifepristone alone (all doses) versus mifepristone + methotrexate (all doses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Mifepristone (all doses) versus danazol (all doses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>629</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.02, 0.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.13, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Specific side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.92, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.25, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.56, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.94 [0.31, 28.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [0.56, 10.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [0.56, 10.27]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Mifepristone (all doses) versus danazol (all doses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Mifepristone versus gestrinone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.32, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.90, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.06, 15.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.19, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.68, 3.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.91, 4.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.17, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Bleeding or spotting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.70, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 Lower abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.35, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Early</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.20, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>975</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.03, 1.82]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Mifepristone versus gestrinone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">High‐dose oestrogens versus Yuzpe</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [0.20, 23.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">High‐dose oestrogens versus Yuzpe</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Danazol (all doses) versus Yuzpe</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.61, 5.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Specific side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.30, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.06, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.75, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.74, 3.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.74, 3.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Danazol (all doses) versus Yuzpe</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Ulipristal acetate (all doses) versus levonorgestrel</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.35, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Observed number of pregnancies (by risk status) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.35, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 High‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.25, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Low‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.30, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Observed number of pregnancies (time from intercourse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.37, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Within 24 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.15, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 24‐48 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.59, 3.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 &gt; 48‐72 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>846</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.11, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 &gt; 72‐96 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.01, 4.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 &gt; 96‐120 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Observed number of pregnancies within 0‐72 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3245</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.37, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Specific side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.93, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.14, 7.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.87, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.78, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3770</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.91, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.53, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.48, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 Spotting/bleeding after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.23, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.54, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10 Lower abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.69, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.11 Upper abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.53, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.12 Back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.80, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.13 Dysmenorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.73, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Early</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.37, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.42, 1.92]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Ulipristal acetate (all doses) versus levonorgestrel</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Levonorgestrel split dose, 24 hours versus 12 hours</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancy (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2060</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.53, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Observed number of pregnancies (by risk status) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.53, 1.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 High‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.13, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Low‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.71, 3.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Specific side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.72, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.37, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.58, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.86, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.40, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Lower abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2071</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.53, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.53, 1.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Levonorgestrel split dose, 24 hours versus 12 hours</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Levonorgestrel single dose versus split dose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.53, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Observed number of pregnancies (by risk status) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.46, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 High‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>792</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.22, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Low‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.51, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Observed number of pregnancies (time from intercourse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.57, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Within 72 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.48, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Later than 72 h</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.46, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Specific side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.88, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.83, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.01, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.79, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.88, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3782</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.91, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.81, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Spotting/bleeding after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.90, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 Lower abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3782</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.77, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10 Heavy menses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.08, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Early</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.54, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.96, 1.46]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Levonorgestrel single dose versus split dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Mifepristone low dose (10 mg) versus low dose (5 mg)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.33, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Specific side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.73, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.69, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.58, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.79, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.51, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Lower abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.52, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Delay of menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Early</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.50, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.91 [2.51, 3.38]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Mifepristone low dose (10 mg) versus low dose (5 mg)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Low dose mifepristone (10 mg) versus split low dose mifepristone (10 mg x2)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.06, 15.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.82, 2.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Early</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.29, 5.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.22, 1.54]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Low dose mifepristone (10 mg) versus split low dose mifepristone (10 mg x2)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Mifepristone mid dose (25‐50 mg) versus mifepristone low dose (&lt; 25 mg)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11914</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.55, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Observed number of pregnancies (by risk status) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.50, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 High‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.36, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Low‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.45, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [1.01, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Specific side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7948</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.97, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.68, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.76, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.79, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.64, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.68, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Spotting/bleeding after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5078</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.55, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.78, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Early</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.87, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [1.11, 1.47]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Mifepristone mid dose (25‐50 mg) versus mifepristone low dose (&lt; 25 mg)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Mifepristone mid dose (50 mg) versus mifepristone mid dose (25 mg)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.41, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [1.39, 2.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Specific side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.44, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 4.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.17, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.54, 4.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.97 [0.12, 72.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.08, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [0.93, 4.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Spotting/bleeding after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>617</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.82, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 Early menses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.8 [0.63, 5.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Delay in menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1945</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.12, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 &gt; 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.75, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 &gt; 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.45, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 &gt; 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1037</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.26, 1.94]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Mifepristone mid dose (50 mg) versus mifepristone mid dose (25 mg)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Mid dose mifepristone split dose comparisons</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 25 mg 12‐hrly x 2 versus 10 mg daily x 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.18, 21.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 25 mg 12‐hrly x 2 versus 10 mg daily x 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.92 [0.24, 101.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 10 mg daily x 3 days versus 10 mg daily x 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.05 [0.13, 74.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 25 mg 12‐hrly x 2 versus 10 mg daily x 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>28.04 [1.69, 464.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 25 mg 12‐hrly x 2 versus 10 mg daily x 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>28.52 [1.72, 472.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 10 mg daily x 3 days versus 10 mg daily x 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Early menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 25 mg 12‐hrly x 2 versus 10 mg daily x 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.63, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 25 mg 12‐hrly x 2 versus 10 mg daily x 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.64, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 10 mg daily x 3 days versus 10 mg daily x 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.60, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Delay menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 25 mg 12‐hrly x 2 versus 10 mg daily x 3 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [1.03, 3.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 25 mg 12‐hrly x 2 versus 10 mg daily x 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.70, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 10 mg daily x 3 days versus 10 mg daily x 5 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.34, 1.14]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Mid dose mifepristone split dose comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Mifepristone high dose (&gt; 50 mg) versus mifepristone low dose (&lt; 25 mg)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.23, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Observed number of pregnancies (by risk status) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.29, 3.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 High‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Low‐risk women</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.29, 3.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.04 [5.13, 33.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Specific side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.42, 6.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.26, 8.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.00, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 101.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.26, 8.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Spotting/bleeding after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [1.89, 2.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Early</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.66, 2.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Mifepristone high dose (&gt; 50 mg) versus mifepristone low dose (&lt; 25 mg)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">Mifepristone high dose (&gt; 50 mg) versus mifepristone mid dose (25‐50 mg)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.50, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.64 [1.57, 4.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Specific side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.36, 4.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.21, 4.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 21.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Breast tenderness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 21.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.21, 4.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Spotting/bleeding after treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.12, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Early</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.0 [1.30, 76.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.34, 1.75]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">Mifepristone high dose (&gt; 50 mg) versus mifepristone mid dose (25‐50 mg)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">Half‐dose Yuzpe versus standard Yuzpe</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.76, 2.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.77, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Specific side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.77, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.36, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.68, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.40, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.43, 1.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">Half‐dose Yuzpe versus standard Yuzpe</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">Copper intrauterine device versus mifepristone (all doses)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies (all women) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>395</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 2.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Any side effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Specific side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Lower abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>73.61 [4.48, 1208.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Menses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.09, 0.64]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">Copper intrauterine device versus mifepristone (all doses)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0036"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">Time elapsed since intercourse in levonorgestrel</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 ≤ 24 h vs &gt; 24‐48 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.50, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 ≤ 24 h vs &gt; 48‐72 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.31, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 &gt; 24‐48 h vs &gt; 48‐72 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.27, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 &lt; 72 h vs &gt; 72 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.31, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">Time elapsed since intercourse in levonorgestrel</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0036">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0037"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">Time elapsed since intercourse (coitus‐treatment interval) in mifepristone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 ≤ 24 h vs &gt; 24‐48 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.29, 3.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 ≤ 24 h vs &gt; 48‐72 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.13, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 &gt; 24‐48 h vs &gt; 48‐72 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>979</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.13, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 &lt; 72 h vs &gt; 72 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.21, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">Time elapsed since intercourse (coitus‐treatment interval) in mifepristone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0037">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0038"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">Time elapsed since intercourse in Yuzpe</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 ≤ 24 h vs &gt; 24‐48 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.26, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 ≤ 24 h vs &gt; 48‐72 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.18, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 &gt; 24‐48 h vs &gt; 48‐72 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.37, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">Time elapsed since intercourse in Yuzpe</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0038">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0039"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">Time elapsed since intercourse in ulipristal acetate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 ≤ 24 h vs &gt; 24‐48 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.16, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 ≤ 24 h vs &gt; 48‐72 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.24, 2.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 &gt; 24‐48 h vs &gt; 48‐72 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [0.77, 6.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 &lt; 72 h vs &gt; 72 h <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.66 [0.28, 77.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">Time elapsed since intercourse in ulipristal acetate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0039">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001324-tbl-0040"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">High‐risk women versus low‐risk women (all hormonal methods)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Observed number of pregnancies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19700</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [2.11, 3.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">High‐risk women versus low‐risk women (all hormonal methods)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001324.pub6/references#CD001324-tbl-0040">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001324.pub6&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD001324-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD001324-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001324-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD001324-note-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD001324-note-0005">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD001324-note-0008">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD001324-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD001324-note-0006">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD001324-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD001324-note-0003">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD001324-note-0022">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001324\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001324\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001324\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001324\x2epub6"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001324\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001324\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001324\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001324\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001324\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001324\x2epub6"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001324\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001324\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001324\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001324\x2epub6"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001324\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001324\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001324\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001324\x2epub6"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001324.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001324.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001324.pub6/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001324.pub6/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001324.pub6%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715322524"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001324.pub6/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715322528"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001324.pub6/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d84403ee4f446',t:'MTc0MDcxNTMyMy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 